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Summary
Despite antiepileptic drug (AED) treatment, up to one third of patients continue to have 
seizures. Refractory epilepsy is a poorly understood subject, both in terms of its 
development and pathogenesis. Outcome studies have focused on terminal remission, but 
little is known about the natural history of epilepsy in terms of its progression to eventual 
remission or persistent refractoriness. Such an understanding is essential to the 
formulation of a rational management approach.
Natural history of treated epilepsy
Long-term outcome of newly diagnosed patients was investigated longitudinally for up to 
15 years. Response to the first drug and successive substitution monotherapy or 
polytherapy was analysed. Outcome among patients with different neuropathologies was 
compared in a separate study.
Among 470 newly diagnosed patients, 64% became seizure-free for at least a year.
Patients with high numbers of pre-treatment seizures were less likely to become seizure- 
free. Epilepsy was controlled by the first AED in 47% of patients. Patients with 
symptomatic or cryptogenic epilepsy were less likely to become seizure-free on the first 
AED, partly because they were more likely to develop intolerable side-effects compared to 
those with idiopathic epilepsy. The majority of such withdrawals occurred at low doses of 
the three most commonly prescribed AEDs, carbamazepine (CBZ), sodium valproate 
(VPA) and lamotrigine (LTG). Over 90% of seizure-free patients also required only a 
moderate daily dose (up to 800mg CBZ, 1500mg VP A, 300mg LTG).
The probability of attaining seizure-freedom declined progressively with successive AED 
regimens. While 47% became seizure-free on the first drug, only 10% did so on the
1
second drug and 1% on the third monotherapy. Three percent became seizure-free on a 
combination of two AEDs. The subsequent seizure-free rate was 41% among those failing 
the first drug due to intolerable side effects, but only 1 1 % among those in whom the first 
AED was well tolerated but did not control the seizures completely.
Among patients with inadequate seizure control on the first well tolerated AED, those who 
received substituted monotherapy and those who received add-on treatment had similar 
seizure-free rates and incidence of intolerable side effects. More patients became seizure- 
free on combinations involving an AED that blocked sodium channels and one with 
multiple mechanisms of action than on other combinations. Combination treatment was 
more effective when prescribed immediately after the first drug failed due to inadequate 
seizure control than when it was delayed until a substitution also proved unsuccessful.
In a separate study, compared with other pathologies identified on magnetic resonance 
imaging, mesial temporal sclerosis (MTS) was associated with the worst prognosis, 
although 42% did become seizure-free on AED treatment.
Pathogenesis of refractory epilepsy
Two candidate biological mechanisms in the pathogenesis of refractory epilepsy were 
studied. Glutamic acid decarboxylase (GAD) autoantibody titres were compared between 
patients with controlled and uncontrolled epilepsy. GAD catalyses the conversion of 
glutamate to y-aminobutyric acid, the major inhibitory neurotransmitter. Autoantibodies 
against GAD are prevalent in insulin dependent diabetes mellitus, and have been 
documented in anecdotal cases of refractory epilepsy.
2
The drug transporter P-glycoprotein (P-gp) was investigated in a series of laboratory-based 
pilot experiments. Encoded by the multidrug resistance gene family (MDR1 in man and 
mdrla and lb  in rodents), P-gp actively extrudes a wide range of xenobiotics out of cells.
Its over-expression is thought to underlie the resistance of some cancers to multiple 
chemotherapeutics. P-gp is physiologically expressed at high level in the cerebral capillary 
endothelium where it contributes to the integrity of the blood-brain barrier. Over­
expression of P-gp in brain tissues resected from patients with refractory epilepsy has been 
reported in surgical case series.
Mdrla(-/-) mice devoid of cerebral P-gp were used to determine whether AEDs were 
substrates of the drug transporter. The pharmacokinetic profiles of four established and 
four new AEDs in mdrla(-/~) mice and wild-type mice were compared.
The technique of quantitative reverse transcriptase-polymerase chain reaction was 
developed and validated to determine tissue concentration of mdrl mRNA as an indicator 
of gene expression. Expression was determined in different regions of the normal rat brain, 
and in brains of genetically epilepsy-prone rats (GEPRs) subject to a single audiogenic 
seizure. To explore the effect of tissue damage, a laser beam was impinged upon the 
cerebral cortex of rats. Mdrl expression was measured in tissues surrounding the focal 
necrosis. Human brain tissues resected during epilepsy surgery were also analysed for 
MDR1 gene expression.
There was no difference in GAD autoantibody titres between patients with controlled and 
uncontrolled epilepsy. Four female patients with uncontrolled epilepsy had elevated 
antibody titres, but three of them also tested positive for pancreatic islet cell antibodies, 
suggesting a possible pancreatic source of GAD antibodies.
3
Topiramate, phenytoin and CBZ reached higher brain concentrations in mdrla(-/~) mice 
compared to wild type mice, suggesting they are substrates of P-gp. Mdrlb was expressed 
to an appreciable level in the hippocampus alone, whereas mdrl a was expressed uniformly 
throughout the normal rat brain. After a single seizure, mdrl a expression became elevated 
at 4 hours in the cerebral cortex of GEPRs, rising to a maximum at 24 hours, returning 
towards basal level at 7 days. Similar time-dependent changes were observed in the 
midbrain, but mdrl a expression remained unchanged in the pons/medulla and 
hippocampus. Focal laser application induced a transient expression of mdrlb in the rat 
cerebral cortex at 1 week. Significant MDR1 expression was detected in brain tissues 
resected from two patients who underwent temporal lobectomy for refractory epilepsy.
Conclusions
Patients with symptomatic epilepsies, particularly those with MTS, and patients with 
inadequate response to initial treatment are likely to develop refractory epilepsy. Nearly 
50% of newly diagnosed patients responded to the first AED, with over 90% doing so at 
moderate dosing. Tolerability was an important factor in determining the overall 
effectiveness of AED treatment. Over-expression of P-gp in the hippocampus, as a result 
of recurrent seizures, might contribute to the pathogenesis of refractory epilepsy (in 
particular temporal lobe epilepsy) by limiting AED access to the seizure focus. A working 
hypothesis regarding early targetting of rational combination therapy or surgery to “high 
risk” patients to prevent the progression to the refractory state is proposed.
4
PARTI
OVERALL INTRODUCTION
5
1 Epilepsy
“Epilepsy” is derived from the Greek word epilambanein, meaning “to seize” or “to 
attack”. It is the most common serious neurological disorder. Between 40 and 70 per 
100000 people develop epilepsy each year. Most epidemiological studies report a point 
prevalence between 4 and 10/1000 (Hauser et al, 1991; Cockerell et al, 1995a; Sander and 
Shorvon, 1996). Epilepsy crosses geographical boundaries. Higher incidence and 
prevalence rates are reported in developing countries, possibly due to more widespread 
parasitic diseases (Lavados et al., 1992; Placentia et al., 1992). Even excluding febrile 
convulsions, which occur in about 5% of children (Nelson and Ellenberg, 1976), it is 
estimated that as many as 8.2% of the population will have a seizure at some point in their 
lives (Hauser et al, 1996). Epilepsy affects all ages, with high rates occurring in early 
childhood, falling to low levels in early adult life, but rising again in those over 55 years.
In the Rochester study, the highest incidence of epilepsy is found in those aged 75 years or 
older (Hauser et al, 1996).
Epilepsy transcends history. Seizures have been recorded by all races and creeds since the 
dawn of literacy. They were formally recognised in the classical Chinese medical text, 
Huang Di Nei Ching (The Yellow Emperor’s Classic of Internal Medicine), written around 
770-221 B.C. (Lai and Lai, 1991). In the West, the oldest written account of epilepsy is 
perhaps found in a Babylonian treatise discovered in South Turkey, which ascribed it as 
“the result of possession by a demon or departed spirit” (Kinnier Wilson and Reynolds, 
1990).
The stigmatisation of epilepsy is deep-rooted. In ancient cultures, epileptics were 
considered unclean or evil, and an epileptic fit constituted a bad omen. The Romans called 
epilepsy the morbus comitialis, attributing the name to the belief that an epileptic attack
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would spoil the day of the comitia, the assembly of the people. Even physicians advised 
spitting upon seeing an epileptic in order to “throw back contagion” (Tempkin, 1971). 
Galen's idea (130-220 A.D.) of "animal spirits" in body tubes was still being quoted by 
Willis in the late 17th century (Stevens, 1973), and Albich in the 18th century warned 
"neither talk nor bathe with them (epileptics), since by their mere breath they infect 
people" (Tempkin, 1971). Even today, although generally to a lesser degree, society's 
prejudice and ignorance is still felt by many patients (Baker et al, 2000), not least fuelled 
by often distorted and sensationalised depiction of seizures in the media (Kerson et al, 
1999; Krauss et al, 2000) and literature (Vanzan Paladin, 1995).
The first attempt to dispel superstitious and magical beliefs and explain epilepsy rationally 
was found in the Hippocratic collection of medical writings from about 400 B.C. What the 
author wrote in the introduction to the book On the Sacred Disease may still be applicable 
today:
“I do not believe that the so-called ‘Sacred Disease’ is any more divine or 
sacred than any other diseases. It has its own specific nature and cause; 
but because it is completely different from other diseases men through 
their inexperience and wonder at its peculiar symptoms have believed it to 
be of divine origin.” (Longrigg, 2000)
In the author’s opinion, epilepsy is “hereditary”, its cause lies in the brain from where 
phlegm overspills into the blood stream, producing a variety of symptoms depending on 
the organs affected (Tempkin, 1971). Distinction was made between tonic and clonic 
seizures, and changes in pulse and respiration were noted. By the time of the second 
century, seizures were further classified according to their clinical manifestation, with the 
key central theme being alteration of consciousness and amnesia of the ictal event (Gross,
1992). The term “aura”, still widely used today to refer to warning symptoms in general, 
was introduced by Galen to denote a particular sensation that was described to him as a 
“cold breeze” by one of his patients. Various provoking factors were recognised, such as 
alcohol, pregnancy (eclampsia) and head trauma (Gross, 1992).
The development of a rational understanding of epilepsy took a step back in the Middle 
Ages. The "falling sickness" was believed to be the result of divine or demonic possession, 
and the variety and range of signs were interpreted according to the different views of 
supernatural forces prevalent at the time (Gross, 1992). Extraterrestrial influences were 
evoked. Theological interpretations were particularly prevailing, drawing examples from 
the Gospels of Mark and Luke which recorded Jesus driving out "unclean spirit" from a 
boy suffering from convulsions.
Renaissance saw a re-thinking of the views towards epilepsy and a re-emphasis on 
objective observation rather than dogma. The rise in anatomy allowed the recognition that 
epilepsy might be associated with other disorders, including syphilis, measles, making the 
major leap in understanding that seizures could be a symptom of other diseases. "Minor", 
"medium" and "major" seizures were recognised by their signs and symptoms, and 
obstruction of arteries, nerves or ventricles was thought to be the cause. This humoral 
theory was finally abandoned when Le Pois found no evidence of ventricular obstruction 
but observed local "irritation" in postmortem examinations (Gross, 1992). Thus the 
foundation was laid for the modem scientific approach to the understanding of epilepsy 
that began during the Enlightenment.
The rise of the disciplines of anatomy, chemistry, pathology and physiology allowed the 
development of rational pathophysiological hypotheses of seizures and epilepsy. Epilepsy
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and hysteria were distinguished. The association with the phases of the moon was 
scientifically disproved by independent prospective observations by Leuret and Moreau 
(Tempkin, 1971), notwithstanding today's interest in catamenial epilepsy, which was also
iL #
noted in the early 18 century by Maisonneuve (Esquirol, 1845). Absence, partial and 
generalised seizures and status epilepticus were coined in the new terminology. Aided by 
advances in anatomy and the emerging view of cerebral localisation, various intracranial 
abnormalities were recognised to cause epilepsy, which was classified as "idiopathic". 
Work by Todd and Bright dispelled the notion of "sympathetic" epilepsy due to peripheral 
irritation and demonstrated that diseases within the brain could also be responsible for 
focal seizures (Gross, 1992). Tissot further provided a framework from which the present 
day classification systems were loosely derived (Dreifuss, 1997). Epileptic seizures were 
classified and distinguished from the underlying causative conditions that we now call the 
epilepsies. An epilepsy was noted to be composed of an ongoing predisposing condition 
but individual seizures were the expression of the epileptic process, the presenting 
symptom thereof.
The modem chapter of epilepsy began when the Yorkshireman John Hughlings Jackson 
linked these clinical observations with new electrophysiological data that showed that 
electrical stimulation of discrete areas of cortex elicited specific motor effects (Fritsch and 
Hitzig, 1870). He was able to formulate a complete pathophysiological model of epilepsy 
in his Investigations o f Epilepsies (1873), asserting that:
"A convulsion is but a symptom, and implies only that there is an 
occasional, an excessive, and a disorderly discharge of nerve tissue on 
muscles."
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Jackson believed that epilepsy was due to a paroxysmal discharge of neurones within a 
local area that could then affect more normal areas of the brain. Here, finally, was a 
statement that linked the diverse symptomatology of seizures to their physiology: 
"According as the seat of the discharge varies the symptoms of the paroxysm vary." All 
seizures, therefore, have a similar pathophysiology - a hypothesis still actively investigated.
Objective evaluations of the epilepsies ensued. Gowers' elegant description of seizures 
around the turn of the century was remarkable in its detail and depth. He discussed his 
cases in light of recent physiological advances and emphasised the relationship of partial 
seizures to focal lesions and the lack of focal pathology in cases of generalised seizures 
(Gowers, 1881). In the 1930s, Berger discovered typical electroencephalographic (EEG) 
abnormalities in patients with epilepsy. This, together with the work of Penfield and 
Jasper (1954), who reported a relationship between the functional anatomy of the brain and 
the specific nature of ictal activity, laid the foundations of the present understanding and 
classification of epilepsy.
1.1 Definitions
As eluded above, epilepsy is not a single disease entity. Rather, the generic term refers to a 
collection of conditions with a wide range of underlying aetiologies and pathologies, all 
with the common and fundamental characteristic of recurrent, usually unprovoked epileptic 
seizures (Engel and Pedley, 1997). Strictly speaking, epilepsy is a mere symptom of the 
underlying aetiology. A person is said to have epilepsy if he/she is prone to experiencing 
recurrent seizure. This definition invites uncertainty, as in marginal cases it may be 
difficult to clearly define a liability to future attacks. In most practical situations epilepsy 
is diagnosed when two or more unprovoked seizures have occurred.
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An epileptic seizure is defined as the manifestation of an abnormal and excessive 
synchronised discharge of a set of neurones in the brain. The clinical features consist of a 
wide range of sudden and transitory abnormal phenomena which may include alterations of 
consciousness, motor, sensory, autonomic, or psychic events (Commission, 1993). By this 
definition, subclinical attacks in which epileptic discharges detectable on EEG but not 
accompanied by evident symptoms or signs are not considered to be epileptic seizures. A 
given patient may exhibit more than one type of seizures.
Separate systems have been proposed by the International League Against Epilepsy (ILAE) 
to classify epileptic seizures and epileptic syndromes.
1.2 Classification of seizures
Since seizures are by definition a symptom rather than a distinct disease, their 
classification is necessarily arbitrary and phenomenal. The present commonly used 
classification was proposed by the ILAE nearly twenty years ago (Commission, 1981) 
using clinical description and EEG characteristics (Table 1). With the advances in imaging 
and neurophysiology over the years, the limitations of the present classification are 
becoming increasingly apparent. According, it is under current review. A seizure 
classification based exclusively on ictal semiology has been advocated to avoid confusion 
with the classification of epileptic syndromes (Liiders et al, 1998). Nevertheless, the 
present system has gained widespread acceptance and has provided an effective means of 
communication among clinicians.
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Table 1. International classification of epileptic seizures*
I Partial (focal) seizures (seizures beginning locally)
A Simple (consciousness not impaired)
i with motor symptoms
ii with somatosensory or special sensory symptoms
iii with autonomic symptoms or signs
iv with psychic symptoms
B Complex (with impaired consciousness)
i simple partial onset followed by impairment of consciousness
ii impaired consciousness at onset
C Partial seizures evolving into secondary generalised seizures
II Generalised seizures (convulsive or non-convulsive)
A Absence seizures
i typical (petit mal)
ii atypical
B Myoclonic seizures
C Clonic seizures
D Tonic seizures
E Tonic-clonic seizures (grand mal)
F Atonic seizures
III Unclassified seizures
* Adapted from Commission, 1981.
12
The current classification divides seizures broadly into partial and generalised. Partial 
seizures originate in a focal region of the cortex in one hemisphere and are subdivided into 
those that occur without alteration of consciousness (simple partial) and those in which 
consciousness is impaired (complex partial). The behavioural manifestations of a simple 
partial seizure are determined by the functions normally served by the cortical region from 
which the seizure arises. The majority of complex partial seizures originate from the 
temporal lobe. Both types of partial seizures can spread rapidly to other cortical areas 
through neuronal networks, resulting in secondary generalised tonic-clonic seizures.
Generalised seizures are characterised by widespread cortical and subcortical involvement 
at the outset and consciousness is usually impaired. They are accompanied by bilateral, 
symmetrical synchronous EEG discharges. An absence seizure (petit mal) is characterised 
by an abrupt cessation of ongoing activities associated with a blank stare lasting a few to 
30 seconds and followed by an abrupt return to normal behaviour. An atypical absence 
seizure lasts longer and is often associated with changes in muscle tone. A myoclonic 
seizure consists of brief, shock-like muscle contractions that may occur singly or in 
clusters, and can affect any group of muscles. Recovery is immediate and the patient often 
maintains that consciousness was not lost. A tonic seizure consists of sustained muscle 
contractions, whereas muscle contractions are rhythmic and irregular in a clonic seizure. 
Tonic-clonic seizures (grand mal) are the form of attack most recognised by clinicians and 
the general public alike. There is sudden loss of consciousness and falling to the ground, 
often preceded by a cry. The initial tonic phase, typically lasting 10-30 seconds, is 
followed by bilateral symmetrical convulsive movements, sometimes with tongue biting 
and urinary incontinence. Post-ictally the patient is confused and often lapses into deep 
sleep, returning to normal minutes or hours later. In an atonic seizure, there is a sudden
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loss of muscle tone, which can be generalised causing collapse, or restricted to certain 
muscle groups (Dreifuss, 1997).
1.3 Classification of epilepsy
The assignment of seizures to a particular category is largely observational and does not 
accurately reflect such characteristics as underlying aetiology, anatomical site of seizure- 
focus, prognosis and response to treatment. A separate classification system of epilepsies 
and epileptic syndromes was proposed by the ILAE in 1985 and revised in 1989 
(Commission, 1989), which takes into account the characteristics of the seizures, EEG 
changes, age of onset, family history, etc (Table 2). Epilepsies are separated into 
generalised and localisation-related (focal, partial) according to the mode of onset of 
seizures, and each is further subdivided into idiopathic, symptomatic and cryptogenic 
based on the knowledge of aetiology. Idiopathic epilepsies are "not preceded or 
occasioned by another", and are presumed to be genetic in origin. Symptomatic epilepsies 
are considered the consequence of a known cerebral abnormality, such as mesial temporal 
sclerosis (MTS), cortical dysplasia, arteriovenous malformation, stroke, or cerebral palsy. 
Cryptogenic epilepsies are presumed to be symptomatic but with unidentified underlying 
abnormality on the basis of clinical information and investigation results.
While the full version of the classification is complex (and perhaps confusing), 
categorising a patient's epilepsy into idiopathic, symptomatic or cryptogenic does give 
broad indication of possible underlying aetiology and can have implications for 
management and prognosis. Making an accurate diagnosis of an epileptic syndrome, 
particularly the idiopathic epilepsies, may allow the clinician to define the likely prognosis, 
provide appropriate genetic counselling and choose the most appropriate AED therapy 
(Brodie and French, 2000).
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Table 2. International classification of epilepsies and epileptic syndromes*
1 Localisation-related (focal, local, partial)
1.1 Idiopathic (primary)
• Benign childhood epilepsy with centrotemporal spike
• Childhood epilepsy with occipital paroxysms
• Primary reading epilepsy
1.2 Symptomatic (secondary)
• Chronic progressive epilepsia partialis continua of childhood
• Seizures with specific modes of precipitation
• Temporal lobe epilepsies
• Frontal lobe epilepsies
• Parietal lobe epilepsies
• Occipital lobe epilepsies
1.3 Cryptogenic
2 Generalised
2.1 Idiopathic
• Benign neonatal familial convulsions
• Benign neonatal convulsions
• Benign myoclonic epilepsy in infancy
• Childhood absence epilepsy
• Juvenile absence epilepsy
• Juvenile myoclonic epilepsy
• Epilepsy with grand mal on awakening
• Others
• Seizures precipitated by specific modes of activation
2.2 Cryptogenic or symptomatic
• West syndrome
• Lennox-Gastaut syndrome
• Epilepsy with myoclonic-astatic seizures
• Epilepsy with myoclonic absences
2.3 Symptomatic
• Early myoclonic encephalopathy
• Early infantile epileptic encephalopathy with burst suppression
• Others
• Specific syndromes
• Epilepsies in other disease states
3 Undetermined whether focal or generalised
4 Special syndromes
4.1 Febrile convulsions
4.2 Isolated seizures or isolated status epilepticus
4.3 Acute metabolic or toxic factors
* Adapted from Commission, 1989
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Shortcomings of the present classification are well recognised even when it was first 
proposed (Commission, 1989). Patients may move from one syndrome to another during 
the evolution of the disorder. Some syndromes can be the result of many diseases and do 
not represent a single condition, e.g. Lennox-Gastaut syndrome, while the same pathology 
may manifest as different syndromes, e.g. tuberous sclerosis. The dichotomy between 
generalised and localisation-related (focal) is arbitrary and observational and heavily 
reliant upon EEG findings. However, bilateral EEG epileptiform discharges often have 
distinct regional accentuation or in fact, on closer inspection a focal origin with rapid 
secondary spread. The inadequacy of the present system is perhaps best illustrated by 
MTS, the most common pathological finding in refractory epilepsy (Semah et al, 1998). 
Whether it is the cause or consequence of mesial temporal lobe epilepsy (MTLE) and how 
it should be classified is one of the most fervent controversies in epileptology (Wolf, 1997). 
Advances in genetics have led to discovery of mutations of ion channels in some hereditary 
epilepsies (Steinlein et al, 1995; 1997; Singh et al, 1998; Wallace et al, 1998), which may 
influence the patient's response to drug treatment (Picard et al, 1999). It has also been 
shown that the same genetic defect can produce heterogeneous clinical phenotypes, which 
would be separated into different categories under the current system (Scheffer and 
Berkovic, 1997). An increasing number of structural abnormalities can be identified in 
vivo with more sophisticated neuroimaging, which may impart a different prognosis 
although all fall under the category of "focal symptomatic" epilepsies (Semah et al, 1998). 
The present classification systems are under current review to take into account underlying 
pathology more accurately to better reflect prognosis and other dimensions (Engel, 1998a).
1.4 Common aetiologies in adolescents and adults
The range of aetiologies of epilepsy varies in different age groups and geographical 
locations. Aetiologies in relation to age commonly encountered in industrialised countries
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are shown in Figure 1. Generally speaking, epilepsy in childhood is most commonly 
caused by congenital and genetic conditions, which may only begin to manifest in late 
childhood or adolescence. In young adults, MTS, cortical dysgenesis, alcohol/drug abuse 
and trauma are important causes. In the elderly, cerebrovascular disease is common. 
Tumours and intracranial infections occur at all ages, although malignant neoplasm is more 
likely over the age of 30 years.
1.4.1 Idiopathic syndromes
Idiopathic generalised epilepsy (IGE) is a genetic disorder and the core group with onset in 
childhood or adolescence is currently subclassified into four distinct but overlapping 
syndromes (Table 2; Janz, 1997). It is debatable, however, whether they actually represent 
a biological continuum (Berkovic et al, 1987). They are characterised by a triad of seizure 
types -  generalised tonic-clonic seizure (GTCS), generalised absence and myoclonus -  
with varying degree of dominance. Other shared features include a positive family history, 
onset in childhood or adolescence, 3 Hz spike and wave ictal EEG discharges that are often 
activated by hyperventilation or photic stimulation, and a good response to AED treatment 
(Duchowny and Harvey, 1996).
Juvenile myoclonic epilepsy is the most common idiopathic epilepsy syndrome, 
accounting for approximately 7% of all epilepsies (Dreifuss, 1989). Symptoms usually 
begin in the teenage years. The cardinal feature of JME is myoclonic seizures, which 
typically occur within the first few hours after waking, with very short and bilaterally 
symmetrical jerks that usually involve the upper extremities without impairing
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consciousness. They are exacerbated by sleep deprivation and alcohol intake and the 
patient may spill or drop things as a result. Myoclonic jerks may occur in series leading to 
GTCS, which occur in 90% of patients. About 30% of patients also complain of absence 
seizures. The condition is likely to be under-reported since the myoclonic jerks can be 
mild and easily overlooked. Linkage to chromosomes 6 (Greenberg et al, 1988) and 15 
(Elmslie et al, 1997) has not been consistently demonstrated (Whitehouse et al, 1993; 
Elmslie et al, 1996; Obach et al, 2000) and polygenic inheritance is likely. The EEG 
shows a characteristic 3.5-6 Hz spike-and-wave pattern and multiple spike-and-wave 
complexes. The seizures respond well to treatment, but usually relapse when medication is 
withdrawn (Dreifuss, 1989).
Although childhood absence epilepsy has onset between 4 and 8 years of age, it may be 
undiagnosed until late childhood/adolescence. Absence seizures may be accompanied by 
eye deviation and retropulsion of the head and trunk, and can be very frequent, up to 
hundreds per day. Ictal EEG shows generalised symmetrical 3 Hz spike and wave 
discharges on a normal background. GTCS develop in 30-40% cases (Stefan and Snead,
1997).
The age of onset of juvenile absence epilepsy is around puberty. The absence seizures are 
less frequent than in childhood absence epilepsy, and retropulsive movements less 
common. There is more frequent association with GTCS and myoclonic seizures (Porter,
1993).
While GTCS occur in a great variety of epilepsy syndromes, epilepsy with grand mal on 
awakening refers to a specific syndrome with onset mostly in the second decade of life. 
GTCS occur exclusively, or predominantly, shortly after awakening and are exacerbated
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by sleep deprivation and alcohol. There may be a second seizure peak in the evening 
period of relaxation. Absence and myoclonus are rare. Patients with GTCS without such 
diurnal pattern but fulfilling the criteria for a diagnosis of IGE, are classified as having IGE 
with GTCS (Janz and Wolf, 1997).
The other IGE syndromes (benign neonatal familial convulsions, benign neonatal 
convulsions and benign myoclonic epilepsy in infancy) and the idiopathic localisation- 
related epilepsies have onset in infancy or early childhood and are rarely seen in newly 
diagnosed patients at adult epilepsy centres.
There have been dramatic advances in the understanding of the genetic basis of the 
idiopathic epilepsies in the past decade (Treiman, 1993; Callenbach and Brouwer, 1997). 
The underlying genetic mutations in a number of animal models have been identified 
(Prasad et al, 1999) and single gene defects in ion channels (channelopathies) have been 
discovered in several, albeit relatively rare, epilepsy syndromes (Berkovic and Scheffer, 
1997; Singh et al, 1998; Wallace et al, 1998). For the majority of common idiopathic 
syndromes (e.g. JME) multiple genes are likely to be involved with complex gene- 
environment interactions (Ottman, 1997; Serratosa, 1999).
1.4.2 Mesial temporal sclerosis
Mesial temporal sclerosis (MTS) is the most common pathology in intractable temporal 
lobe epilepsy, accounting for 50-70% of cases (Margerison and Corsellis, 1966; Falconer, 
1974; Blumcke et al, 1999). The term “Ammon’s horn sclerosis” was originally coined to 
describe the characteristic selective neuronal loss and gliosis involving the hippocampus 
proper (Sommer, 1880; Blumcke et al, 1999). MTS is used when other mesial temporal
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structures such as the amygdala, uncus and parahippocampal gyrus are involved, as is often 
the case (Falconer and Taylor, 1968).
There is growing evidence to support the current concept that MTLE associated with MTS 
is a discrete syndrome with characteristic clinical features, although it is not recognised as 
such in the current ILAE classification (Engel, 1996a). Onset of seizures is usually before 
puberty, often preceded by febrile convulsions (Falconer et al, 1964; Annegers et al, 1987) 
or other initial injury, such as intracranial infection or head trauma, within the first 4 or 5 
years of life (Mathem et al, 1995). There is an increased incidence of family history of 
seizure disorder (Engel, 1996a). In terms of semiology, a seizure typically begins with 
vegetative auras, such as epigastric rising, or affective symptoms (most commonly fear), 
but may consist of complex delusional experiences or hallucinations or olfactory or 
gustatory sensations, all indicative of involvement of mesial temporal limbic structures 
(Engel et al, 1997). Classically, the partial seizure remains unilateral and “simple”, 
reflecting the fact that there is little transfer across the hippocampal commissure (Engel, 
1996a). When complex partial seizure does ensue, impairment of consciousness is usually 
heralded by arrest and stare, followed by oroalimentary, gestural, and reactive automatisms 
lasting 1 to 2 minutes for which the patient is amnesic. Afterwards, the patient is confused 
for varying periods. There may be postictal dysphasia if the seizure involves the language- 
dominant hemisphere. Secondary generalisation is not uncommon.
The diagnosis of MTLE associated with MTS is supported by anterior temporal interictal 
spikes on a surface EEG, a characteristic unilateral sphenoidal ictal EEG onset pattern 
(Engel, 1996a), and hippocampal atrophy on Ti-weighted and increased mesial temporal 
signal on T2-weighted magnetic resonance imaging (MRI; Bronen, 1992). Localised 
temporal lobe hypometabolism on positron emission tomography (PET) with
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fluorodeoxyglucose, characteristic findings on magnetic resonance spectroscopy (MRS) 
and ictal or postictal single photon emission computerised tomography (SPECT), usually 
performed during pre-surgical evaluation, further support the diagnosis (Engel, 1996a).
Documentation of the natural history of MTS-related epilepsy is difficult due to its low 
prevalence (Murakami et al, 1996; van Paesschen et al, 1997a). Data derived from surgical 
series (Wieser, 1996; Briellman et al, 1998; Fisher and Blum, 1999) and specialist centres 
(Semah et al, 1998; Kim et al, 1999) suggest that patients with MTS have worse seizure 
control than those with other underlying abnormalities. However, 80% of patients can be 
rendered seizure-free by anteromesial temporal lobectomy, which may be performed 
without invasive evaluation in patients with refractory seizures who have a concordance of 
the above investigation findings all pointing to the same temporal lobe (Engel, 1996b).
Since its relationship with epilepsy was recognised nearly 200 years ago (Bouchet and 
Cazauvieilh, 1825), MTS has been the most intensively studied pathological abnormality 
associated with epilepsy, and its aetiology the most hotly debated. Whether it is the cause 
or consequence of seizures is highly controversial. That it is a result of damage by febrile 
seizures or other insults in an age-specific time window has long been postulated (Falconer 
et al, 1964; Mathem et al, 1995). This concept is supported by long-term prospective 
studies which confirm the association of prolonged febrile seizures and MTLE (Annegers 
et al, 1987), and recent documentation of evolution of MTS after prolonged febrile seizures 
and other acute insults in case series (Berkovic and Jackson, 2000). Animal data also show 
that chemically induced limbic seizures can result in histological changes resembling 
human MTS (Pringle et al, 1993; Liu et al, 1995). Other researchers point to the lack of 
association between the extent of MTS and seizure duration (Liu et al, 1995) and the 
observation that many patients with MTS lack a history of febrile seizures and that MTS is
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often unilateral (Swanson, 1995). It is possible that both camps are correct: MTS is both 
the cause and effect of seizures, in patients who have pre-existing factors that predispose 
the hippocampus to injury (Fisher et al, 1998; Lewis, 1999; Berkovic and Jackson, 2000). 
Such factors may be developmental, such as cortical dysgenesis (Raymond et al, 1994; 
Lewis, 1999), or genetic (Kanemoto et al, 2000). Thus, prolonged seizures in predisposed 
individuals induce neuronal loss which, in turn, leads to formation of new synaptic 
connections (Pringle et al, 1993) that can express abnormal hyperexcitability and cause 
more seizures (Swanson, 1995; Blumcke et al, 1999), resulting in a vicious cycle that 
ultimately leads to refractory epilepsy. However, it remains unclear why MTS should be 
particularly pharmacoresistant compared to other pathologies. This will be discussed 
further in Part I; Section 5.
1.4.3 Other symptomatic causes
Cortical dysplasia (CD) is a heterogenous disorder of cortical development and 
organisation. It may be completely asymptomatic, but is often manifest as epilepsy. There 
may be associated learning disabilities or cognitive deficits, and systemic features may be 
present (e.g. cutaneous lesions in tuberous sclerosis). Previously only detected at autopsy, 
CD is now increasingly recognised as a significant cause of epilepsy owing to the advent 
of MRI (Shorvon, 1997). In one MRI study, 25% of patients with refractory, apparently 
cryptogenic epilepsy were found to have underlying CD (Raymond et al, 1995), suggesting 
it may also be particularly pharmacoresistant. CD may result from defects at any phase of 
neural development, and the pathological features depend largely on the timing of the 
defect in the developmental process and to a lesser extent on the cause of the defect. Based 
on MRI findings, a wide variety of changes are recognised, including abnormalities of 
neocortical gyration (e.g. lissencephaly), megalencephaly, heterotopias, tuberous sclerosis, 
focal cortical dysplasia, CD associated with neoplasia (e.g. dysembryoplastic
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neuroepithelial tumour), dentate gyral abnormality, and microdysgenesis (Shorvon, 1997). 
The last abnormality has been suggested to underlie many “cryptogenic” epilepies or even 
IGE, but sophisticated MRI techniques are required for its detection in vivo (Sisodya et al, 
1996).
Epilepsy is one of the most common symptoms of primary brain tumours (Lieu and Howng, 
2000). Although they account for only approximately 5% of all newly diagnosed epilepsy 
(Hauser et al, 1993), 40% of adults presenting with new onset focal epilepsy are said to 
have cerebral neoplasms (Nashef, 1996). Slow growing tumours are more likely to present 
with seizures than rapidly growing ones (Villemure and de Tribolet, 1996). Ten to 30% of 
patients with chronic refractory focal epilepsy may have MRI-detectable low-grade 
cerebral tumours, many of which are missed by CT scan (Morris et al, 1998).
Vascular malformations include arteriovenous malformations (AVMs), cavernous 
haemangiomas, and venous and capillary malformations, although the latter is frequently 
an incidental finding and its causal relationship with epilepsy is unclear (Kraemer and 
Awad, 1994). AVMs are more likely to bleed (1-3% per year) than cavernous 
haemangiomas (around 0.5% per year; Moran et al, 1999). The latter is thought to be 
inherited in an autosomal dominant fashion with incomplete penetrance, and up to 75% of 
sporadic cases with multiple lesions are in fact familial cases when family members are 
screened by MRI (Labauge et al, 1998).
Stroke is the single most common cause of epilepsy in elderly people (Stephen and Brodie, 
2000). The risk of single or recurrent seizures after a stroke is estimated to be around 10% 
in the first 5 years (Bum et al, 1997). Seizures are more likely to be associated with larger
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haemorrhagic areas or infarction, and with cortical rather than subcortical involvement 
(Stephen and Brodie, 2000).
Post-traumatic epilepsy is an uncommon cause of epilepsy as a whole, but is considerably 
more frequent in the presence of depressed fracture, dural tear, focal signs, long post- 
traumatic amnesia and early seizures occurring within 1 week of the head injury (Jennett, 
1975). Convulsions occurring immediately on impact do not carry an excess risk of late 
epilepsy (McCrory et al, 1997). There is no evidence that prophylactic AED treatment 
prevents the development of late post-traumatic epilepsy (Chadwick, 2000). Although 
seizures are frequent during the acute phase of bacterial or viral meningoencephalitis, CNS 
infections are uncommon causes of chronic epilepsy (Hauser et al, 1993).
2 Diagnosis of epilepsy
The diagnostic procedure aims to determine whether the patient has epilepsy, and if so, the 
syndromic classification and underlying aetiology which can have implications on 
prognosis and choice of therapy (Brodie and French, 2000). A wide range of conditions 
may mimic epileptic seizures and must be considered in the differential diagnosis. 
Syncopal attacks, during which there may be clonic movements and incontinence, are 
commonly misdiagnosed as epileptic seizures (Smith et al, 1999). Pseudoseizures or 
nonepileptic psychogenic seizures are estimated to account for 10 to 45% of patients with 
apparently refractory epilepsy (Devinsky, 1999). Misidentification of other conditions as 
epilepsy leads to unnecessary and potentially harmful treatments and delay in initiating 
appropriate therapy as well as other deleterious psychosocial and socioeconomic 
consequences (Smith et al, 1999). The temptation to attach a label of “epilepsy” should be 
resisted when there is doubt and the physician (and patient) should simply await the 
passage of time before coming to a firm conclusion.
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2.1 History and examination
Despite dramatic advances in investigational techniques, the diagnosis of epilepsy remains 
essentially clinical, and is based on a detailed description of events experienced by the 
patient before, during, and after a seizure and, more importantly, on an eye witness account 
(Chadwick, 1994). Physical examination is usually unremarkable, although there may be 
focal neurological signs corresponding to any underlying focal structural abnormality.
2.2 Investigations
2.2.1 Neuroimaging
Neuroimaging aims to identify any underlying epileptogenic structural abnormalities and is 
indicated in patients suspected to have localisation-related epilepsy. MRI is undoubtedly 
the investigation of choice (Duncan, 1997). Since its initial application in 1984, its 
development has revolutionised the investigation and treatment of epilepsy. The 
superiority of MRI over X-ray computed tomography (CT) scanning in terms of sensitivity 
and specificity for identifying the aetiology of epilepsy in both adults and children is firmly 
established (Bronen, 1992; Duncan, 1997). The most common abnormalities identified by 
MRI are HS, CD, vascular malformations, tumours and acquired cortical damage. The 
“standard” MRI protocol includes Ti- and T2-weighted sequences covering the whole brain 
in at least two orthogonal planes, with the minimum slice thickness possible on the scanner 
used. Although quantitative volumetric measurement of the hippocampus is often used in 
specialist centres and research, in clinical practice, visual inspection has been shown to be 
comparable in sensitivity and specificity in detecting HS (Bronen et al, 1997; Cheon et al, 
1998; Kim et al, 1999). Rapid advances in MRI techniques, e.g. fluid attenuated inversion 
recovery (FLAIR) sequence, diffusion-weighted imaging, are likely to uncover the
26
underlying pathologies in many patients currently categorised as having “cryptogenic” 
epilepsy (Duncan, 1997).
CT should be used in preference to MRI only if the latter is contraindicated (e.g. in a 
patient with cardiac pacemaker, metal aneurysm clip, or severe claustrophobia), when there 
is the possibility of acute intracranial haematomas, or from a practical point of view, when 
MRI is not available.
Positron emission tomography (PET) may be used to map cerebral blood flow and regional 
cerebral glucose metabolism using appropriate radiolabelled tracers, and to demonstrate 
the binding of specific ligands. Single photon emission computerised tomography (SPECT) 
is less expensive than PET and has the added advantage of being able to detect changes in 
cerebral blood flow during a seizure, providing useful localisation information in partial 
seizures. Magnetic resonance spectroscopy (MRS) is another new technique for measuring 
cerebral metabolism, usually of selected neurotransmitters (Duncan, 1997). Currently, 
these imaging techniques are largely confined to presurgical evaluation or for research 
purposes.
2.2.2 Electroencephalography
Electroencephalography (EEG) remains valuable in providing support for the diagnosis of 
epilepsy and in aiding the classification of epilepsies and epilepsy syndromes (King et al,
1998). However, its limitations in the diagnostic setting must be recognised for proper 
interpretation (Binnie and Stefan, 1999). Approximately 0.5% of normal adults exhibit 
epileptiform activity on an EEG (Gregory et al, 1993). Even ictal EEG can be normal in 
partial seizures. About 15% of patients never show epileptiform activities on routine 
interictal EEG. A single routine interictal scalp EEG detects epileptiform abnormalities in
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only 50% patients with epilepsy, although the sensitivity can be substantially increased by 
performing within 24 hours of a seizure (King et al, 1998), repeat recordings (Salinsky et 
al, 1987), or recording during sleep (Binnie and Stefan, 1999). Activation techniques, such 
as hyperventilation and photic stimulation, can be helpful in uncovering abnormalities and 
identifying precipitating factors. Video-EEG telemetry is an essential part of preoperative 
evaluation for epilepsy surgery, and can provide conclusive evidence in diagnosing non­
epileptic pseudoseizures.
3 Treatment of epilepsy
3.1 Historical perspective
“There is scarcely a substance in the world capable of passing through the gullet of 
man that has not at one time or other enjoyed the reputation of being an 
antiepileptic.” -  Sir Edward Henry Sieveking, 1861.
Even when Hippocrates was trying to rationalise the condition, a regime of drugs, lifestyle 
changes, and dietary manipulation was formulated to treat epilepsy (Temkin, 1971).
Dietary measures ranged from the abstention from meat to the absolute avoidance of all 
food and drink. Phlebotomy and the drinking of urine or vinegar were other simple 
regimens, while more peculiar procedures included the provocation of sneezing before 
going to bed, rubbing of affected limbs with the genitals of the seal, or the ingestion of the 
genitals of various exotic animals. In many different cultures, skull trephination was 
carried out in an attempt to allow the escape of evil spirits (Gross, 1992).
Confusion between epilepsy, madness and spiritual possession in the Middle Ages might 
explain the continued reliance on magical potions or religious rituals, even by physicians.
thAlthough Jackson’s observations in the late 19 century with regard to the physiological
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basis of epilepsy were surprisingly accurate for their time, he continued to claim that 
“ there can be no question that ligature is a most valuable means of arresting such fits” 
(Jackson, 1873). Silver nitrate was commonly used in hospices around England, and 
Gowers listed mistletoe, turpentine, trephining and castration or circumcision as possible 
treatments (Gross, 1992).
Amid such a plethora of unproven (and ineffective) therapeutic interventions, bromide was 
welcomed enthusiastically as the first pharmacological treatment with demonstrated 
benefits. Working on the erroneous assumption that epilepsy was a manifestation of either 
hysteria or sexual frustration, Sir Charles Locock was able to achieve unprecedented 
results with potassium bromide (Locock, 1857). An improvement among 84% patients and 
a seizure-free rate of 32% were enviable even by today’s standard (Hammond, 1871). The 
ascendant position of bromides was further confirmed by Gowers, who might also be 
credited to be the first to advocate adjunctive pharmacotherapy including digitalis,
i L
belladona and cannabis (Gowers, 1881). By the end of the 19 century, 4 kg of bromides 
were being used annually at the National Hospital for Nervous Diseases (Shorvon and 
Sander, 1996). However, the toxicity of bromide therapy was soon to be recognised, 
notably afflictions of the skin and mental slowing, rendering it obsolete once a better 
tolerated alternative was found.
The discovery of the anticonvulsant properties of phenobarbital (PB) in 1912 heralded the 
beginning of the modem pharmacotherapy of epilepsy (Table 3). Unable to get a night of 
uninterrupted sleep having been assigned to a room above his ward of patients with 
epilepsy, Alfred Hauptmann, a German physician, provided them with a blanket 
prescription of PB as a hypnotic. To his surprise and delight, seizure frequency was 
reduced in many patients (Brodie and Dichter, 1997). In spite of its propensity to cause
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Table 3. Currently available antiepileptic drugs (AEDs) and the UK launch dates of the 
new agents.
“Established” AEDs “New” AEDs
Barbiturates (phenobarbital, primidone) Vigabatrin*J 1989
Benzodiazepines (clobazam, clonazepam) Lamotrigine 1991
Phenytoin Gabapentin*f 1993
Carbamazepine Topiramate* 1995
Sodium valproate Tiagabine* 1998
Ethosuximide Fosphenytoin 1998
Acetazolamide Oxcarbazepine 2000
Levetiracetam* 2000
Felbamatet ) Available in
Zonisamide ) other countries
* Only licensed as add-on treatment in the UK. 
t  Licensed as monotherapy in some countries but not in the UK. 
J Licensed as monotherapy for infantile spasms.
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sedation and other cognitive and behavioural side effects, PB remained unrivalled for the 
treatment of epilepsy for almost 30 years and is still widely used in developing countries 
as it is inexpensive and easy to use. Phenytoin (PHT) was discovered as the result of the 
search by Merrit and Putnam (1938) for a non-sedatory analogue of PB by screening a 
wide variety of compounds against electrically induced seizures in animals.
Carbamazepine (CBZ) was manufactured by Schindler at Geigy in 1953. It was originally 
developed as an antipsychotic and its antiepileptic properties were not observed clinically 
until 1963 (Brodie and Dichter, 1997). The clinical utility of sodium valproate (VPA) was 
unknown until its anticonvulsant activity was fortuitously discovered in 1963 by Meunier 
who used it as a solvent in testing other potential AEDs (Fariello et al, 1995).
Ethosuximide (ESM) for absence seizures, primidone, a prodrug of PB, acetazolamide, and 
some benzodiazepines (BDZ), particularly clobazam (CLB) and clonazepam, have also 
become available between the 1950s and 1980s. But it was the late 1980s when the 
number of AEDs started to increase dramatically (Figure 2).
No less than 9 new AEDs have become available worldwide since 1989. Lamotrigine 
(LTG) was developed on the erroneous hypothesis that the effectiveness of an AED might 
be related to its antifolate properties (Reynolds et al, 1966). Zonisamide (ZNS), felbamate 
(FBM) and topiramate (TPM) were discovered by random drug screening using animal 
seizure models (White, 1997). Oxcarbazepine (OXC) was derived from CBZ in order to 
mimic the latter’s action while improving its side effect profile (Macdonald and Kelly, 
1995). Fosphenytoin is a prodrug of PHT and was developed as an alternative method of 
administering parental PHT in status epilepticus with better tolerability and safety profile 
(Luer, 1998). Vigabatrin (VGB), tiagabine (TGB) and gabapentin (GBP) can be claimed 
as the results of rational drug development. They were designed to facilitate the inhibitory 
action of y-aminobutyric acid (GABA), although the mechanism of GBP remains to be
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definitively determined. The anticonvulsant effect of levetiracetam (LEV), the latest AED 
introduced, was initially undetected by the traditional seizure models and only discovered 
by further investigation in alternative models (Bialer et al, 1999). Retigabine, pregabalin, 
and rufmamide, to name only a few, are compounds currently under development as novel 
AEDs.
Such rapid expansion of the pharmacopoeia in the last decade results partly from greater 
appreciation of the role of amino acids in neurotransmission, leading to a search for drugs 
with discrete, well-defined neurochemical actions. It is also testimony to the fact that 
many patients continue to suffer from recurrent seizures despite AED treatment. The 
“magic bullet” to pass through their gullet is yet to be found.
3.2 Mechanisms of action of antiepileptic drugs
It is important to appreciate the mode of action of the AEDs since it may be one of the 
criteria when making an appropriate drug choice for the individual patient, both as 
monotherapy and in combination treatment. Patients not responding to one AED may 
become seizure-free when changed to another with a different mode of action (Brodie et al, 
1999b). A mechanistic approach may also provide a template for rational combination 
therapy. There is accumulating clinical data suggesting combination of a Na+ channel 
blocker with a drug that enhances GABAergic inhibition or has multiple actions may be 
efficacious (Stolarek et al, 1994; Brodie et al, 1997b; Deckers et al, 2000). In addition, 
understanding the mode of action of the AEDs may shed light on the pathophysiology of 
seizures and epilepsy, which in turn may provide a framework for more rational drug 
development.
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Although the mode of action of the currently marketed AEDs is still not fully understood, 
at the cellular level, three basic mechanisms are recognised (Table 4): modulation of 
voltage-dependent ion (Na+, Ca2+, K+) channels, enhancement of GABA-mediated 
inhibitory neurotransmission, and inhibition of excitatory (particularly glutamate-mediated) 
transmission.
These targets of AED action will be briefly discussed and the mechanisms of action of the 
AEDs relevant to the studies described in this thesis will be outlined below. They include 
the established drugs PB, PHT, CBZ and VP A, and the newer agents LTG, OXC, GBP, 
TPM, VGB and TGB. They are grouped below according to their "primary" mode of 
action, although many less well-characterised, "minor" mechanisms may well contribute to 
a drug’s antiepileptic effect. Some drugs exert their antiepileptic effect via multiple 
mechanisms, while the primary mode of action of some others is yet to be discovered.
3.2.1 Sodium channels
In the nervous system, voltage-gated ion channels control the flow of cations across 
surface and internal cell membranes (Barchi, 1998). Of these, the Na+ channel is arguably 
of principal importance. The main structural component of the neuronal Na+ channel is the 
a-subunit which forms the ion conducting pore and confers voltage-dependency (Catterall, 
1992). In mammalian brain, the a-subunit associates with two auxiliary subunits 
designated (31 and (32. The p-subunits are not required for basic Na+ channel activity, but 
modulate the expression and function of individual channels (Ragsdale and Avoli, 1998).
Voltage-dependent Na+ channels are responsible for the upstroke of the neuronal action 
potential and ultimately control the intrinsic excitability of the nervous system (Porter and
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Table 4. Proposed mechanisms of action of antiepileptic drugs. (Upton, 1994; Macdonald 
and Kelly, 1995; Schachter, 1995; Meldrum, 1996; Coulter, 1997; White, 1999)
lN a +
channels
-l Ca2+ 
channels
T k +
channels
T g a b a
transmission
I  glutamate 
transmission
Established
Phenytoin +++
Carbamazepine +++ +
Valproate + + ++ +
Ethosuximide +++
Phenobarbital + +++ +
Benzodiazepines +++
Newer
Lamotrigine +++ +
Vigabatrin +++
Gabapentin + + ++
Topiramate ++ ++ ++ ++
Felbamate ++ + ++ ++
Tiagabine +++
Oxcarbazepine +++ + +
Zonisamide ++ ++
Levetiracetam + + +
+++ = primary action; ++ = probable action; + = possible action
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Rogawski, 1992). At normal membrane potentials, most Na+ channels exist in a closed, 
resting state. Upon depolarisation, the channel activates, facilitating ion flux. Thereafter, 
the Na+ channel enters an inactivated state from which it is not readily re-activated. 
Repolarisation of the neuronal membrane rapidly converts the channel back to a resting 
state, from which it can respond to subsequent depolarisations (Catterall, 1992; Ragsdale 
and Avoli, 1998). Neuronal Na+ channels can cycle through these functional states within 
a few milliseconds. This characteristic is essential for sustaining the rapid bursts of action 
potentials necessary for some normal brain functions and is implicated in epileptic 
discharges. The neuronal Na+ channel represents one of the most important targets for 
AED action (Upton, 1994; Macdonald and Kelly, 1995; Meldrum, 1996; White, 1999).
3.2.2 Calcium channels
94 -Voltage-sensitive Ca channels can be broadly classified into low or high threshold, 
according to the membrane potential at which they are activated (Hofmann et al, 1994).
The low threshold T-type Ca2+ channel is expressed predominantly in thalamocortical relay 
neurones where it is believed to be instrumental in the generation of the rhythmic 3-Hz 
spike-and-wave discharge, characteristic of generalised absence seizures (Coulter et al, 
1989a). It is the well-recognised target of ESM (Coulter et al, 1989b; 1989c). High
94 -threshold Ca channels are subclassified by their pharmacological properties into L-, N-,
P-, Q- and R-types (Hofmann et al, 1994; Catterall, 1995; Dolphin, 1995). These channels 
are distributed throughout the nervous system on dendrites, cell bodies and nerve terminals. 
The N-, P- and Q-type channels, in particular, have been implicated in the control of 
neurotransmitter release at the synapse (Stefani et al, 1997).
• 2+Interest in Ca channels has heightened in recent years following the identification of 
subunit specific genetic mutations which can alter channel structure and/or function and
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which have been implicated in several human neurological diseases (Ophoff et al, 1998).
^  I
Several AEDs have also been reported to block voltage-sensitive Ca channels, in a 
subtype-specific manner, an effect that may contribute to their antiepileptic actions (Stefani 
et al, 1997).
3.2.3 Potassium channels
At the neuronal level, K+ channels are intimately involved in excitability. They are 
responsible for the action potential downstroke or, more specifically, repolarisation of the 
plasma membrane in the aftermath of Na+ channel activation (Pongs, 1999). Direct 
activation of voltage-dependent K+ channels hyperpolarises the neuronal membrane and 
limits action potential firing (Porter and Rogawski, 1992). Accordingly, K+channel 
activators have anticonvulsant effects in some experimental seizure models (Gandolfo et al, 
1989; Rostock et al, 1996), whereas K+ channel blockers precipitate seizures (Yamaguchi 
and Rogawski, 1992).
3.2.4 GABA-mediated inhibition
GAB A is the predominant inhibitory neurotransmitter in the mammalian central nervous 
system where it is released at up to 40% of all synapses (Olsen and Avoli, 1997). GAB A 
is synthesised from glutamate, exclusively in GABAergic neurones, by the action of the 
enzyme glutamic acid decarboxylase (GAD; Loscher, 1999). Upon synaptic 
release, GABA acts on its three specific receptors, GABAa, GABAb and the newly 
characterised GAB Ac. GABA receptors are distinguished by their pharmacology and 
functions (Johnston, 1996). The GABAa receptor belongs to the ligand-gated ion channel 
superfamily and responds to GABA binding by increasing Cl" conductance, resulting in 
neuronal hyperpolarisation (Rabow et al, 1995). GABAb receptors are G-protein-linked, 
activation of which leads to an increase in K+ conductance (Olsen and Avoli, 1997). It has
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recently been proposed that GABAa and GABAb receptors may have evolved from the 
GABAc receptor which is comparatively simpler in structure and pharmacology (Johnston,
1996).
Following receptor activation, GABA is removed from the synaptic cleft, into localised 
nerve terminals and glial cells, by specific membrane-bound transport molecules. Currently, 
four active transport systems, GAT-1, GAT-2, GAT-3 and BGT-1, have been described 
(Borden et al, 1992). GABA has a variable affinity for these transporters and only GAT-1, 
predominantly located in the cerebral cortex and hippocampus, has GABA as its principal 
substrate (Gaustella et al, 1990). After removal from the synapse, GABA is either recycled 
to the readily releasable neurotransmitter pool (GABAergic nerve terminals only) or 
metabolised (neurones and glial cells) to the inactive molecule succinic acid semialdehyde 
by the action of the mitochondrial enzyme GABA-transaminase (GABA-T; Meldrum,
1995).
Impairment of GABA function is widely recognised to provoke seizures, whereas 
facilitation has an anticonvulsant effect (Loscher, 1999). Accordingly, potentiation of 
GABA is regarded as one of the most attractive, and successful, mechanisms of AED 
action and can be achieved by increased synthesis, increased release, allosteric receptor 
facilitation or reduced inactivation (Sills et al, 1999; Figure 3).
3.2.5 Glutamate-mediated excitation
Glutamate is the principal excitatory neurotransmitter in the mammalian brain (Meldrum, 
2000). Focal injection of glutamate induces seizures in animals, and over-activation of 
glutamatergic transmission or abnormal glutamate receptor properties are observed in 
certain experimental seizure models and human epilepsy syndromes (Meldrum, 1995).
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Following synaptic release, glutamate exerts its pharmacological effects on several 
receptors, categorised into ionotropic and metabotropic families. The former are classified 
into three specific subtypes, AMP A (a-amino-3-hydroxy-5-methyl-isoxazole-4-propionic 
acid), kainate and NMD A (N-methyl-D-aspartate), which form ligand-gated ion channels, 
permeable to Na+ and, depending on subtype and subunit composition, Ca2+ ions (Trist, 
2000). The NMD A receptor is further distinguished by having glycine as a co-agonist.
The AMPA and kainate subtypes of glutamate receptor are implicated in fast excitatory 
neurotransmission, whereas the NMDA receptor, quiescent at resting membrane potential, 
is recruited during periods of prolonged depolarisation (Meldrum, 2000). The metabotropic 
family of glutamate receptors, also classified into three distinct subtypes (Groups I, II and 
III), are G-protein linked and predominantly pre-synaptic, possibly controlling 
neurotransmitter release (Meldrum, 2000).
Although none of the commonly used AEDs exert their pharmacological effects solely by 
an action on the glutamate system, blockade of ionotropic glutamate receptors is believed 
to contribute to the antiepileptic activity of several compounds (Upton, 1994; Macdonald 
and Kelly, 1995; Meldrum, 1996; White, 1999). In addition, several AEDs have been 
reported to reduce glutamate release, although this effect may be more indicative of their 
actions on neuronal calcium channels than a direct effect on the glutamate system (Stefani 
et al, 1997).
3.2.6 Modulation of ion channels
3.2.6.1 Phenytoin
PHT is the prototypic antiepileptic Na+ channel blocker (Rogawski and Porter, 1990; 
Ragsdale and Avoli, 1998). It blocks Na+ currents in a voltage- and frequency-dependent 
fashion by prolonging the inactivation phase (Tunnicliff, 1996). As a result, it produces a
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reduction in the frequency of sustained repetitive firing of action potentials without 
affecting their amplitude or duration (McLean and Macdonald, 1983). An effect on 
persistent Na+ currents by PHT has also been suggested (Lampl et al, 1998).
3.2.6.2 Carbamazepine
Like PHT, CBZ has been shown to stabilise the inactive form of Na+ channels in a voltage-, 
frequency-, and time-dependent fashion (Courtney and Etter, 1983). However, subtle but 
important differences in binding characteristics (Kuo et al, 1997) and effectiveness of 
blockade (Schwartz and Grigat, 1989) between the two drugs may contribute to their 
different clinical profile (see Table 5). CBZ may also exert its antiepileptic effect via 
inhibition of glutamatergic transmission (Waldmeier et al, 1995; Hough et al, 1996).
Effects on the serotonin (Dailey et al, 1997a; 1997b) and adenosine (Marangos et al, 1983) 
systems have been reported. Whether these additional actions contribute to the 
anticonvulsant effects of the drug is unclear.
3.2.6.3 Lamotrigine
There is no evidence that LTG’s antiepileptic activity is related to its weak antifolate effect 
(Macdonald and Kelly, 1995). Instead, like PHT and CBZ, it acts primarily by blocking 
Na+ channels in a voltage- and use-dependent fashion (Cheung et al, 1992; Lang et al, 1993; 
Zona and Avoli, 1997). Its broader clinical and preclinical profiles suggest LTG may 
differ from PHT and CBZ in its effects on Na+ currents. Unlike PHT, LTG acts principally 
on the slow inactivated state of the sodium channel (Kuo and Lu, 1997). In addition, LTG 
may exhibit differential sensitivity for the various a-subunits of the channel (Coulter,
1997). It has been suggested that LTG may selectively target Na+ channels on neurones 
that synthesise glutamate and aspartate (Leach et al, 1986)
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In addition to Na channel effects, LTG reduces whole-cell Ca currents in rat amygdalar 
neurones, possibly via the N- and P-type channels (Wang et al, 1996; Stafani et al, 1997). 
This might explain the inhibition of electrically stimulated glutamate release from rat 
spinal dorsal horn slices observed with the drug (Teoh et al, 1995). It remains possible, 
however, that LTG possesses additional unidentified mechanisms that confer its relatively 
broader clinical spectrum when compared with other Na+ channel blocking agents.
3.2.6.4 Oxcarbazepine
OXC is a structural analogue of CBZ. Keto substitutions at the 10, 11 positions of the 
dibenzazepine nucleus do not affect the therapeutic profile of the drug when compared to 
CBZ, but result in altered biotransformation and better tolerability (Macdonald and Kelly, 
1995). OXC is essentially a pro-drug and is rapidly and completely reduced in the liver to 
its active metabolite, 10, 11-dihydro-10-hydroxycarbazepine (MHD; McLean et al, 1994). 
Both OXC and MHD appear to act primarily by blocking voltage-dependent Na+ channels 
in a manner similar to that reported for PHT and CBZ (McLean et al, 1994). Blockade of
• 9 *1* ^high-threshold Ca currents (Stefani et al, 1997) and promotion of K channel 
conductance (McLean et al, 1994) have also been suggested.
3.2.7 Potentiation of GABA
3.2.7.1 Barbiturates and benzodiazepines
PB exerts its pharmacological effects by allosteric activation of the GABAa receptor, 
increasing the duration of chloride channel opening, without affecting frequency of 
opening or channel conductance (Macdonald et al, 1989; Twyman et al, 1989). The 
barbiturates can also activate the GABAa receptor directly, in the absence of GABA, an 
effect that may underlie their sedative properties (Rho et al, 1996; White, 1999).
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Unlike PB, the benzodiazepines, such as clonazepam and clobazam, increase the frequency 
of chloride channel opening, without affecting open duration or channel conductance 
(Study and Barker, 1981; Twyman et al, 1989). They are unable to directly activate the 
GABAa receptor in the absence of GABA (White, 1999).
3.2.7.2 Vigabatrin
VGB is an ethyl analogue of GABA that is widely recognised to exert its pharmacological 
effects by irreversible inhibition of GABA-T, the enzyme responsible for the catabolism of 
GABA (Jung et al, 1977). As a consequence, it elevates GABA levels, and thus 
potentiates inhibitory neurotransmission, throughout the brain (Schechter et al, 1977). A 
single dose of VGB reduces mouse brain GABA-T activity to around 20% of control levels 
and produces a 4 -  fold increase in whole brain GABA concentrations. This effect persists 
for over 24 hours, with GABA-T activity and GABA concentrations only returning to 
normal upon the synthesis of new enzyme protein over a period of 4 -  5 days (Schechter et 
al, 1977). Similar effects on the GABA system are also observed in man (Petroff et al, 
1996a).
3.2.7.3 Tiagabine
TGB is an analogue of nipecotic acid, a prototypic GABA uptake blocker, which is widely 
recognised to prevent GABA transport into both neurones and glial cells (Krogsgaard- 
Larsen et al, 1987). Nipecotic acid, however, fails to cross the blood-brain barrier 
following systemic administration. This problem is overcome by linking it to a lipophilic 
anchor to form TGB which is able to cross the blood-brain barrier more readily (Brodie,
1995). TGB inhibits GABA uptake predominantly by an action on the GAT-1 transporter 
with little or no activity on GAT-2 or GAT-3 (Braestrup et al, 1990; Borden et al, 1994).
As a result, the pharmacological effects of TGB reflect the regional distribution of GAT-1
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and are mainly restricted to the cerebral cortex and hippocampus (Meldrum and Chapman, 
1999).
Unlike VGB, which elevates whole brain GABA concentrations, TGB temporarily 
prolongs the presence of GABA in the synaptic cleft (Sills et al, 1999). In rat hippocampal 
slices, TGB prolongs the duration, but not the magnitude, of the peak inhibitory 
postsynaptic current, consistent with delayed clearance of GABA from the synapse 
(Roepstorff and Lambert, 1992). Inhibition of GABA uptake is the only known 
mechanism of TGB action.
3.2.8 Drugs with multiple mechanisms of action
3.2.8.1 Sodium valproate
The precise mechanisms by which VPA exerts its antiepileptic effects remain to be 
conclusively determined. One possible action is blockade of voltage-dependent Na+ 
channels, in a manner similar to that reported for PHT and CBZ (McLean and Macdonald, 
1986; van Dongen et al, 1986; Zona and Avoli, 1990). Another possible mechanism of
^  I t
action is inhibition of Ca currents in a fashion similar to that described for ESM, which 
may explain its effectiveness against generalised absence seizures. However, its reduction 
of T-type Ca currents in rat primary afferent neurones is modest and requires relatively 
high concentrations (Kelly et al, 1990). There is evidence to suggest that VPA elevates 
whole brain GABA levels and potentiates GABA responses, possibly by enhancing GAD 
activity and inhibiting GABA degradation (Loscher, 1999). Acute doses of VPA decrease 
brain levels of the excitatory amino acid aspartate, without influencing those of glutamate 
or GABA (Schechter et al, 1978). The potential contribution of any of the above effects to 
the clinical activity of VPA remains to be determined.
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3.2.8.2 Topiramate
The sulfamate derivative TPM possesses multiple mechanisms of action, including 
inhibition of Na+ and Ca2+ currents, blockade of the AMPA/kainate subtype of glutamate 
receptor, and facilitation of GABA. It also inhibits carbonic anhydrase, although this 
effect is not believed to contribute to its antiepileptic action (Shank et al, 1994).
TPM reduces voltage-dependent Na+ currents in cultured cerebellar granule cells (Zona et 
al, 1996). In this respect, its action is similar to that of PHT and CBZ, delaying recovery 
of Na+ channels from the inactive state. It has also been reported that TPM blocks whole 
cell Ca2+ currents, possibly by an action on the high-voltage-activated L-type channel 
(Zhang et al, 2000a). In hippocampal neurones, TPM blocks inward currents evoked by 
kainate but not NMDA (Coulter et al, 1995), implying a selective effect on the AMPA / 
kainate subtype of glutamate receptor. TPM also interacts with the GABAa receptor. It 
enhances GABA-stimulated chloride flux into cerebellar granule neurones and increases 
chloride currents evoked by GABA in mouse cerebral cortical neurones (White et al, 1997). 
TPM elevates brain levels of GABA and its metabolites in patients with refractory epilepsy 
(Petroff et al, 1999).
3.2.8.3 Gabapentin
GBP was originally designed to mimic the action of GABA, but subsequent studies have 
shown that it does not directly interact with GABA receptors (Taylor et al, 1998) or 
transporters (Su et al, 1995; Macdonald and Greenfield, 1997). There is evidence that 
GBP may increase the synthesis (Taylor et al, 1992) and non-vesicular release of GABA 
(Gotz et al, 1993) and prevent its metabolism (Leach et al, 1997). Using [!H] nuclear 
magnetic resonance spectroscopy, GBP has been shown to elevate GABA concentrations 
in the occipital cortex of epileptic patients (Petroff et al, 1996b). Whether this observation
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is the result of enhanced synthesis, increased release or reduced metabolism of GABA 
remains to be determined.
Early efforts to identify the mechanism of GBP proposed an interaction with the L-amino 
acid transport system resulting in alterations in the cytosolic and extracellular 
concentrations of several amino acids, including L-leucine, L-valine and L-phenylalanine 
(Su et al, 1995). Inhibition of branched chain amino acid transferase and augmentation of 
glutamate dehydrogenase activities have also been mooted (Goldlust et al, 1995).
Evidence supporting an influence on neuronal firing via an effect on Na+ channel function 
by GBP is conflicting (Taylor et al, 1988; Wamil and McLean, 1994).
The identification of a specific binding site for GBP in mammalian brain, and its 
subsequent unveiling as the a25 subunit of the L-type voltage-dependent calcium channel 
(Gee et al, 1996), suggested another potential pharmacological mechanism. The 
implications of these findings remain to be fully investigated, but the lack of effect of GBP 
on whole cell Ca currents in human dentate granule cells acutely isolated from patients 
with temporal lobe epilepsy (Schumacher et al, 1998) questions the relevance of this 
finding.
3.3 Clinical use of antiepileptic drugs
3.3.1 Initiation of treatment
The goal of treatment should be restoration of a normal life through complete control of 
seizures with minimal or no side effects, unless there is a good reason to be less ambitious. 
Most patients with recurrent seizures require treatment. The exceptions are those with 
provoked seizures which can be avoided by lifestyle changes (e.g. alcohol related seizures), 
or those with widely separated episodes (Brodie and Dichter, 1996). The question of
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whether to treat a single seizure is contentious. Depending on other risk factors, only 30- 
70% of people will have further attacks (i.e. epilepsy) after an unprovoked seizure (Hauser 
et al, 1990; Shinnar et al, 1990). A recent multicentre randomised study showed that while 
treatment after a single seizure reduced the chance of recurrence, it did not alter the long­
term prognosis (Musicco et al, 1997). All AEDs have side effects, some potentially 
serious. It would, therefore, seem reasonable to withhold treatment until a second event 
occurs. Patients with underlying cerebral lesions or specific syndromes, such as juvenile 
myoclonic epilepsy, are at higher risk of developing recurrent seizures and should probably 
be treated after one episode (Brodie and Dichter, 1997). The wishes of the patient, which 
may include consideration of employment and driving, should also be taken into account. 
The decision about treatment should only be made after ample discussions with the patient 
about the risks and benefits of treatment (Perucca et al, 2000). Treatment is doomed to 
failure in an uncooperative patient. Compliance can be monitored for some drugs with the 
aid of measurement of plasma concentration (McKee and Brodie, 1997).
Whether used as monotherapy in a newly diagnosed patient or polytherapy for refractory 
seizures, AEDs should be chosen by “matching” the individual characteristics of the 
patients (age, gender, body habitus, concomitant disease and medications), the seizure 
disorder (seizure type, epilepsy syndrome), and the drug (mode of action, range of efficacy, 
tolerability, side effect and interaction profiles; Tables 5 and 6 ).
3.3.2 Monotherapy for newly diagnosed epilepsy
Since the advantages of monotherapy over multiple-drug treatment, particularly in terms of 
side effect profile, were demonstrated by a series of studies in the late 1970s and early 
1980s (Shorvon and Reynolds, 1977; Shorvon and Reynolds, 1979; Reynolds and Shorvon,
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Table 5. Efficacy of antiepileptic drugs against common seizure types (Brodie and Kwan, 
2001).
Drug Partial Secondary generalised Tonic-clonic Absence Myoclonic
Carbamazepine + + + - -
Gabapentin + + ?+ ? -
Lamotrigine + + + + +
Oxcarbazepine + + + ? ?
Phenobarbital + + + 0 ?+
Phenytoin + + + - -
Sodium valproate + + + + +
Tiagabine + + ?+ - ?
Topiramate + + + ? +
Vigabatrin + + 0 - -
Key: + proven efficacy, ?+ probable efficacy, 0 ineffective, - worsens seizures, ? unknown
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Table 6. Factors to be considered when choosing an antiepileptic drug regimen (Brodie and
Kwan, 2001).
Patients Seizures Drugs
Infants/Children First seizure Mechanism
Teenagers Newly diagnosed Kinetics
Pregnancy Idiopathic Efficacy
Elderly Localisation-related Toxicity
Learning disabled Syndrome Interactions
Concurrent diseases Refractory Teratogenicity
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1981; Schmidt, 1982; Schmidt, 1983), monotherapy has rightly become the established 
principle for managing new onset epilepsy. Significant differences in efficacy as 
monotherapy have not been consistently demonstrated for the common seizure types in 
clinical trials among the established AEDs (Mattson et al, 1985; Callaghan et al, 1985; 
Mattson et al, 1992; Richens et al, 1994; De Silva et al, 1996). A few studies have 
compared a modem agent with an established one (Brodie et al, 1995; Bill et al, 1997; 
Guerreiro et al, 1997; Christie et al, 1997; Chadwick et al, 1998; Brodie et al, 1999a, 
Chadwick, 1999) or with another new AED (Brodie et al, in press). Since the majority of 
newly diagnosed patients will have a good prognosis (see Part I; Section 4.2), the emphasis 
for them is tolerability and the avoidance of potentially serious side effects or chronic 
complications of long-term treatment (Brodie, 1999).
3.3.3 Combination therapy for refractory epilepsy
The controversy of management strategy arises mainly after the first AED proves 
ineffective. Despite being commonly used in patients unresponsive to monotherapy, when 
and how AED combinations should be employed has not been well studied. An alternative 
drug is unavoidable when the patient develops intolerable adverse events, but when 
seizures persist despite a sufficient dose being tolerated, it is unclear whether or not 
substitution should be tried before a combination of two drugs is used (Schmidt and Gram,
1995). Advocates of persistence with alternative monotherapy point to the toxicity of 
polytherapy and success of alternative drugs, as demonstrated in the Veteran Affairs study 
(Mattson et al, 1985). However, in this study many patients were initially treated with PB 
or primidone, neither of which would nowadays be considered as a first line drug in 
industrialised countries. The arrival of new AEDs in the past decade, with their diverge 
mechanisms of action and generally better tolerability, has raised the possibility of
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effective and safe combinations for patients unresponsive to monotherapy (Brodie, in 
press).
Although data directly evaluating the effectiveness of AED combinations are scarce, some 
regimens, such as VPA with ESM for absence seizures (Rowan et al, 1983), VPA with 
LTG for partial-onset and generalised seizures (Brodie et al, 1997b), LTG with VGB for 
partial seizures (Stolarek et al, 1994; Schapel et al, 1996), VGB and TGB for partial 
seizures (Leach and Brodie, 1994), and LTG with TPM for a range of seizure types 
(Stephen et al, 1998) have been suggested to have additive or even synergistic effects.
A related question is at what dose a drug should be deemed non-efficacious and alternative 
treatment, whether substitution or combination therapy, be considered. The usual 
recommendation of escalating the dose to near-toxic levels in patients with persistent 
seizures (Perucca, 1996) assumes a positive dose-response relationship. Direct evidence 
supporting this approach is lacking. Such controversies concerning management approach 
arise largely because the “natural history” of newly diagnosed epilepsy in response to 
treatment is not well understood. This problem will be further discussed in Part I; Section 
4.
The clinical properties of the AEDs relevant to the studies described in this thesis will be 
outlined below.
3.3.4 Established antiepileptic drugs
3.3.4.1 Phenobarbital
PB is the oldest among the currently licensed AEDs (see Part I; Section 3.1) and is 
indicated for the treatment of both partial and GTCS (Brodie and Dichter, 1996). Despite
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being similarly efficacious, PB is less well tolerated than CBZ and PHT, mainly due to its 
sedative, cognitive and behavioural side effects (Mattson et al, 1985). PB is the archetypal 
enzyme inducer and so can accelerate the metabolism of a range of lipid soluble drugs 
(Patsalos and Duncan, 1993). For these reasons, it is rarely prescribed as a first-line AED 
for adults with newly diagnosed epilepsy in the industrialised world, although its low cost 
is relevant to its widespread use in developing countries.
3.3.4.2 Phenytoin
PHT is also effective against partial and GTCS. It is one of the few drugs in clinical use 
whose pharmacokinetics change from first to zero order at therapeutic dosage (Thomson 
and Brodie, 1992). To avoid toxicity, frequent monitoring of the plasma level is required. 
PHT is an enzyme inducer and a target for enzyme inhibitors (Brodie and Dichter, 1996). It 
can produce a range of neurotoxic symptoms and long-term cosmetic changes (gum 
hypertrophy, acne, hirsutism, facial coarsening). PHT is also teratogenic.
3.3.4.3 Carbamazepine
CBZ is effective against partial and GTCS, but can exacerbate myoclonic and absence 
seizures (Brodie and Dichter, 1996). Superior efficacy of CBZ (Mattson et al, 1992) as 
monotherapy for partial seizures over PHT and VPA has not be consistently demonstrated 
(Callaghan et al, 1985; Richens et al, 1994; Heller et al, 1995; De Silva et al, 1996). Its 
neurotoxic profile has been highlighted in comparative monotherapy studies (Brodie et al, 
1995; Chadwick et al, 1998; Brodie et al, 1999a; Chadwick, 1999). Rash is common (10%) 
and may necessitate withdrawal of treatment. Other potentially serious idiosyncratic 
reactions include hepatotoxicity and blood dyscrasia. CBZ induces its own metabolism as 
well as that of other lipid-soluble drugs and is a target for inhibitors (Brodie, 1992). It is 
also teratogenic.
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3.3.4.4 Sodium valproate
VPA is effective in patients with all types of seizures, with particular value in the IGEs 
(Brodie and Dichter, 1996). There is accumulating evidence to support a synergistic effect 
with LTG across a range of seizure types (Panayiotopoulos et al, 1993; Ferrie and 
Panayiotopoulos, 1994; Veggiotti et al, 1994; Brodie et al, 1997b; Pisani et al, 1999). VPA 
is easy to use and does not require routine monitoring of plasma concentration. It is 
generally well tolerated. Weight gain may be troublesome in some patients. An 
association with polycystic ovarian syndrome and hyperinsulinaemia in young women has 
been suggested recently (Isojarvi et al, 1993), although the overall impact is likely to be 
small and other predisposing factors may play a role (Stephen et al, 2000). Hepatotoxicity 
is rare (Dreifuss et al, 1987), but dose-related tremor and thrombocytopaenia are more 
common. In utero exposure to VPA increases the risk of neural tube defects to 1-2% 
(Crawford et al, 1999). VPA inhibits the metabolism of other AEDs, particularly PHT, PB, 
CBZ and its epoxide, and LTG (McKee and Brodie, 1994).
3.3.5 New antiepileptic drugs
The majority of the newer AEDs have been licensed only as adjunctive therapy, with the 
exception of LTG and OXC which are also available as monotherapy in the UK. GBP is 
approved as monotherapy in other parts of the world, while VGB can be used as 
monotherapy for infantile spasm. Many possess a diverse mechanistic profile (Table 4). 
Compared with their older counterparts, the newer AEDs tend not to affect hepatic 
metabolising enzymes, and are thus less prone to pharmacokinetic interactions (Brodie,
1992). There is also a growing impression that some of the more modem drugs, e.g. LTG 
and GBP, are more tolerable in their neurotoxicity profile (Kalviainen et al, 1996; Brodie,
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1999). There are still insufficient monotherapy data in humans to confirm lack of 
teratogenicity with the newer AEDs (Morrell, 1996).
3.3.5.1 Lamotrigine
LTG has a wide spectrum of activity (Brodie, 1996). It is not sedative and generally well 
tolerated. It has demonstrated similar efficacy but better tolerability than PHT (Steiner et 
al, 1994) and CBZ (Brodie et al, 1995) in double-blind monotherapy trials in patients with 
partial and GTCS. There is evidence supporting an additive or synergistic effect when 
LTG is combined with VPA or TPM (Part I; Section 3.3.3). Rash occurs particularly in 
those receiving VPA, but the risk can be reduced by low dosage introduction and slow 
titration (Guberman et al, 1998). Animal and human data so far suggest low teratogenic 
potential (Crawford et al, 1999), although longer observation is required for confirmation. 
Drug interactions occur only with other AEDs.
3.3.5.2 Gabapentin
GBP is effective against partial-onset seizures and has few side effects (Dichter and Brodie,
1996). It was particularly well tolerated in add-on trials (Marson et al, 1997) and in 
monotherapy comparisons with CBZ (Chadwick et al, 1998) and LTG (Brodie et al, in 
press). No pharmacokinetic interactions with other drugs have been reported with GBP. 
Weight gain has been reported at high dosage (DeToledo et al, 1997).
3.3.5.3 Oxcarbazepine
OXC has a similar extent and range of efficacy to CBZ as monotherapy (Dam et al, 1989), 
but causes fewer idiosyncratic reactions and neurotoxic side effects (Shorvon, 2000). It is 
as effective for partial seizures with or without generalisation as PHT (Bill et al, 1997; 
Guerreiro et al, 1997) and VPA (Christie et al, 1997), although it was clearly better
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tolerated than the former. OXC selectively induces the metabolism of female sex 
hormones, necessitating high oral contraceptive dosage (Fattore et al, 1999).
3.3.5.4 Topiramate
Although not always tolerated, TPM is highly efficacious for patients with refractory 
epilepsy (Marson et al, 1997; Stephen et al, 2000). It has a broad spectrum of action, being 
effective against partial-onset seizures as well as primary GTCS (Wilson and Brodie,
1996). Side effects include fatigue, paraesthesia and weight loss, less commonly word- 
finding difficulties, and rarely renal calculi. Its metabolism is induced by PHT and CBZ 
(Dichter and Brodie, 1996), and it selectively induces the metabolism of the hormonal 
components of the oral contraceptive pill (Rosenfeld et al, 1997).
3.3.5.5 Tiagabine
TGB is effective for treatment of partial seizures with or without secondary generalisation 
(Leach and Brodie, 1998). Its major practical drawback in clinical use is a short 
elimination half-life of 6 - 8  hours, which is further reduced by enzyme-inducing AEDs, 
such as PHT and CBZ, necessitating thrice-daily dosing in many patients (Wilson and 
Brodie, 1996).
3.3.5.6 Vigabatrin
VGB is approved as adjunctive treatment for partial seizures with or without secondary 
generalisation (Brodie and Dichter, 1996), but was not as efficacious as CBZ as 
monotherapy for partial seizures in adults in a large randomised study (Chadwick, 1999). 
Psychiatric complications including depression and psychosis have long been recognised 
(Sander et al, 1991). However, it is the recent concern over the high incidence of visual 
field defects associated with long-term VGB treatment (Miller et al, 1999) that has
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relegated it to a drug of last choice, although it is still regarded to have particular value 
against infantile spasms (Appleton et al, 1999).
3.4 Surgical treatment of epilepsy
Modem epilepsy surgery dates back over 100 years to the publication of Sir Victor 
Horsley’s classic paper (Horsley, 1886). In the ensuing years it has been met with a 
fluctuation in enthusiasm. The current wave of interest in epilepsy surgery began in the 
late 1980s and can be attributed largely to technical advances in neuroimaging and video 
EEG monitoring, improvements in surgical technique, and a better understanding of the 
anatomical and pathophysiological bases of epilepsy (Engel, 1996b).
The majority of operations for epilepsy are intended to be “curative”, although less 
commonly “palliative” procedures are also carried out (Wieser, 1998). The goal of the 
former is seizure-freedom through complete resection of the seizure-generating focus. 
This type of surgery can be offered to patients with surgically remediable syndromes, the 
prototype of which is MTLE (see Part I; Section 1.4.2; Engel, 1996b). With modem 
techniques, 70-90% of patients with MTLE become seizure-free after anteromesial 
temporal lobectomy (Engel, 1999), with surgical mortality rate close to 0, and significant 
morbidity (e.g. hemiparesis, hemianopia) less than 5% (Wieser, 1998). Patients with 
partial seizures due to discrete structural lesions, such as glial tumours, may also be 
regarded as having surgically remediable syndromes. In a "palliative" procedure (e.g. 
corpus callosotomy, multiple subpial transection), the seizure focus is not resected, but 
rather the pathways important for the spread of epileptiform discharges are dismpted in 
order to ameliorate the seizure tendency (Wieser, 1998).
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Presurgical evaluation aims to delineate the epileptogenic zone to be resected and to 
demonstrate that its removal will not cause additional unacceptable neurological or 
cognitive deficits. The extent of investigations depends on the specific procedure to be 
employed. In most cases, they include interictal and long-term video EEG monitoring to 
localise epileptic excitability, high quality MRI to identify structural abnormalities, 
functional imaging with PET or SPECT, and neuropsychological testing, including 
intracarotid injection of amobarbital to identify the laterality of language and memory 
function tests. In some cases, invasive intracranial EEG recording is needed (Engel,
1996b).
Despite its efficacy and safety for appropriately selected patients, surgical treatment for 
epilepsy is heavily underutilised (Engel, 1999). It is estimated that half of the patients who 
are refractory to AED treatment may benefit from epilepsy surgery (Engel and Shewmon,
1993). In the USA, this translates into 100 000 to 200 000 patients, and an extra 5000 to 
10 000 are being added per year. However, in 1990 only 1500 surgical procedures were 
performed (Engel, 1999). Such underutilisation may in part be due to the perceived 
invasiveness and cost of presurgical evaluation. In addition, epilepsy surgery is still 
largely considered by physicians to be a "last resort" for medically refractory epilepsy, 
which is itself poorly understood and ill defined. With the arrival of so many new AEDs, 
no patient will be able to try every agent (as monotherapy and in combination) in a lifetime. 
At what stage of the disease process does epilepsy become “refractory”, and are there 
clinical features that can help to identify these patients early so that surgery can be 
considered without relentless futile trials of AEDs? These questions can only be answered 
through understanding the natural history of treated epilepsy, which has not been well 
documented.
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3.5 Other non-pharmacological treatment of epilepsy
Vagus nerve stimulation (VNS) is a new, non-pharmacological approach to epilepsy 
treatment. It was approved in 1997 in the USA and subsequently in Canada and the 
European Union countries as adjunctive treatment for refractory partial-onset seizures in 
adults and adolescents. In this system, the left vagus nerve is stimulated via a bipolar lead 
connected to a programmable signal generator implanted subcutaneously in the patient’s 
left upper chest (Schachter and Saper, 1998). The mechanism of action of VNS is 
unknown, and how it complements AED therapy is still unclear. Other forms of 
“stimulation therapy” for epilepsy under development include stimulation of the 
centromedian thalamic nucleus (Velasco et al, 1995) and transcranial magnetic stimulation 
(Ziemann et al, 1998).
4 Natural history of epilepsy
4.1 Untreated epilepsy
Until very recently, the prognosis of epilepsy had traditionally been viewed with 
pessimism. Hippocrates believed that seizures beginning in adulthood lasted until death 
(Tempkin, 1971). Gowers conceded that “the spontaneous cessation of seizures is an event 
too rare to be anticipated in any given case” (1881). However, recent cross-sectional 
population-based studies of untreated patients in rural areas of developing countries 
suggest spontaneous remission may occur in a significant number of patients. One such 
study in Ecuador found 46% of the untreated cases were in long-term remission (Placentia 
et al, 1992). Data from other developing countries such as Nigeria, Ethiopia, China and 
India, where AED therapy is usually not available, reported similar prevalence rates to the 
developed world where most patients are treated, again suggesting that the disease may 
remit spontaneously (Sander, 1993). However, such evidence is uncontrolled and only 
circumstantial. The true spontaneous remission rate can only be ascertained accurately by
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randomly assigning newly diagnosed patients to treatment or no treatment, which is 
difficult to justify ethically given that effective therapy has been available since 1857 and 
AED therapy is usually commenced as soon as epilepsy is diagnosed in developed 
countries.
4.2 Treated epilepsy
Most of the data concerning the natural history of epilepsy, therefore, relate to its response 
to treatment. Until the late 1960s, Gowers’ gloomy opinion was echoed by many 
subsequent studies, which reported remission rate with treatment between 10 and 30% 
(Cockerell, 1996). These studies, however, were small, hospital-based and retrospective. 
Most modem large-scale prospective studies, including only newly diagnosed patients 
followed up for long periods, tended to suggest a remission rate of 60-80% (Table 7).
4.2.1 Population-based studies
The two most influential community-based studies were performed in Rochester, 
Minnesota, USA, and the UK, respectively. In the Rochester Epidemiology Project, 
patients are identified from a medical records-linkage system which includes all medical 
contacts of residents of Olmsted County, Minnesota, since 1935 (Annergers et al, 1996). 
Results primarily concerning the incidence, prevalence and causes of seizures and epilepsy 
have been published in a series of reports, covering the periods from 1935 to 1967 (Hauser 
and Kurland, 1975), 1940-1980 (Hauser et al, 1991), 1935 to 1984 (Hauser et al, 1993), 
1980 to 1984 (Zarrelli et al, 1999), and as summary articles for the 50-year period (Hauser 
et al, 1996; Annegers et al, 1996). The issues of remission and early prognostic factors 
were explored in two reports (Annegers et al, 1979; Shafer et al, 1988). In the initial 
analysis, the probability of being in remission for 5 years at 20 years after diagnosis (i.e. 
terminal remission) was 70% (Annegers et al, 1979). This was revised to 75% in the more
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Table 7. Terminal remission data from selected studies.
Study No. of 
patients
Population 
of study
Median follow- 
up years
Years in 
remission
% in 
remission*
Elwes et al, 1984 106 Hospital 5.5 2 79
Shafer et al, 1988 432 Community 17 5 6 6
Collaborative, 1992 280 Hospital 4 1 70
Cockerell et al, 1995b 564| Community 7 5 6 8
Sillanpaa et al, 1998J 176 Hospital 28 1 80
* Percentage in remission at median follow-up. 
f  Definite epilepsy.
J Children only.
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receilt report (Shafer et al, 1988). Predictors of a better outcome were absence of early-life 
brain damage, absence of generalised epileptiform activity on EEG, and no history of 
GTCS. The predictive value of these factors, however, was weak (Shafer et al, 1988).
In the National General Practice Study of Epilepsy, patients with newly diagnosed or 
suspected epilepsy were identified from 275 general practices throughout the UK between 
1984 and 1987 and followed up for a median of 7.1 years (Cockerell et al, 1995). 
Cumulative remission rates (i.e. acturial estimates of percentage seizure-free at any time 
during follow-up) and terminal remission rates for various durations at various time 
intervals were calculated. Among the 564 patients with “definite” epilepsy, the chance of 
achieving 5-year remission after 9 years from diagnosis was 6 8 %. Analysis of prognostic 
factors had not been published at the time of writing of this thesis.
4.2.2 Relationship between outcome and AED treatment
Although these two projects have provided valuable estimation of the probability of 
remission in relation to time from diagnosis, analysis of prognostic factors was often 
performed irrespective of treatment status. No study has specifically addressed the 
relationship between outcome and the course of AED treatment, i.e. to examine outcome 
with “drug treatment” as the variable instead of “time”. Undoubtedly, it is important to the 
patient to know his/her likelihood of seizure-freedom at at various time points after the 
onset of seizures or diagnosis. However, the great majority of patients, at least in the 
developed countries, would be started on AED treatment when a diagnosis of epilepsy is 
made. From a more practical point of view, it would also be useful to gauge the chance of 
successful treatment with the first AED chosen. Perhaps more importantly, when the first 
drug fails to control the epilepsy, as is often the case, little is known about the proportion
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of patients responding to subsequent monotherapy, combination therapy, and whether there 
is any difference in efficacy between these two treatment strategies.
Such poor documentation of progress in response to treatment has resulted in confusion 
and lack of consensus over the definition of “refractory” epilepsy (Perucca, 1998; Regesta 
and Tanganelli, 1999) and has hindered the development of a strategic approach to 
management. The usual “routine” management consists of monotherapy at diagnosis, 
followed by combinations of AEDs if it fails. When epilepsy remains uncontrolled, it is 
labelled “pharmacoresistant”, “intractable” or “refractory”. Some of these patients will be 
enrolled in experimental drug studies, some offered epilepsy surgery, or more recently, a 
vagus nerve stimulator. But with at least 15 major AEDs available, the lifetime of a patient 
will not be sufficient to allow a trial of all options. How many trials of single AEDs 
should be employed before the patient is treated with duotherapy (Schmidt and Gram, 
1995)? At a practical level, how many trials of drugs, either singly or in combinations, 
have to fail before the seizure disorder can be regarded as “refractory” and potentially 
“curative” surgery considered? At what stage during the course of the disease does 
epilepsy become “pharmacoresistant”? Currently, the diagnosis of “refractory” epilepsy is 
a posteriori, i.e. after it has failed to respond to “appropriate” AED treatment. But are 
some epilepsies refractory de novo (Shorvon, 1990), and can they be identified early by 
their clinical features so these patients may be targeted for epilepsy surgery or effective 
combination drug treatment without unnecessary delay?
A better understanding of how epilepsy responds to AED treatment is needed to allow a 
more accurate assessment of the factors influencing prognosis and help the formulation of 
a more strategic approach to management. Such knowledge cannot be obtained by 
retrospective or case-control studies which are prone to inclusion bias, but only by
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studying newly diagnosed patients prospectively. A series of clinical studies carried out 
for this purpose are described in Part II.
5 Biological basis of refractory epilepsy
Various factors may contribute to pharmacoresistance, some of which may be unrelated to 
the biology of the disease (“pseudoresistance”), such as poor compliance of medication, 
inappropriate lifestyle (e.g. excessive alcohol intake), inappropriate choice of AED or drug 
regimen, and inappropriate assessment of response (Perucca, 1998). These possibilities 
should be considered and rectified before a patient’s epilepsy is labelled “refractory”.
5.1 De novo or an evolving process?
Whether refractory epilepsy evolves over time or is present at the outset remains hotly 
debated. Proponents of the former point to the unfavourable clinical prognostic factors of 
epilepsy, such as a large number of pre-treatment seizures, a long interval between the first 
seizure and initiation of treatment, early onset of seizures, history of complex febrile 
seizures, and a declining interval between seizures in untreated patients (Table 8 ; Reynolds, 
1995; Regesta and Tanganelli, 1999). At the other end of the clinical spectrum, where 
seizure-free patients withdraw from AED therapy, the shorter the remission duration, the 
more likely is the patient to relapse (Medical Research Council, 1991). These observations 
may either be due to a progression of the causative disorder or to secondary 
epileptogenesis, i.e. a deterioration of the seizure disorder caused by the epileptic activity 
itself (Morrell, 1985; 1991). Recent long-term outcome studies of patients undergoing 
temporal lobectomy for refractory epilepsy support the suggestion that secondary 
epileptogenesis at sites distant to the lesion may develop with uncontrolled seizures 
(Eliashiv et al, 1997). The contention that “seizures beget seizures” (Gowers, 1881) can 
be substantiated by the experimental model of kindling, whereby electrical stimulation at
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Table 8 . Poor clinical prognostic factors demonstrated in some studies (Shorvon, 1996; 
Perucca, 1998; Pegesta and Tanganelli, 1999).
Characteristics of seizures 
Early onset of seizures 
Large number of pretreatment seizures 
Long interval between first seizure and treatment 
High seizure frequency 
Partial or mixed seizure types 
Persistence of seizures 
History of status epilepticus
Symptomatic epilepsies 
Complex febrile seizures 
Learning disabilities 
Progressive neurological disorders 
Family history of epilepsy 
Multifocal EEG paroxysms
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what is initially a subconvulsive level in an animal, subsequently becomes sufficient to 
induce seizures after repeated application (Loscher and Schmidt, 1988). Based on similar 
lines of reasoning, it is argued that potentially “curative” epilepsy surgery should be 
performed early to avoid the seizures becoming more severe with time with resultant 
irreversible cognitive decline and psychosocial disability (Engel, 1998b; 1999).
On the other hand, there is no strong clinical data to suggest that kindling is relevant to 
human epilepsy (Shinnar and Berg, 1996). High pretreatment seizure number may simply 
be a marker for rather than the cause of poor prognosis. In a recent Italian multicentre 
study, treatment of the first seizure, although reducing the risk of a second seizure, did not 
improve the long-term probability of seizure-ffeedom (Musicco et al, 1997). In a study of 
children with epilepsy, initiation of treatment after 1 0  or fewer seizures did not influence 
the remission rate (Camfield et al, 1996). In rural Africa where patients may have been 
untreated for many years with numerous seizures, response to AED treatment was similar 
to patients who are treated early in developed countries (Feski et al, 1991; Watts, 1992). 
Randomised trials have shown that treatment with AEDs to prevent the occurrence of acute 
symptomatic seizures, such as febrile convulsions (Berg and Shinnar, 1997), post- 
traumatic seizures (Temkin et al, 1990) and after craniotomy (Foy et al, 1992), does not 
reduce the risk of subsequent epilepsy. Many of the poor prognostic factors, such as brain 
damage, EEG abnormalities, family history of epilepsy and specific syndromes, are present 
at the onset of the disease.
Lastly, it should be noted that much of the discussion on the role of repeated seizures in the 
generation of chronic epilepsy concerns patients at the onset of their disease and does not 
address the possibility of a progressive process in those who continue to have seizures 
despite AED treatment.
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5.2 Mechanism of pharmacoresistance
5.2.1 The “usual suspects”
Given that regardless of the exact definition, up to one third of patients have drug-resistant 
epilepsy, it is surprising that little research has been carried out to address its biological 
mechanism. It is likely to be multifactorial and variable. Among the idiopathic epilepsies, 
prognosis is often determined by the underlying syndrome (Berg and Shinnar, 1997).
There are, for instance, a number of devastating encephalopathic disorders in infancy for 
which no consistently effective treatment is available (Pellock, 1999). Certain structural 
abnormalities (e.g. MTS, CD) appear to be particularly pharmacoresistant (Semah et al, 
1998; Regesta and Tanganelli, 1999), suggesting response to AED treatment may be 
influenced by the causative neuropathology.
Even for MTS which is the most extensively studied epilepsy-related pathology, the 
molecular basis of its pharmacoresistance is poorly understood. The “usual suspects” are 
abnormalities in neuronal network, neurotransmitter receptors and ion channels (Table 9). 
In addition to selective neuronal loss and gliosis in the CA1 and CA3 regions, the 
“sprouting” of mossy fibres which may be hyperexcitable is well recognised in both human 
HS and experimental models (Pringle et al, 1993). The “dormant basket cell” theory, 
which hypothesises that inhibitory neurons survive but are rendered hypofunctional by a 
loss of excitatory systems that normally evoke stimulation (Sloviter, 1991), is another 
attempt to explain the epileptogenicity of HS by plastic changes in neuronal circuitry 
(Lothman, 1994). Pharmacoresistance may be a result of alteration in neurotransmitter 
receptors. Changes in composition of inhibitory GABAa receptors (Brooks-Kayal et al,
1998) and increased expression of subclasses of excitatory glutamate receptors have been 
reported in animal models of MTLE and in man (Bliimcke et al, 1999). With the
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Table 9. Putative factors contributing to the biological basis of refractory epilepsy.
Syndromic classification e.g. childhood epileptic encephalopathies 
Causative neuropathology e.g. mesial temporal sclerosis, cortical dysplasia 
Hyperexcitable and disinhibited neuronal network reorganisation e.g. mossy fibre sprouting 
Altered neurotransmitter receptors e.g. composition/functioning of GAB A/glutamate receptors 
Ion channelopathies e.g. sodium, calcium, potassium channels 
Reactive autoimmunity e.g. autoantibodies against glutamic acid decarboxylase 
Impaired antiepileptic drug penetration e.g. P-glycoprotein expression at blood-brain barrier 
? Pharmacogenetic variations
GAB A = y-aminobutyric acid
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increasing number of ion channelopathies being identified in human genetic epilepsies 
(Wallace et al, 1998; Steinlein, 1999) and animal epilepsy models (Cox et al, 1997; Bentar,
1999), it is possible they may also play a role in the mechanism of drug resistance. 
Epilepsy-related changes in the dynamics of calcium entry through voltage- and 
transmitter-gated channels and in intraneuronal calcium buffering have long been 
recognised (Blumcke et al, 1999).
5.2.2 Other potential factors
Although these studies may have pinpointed factors that contribute to the epileptogenicity 
or seizure susceptibility of a given syndrome, they do not address the mechanism of drug 
resistance. Why do some patients with, say, MTS remain refractory despite treatment with 
4 AEDs while others with a seemingly identical lesion are seizure-free on a modest dose of 
a single drug? The potential role of immunological factors, drug penetration and genetics 
in the genesis of pharmacoresistance has not been fully explored.
Antibodies to the glutamate receptor subtype GluR3 are thought to cause Rasmussen’s 
encephalitis, a rare form of epilepsy characterised by seizures, progressive neurological 
dysfunction and inflammatory histopathology (Andrews and McNamara, 1996).
Antibodies directed against GM1 ganglioside, which are highly epileptogenic in a rat 
model, have been implicated in human epilepsy (Bartolomei et al, 1996). There have been 
recent case reports of elevated glutamic acid decarboxylase (GAD) autoantibodies in 
patients with refractory partial seizures (Martinelli et al, 1978; Solimena et al, 1988; Saiz et 
al, 1996; Nemni et al, 1994; Giometto et al, 1998). Autoantibodies to GAD, which 
catalyses the conversion of L-glutamic acid to GAB A, may, theoretically, impair its 
activity and the subsequent production of GABA resulting in refractory epilepsy. Whether
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elevated GAD autoantibodies contribute to drug resistance in epilepsy is examined by a 
case-control study in Section 5 of Part II.
One of the puzzling features of refractory epilepsy is its resistance to multiple AEDs, either 
singly or in combination, with varied modes of action. This characteristic suggests the 
operation of a universal mechanism affecting AEDs in general. One such possible 
candidate involves alterations at the blood-brain barrier (BBB). AEDs, by default, have to 
cross the BBB to exert their antiepileptic effect. The potential role of changes in the BBB 
at the epileptogenic zone in refractory epilepsy has not been investigated. Changes in the 
BBB, especially a non-specific “opening”, during acute seizures have been described 
(Comford and Oldendorf, 1986; Duncan and Todd, 1991; Comford, 1999). However, little 
is known about changes in chronic epilepsy (Comford, 1999). If the function of the BBB 
was enhanced around the epileptogenic focus by some mechanisms, AEDs might be 
prevented from entering their site of action, but could still penetrate the rest of the brain to 
cause neurotoxicity. The epilepsy might, therefore, display resistance to multiple AEDs 
with different mechanisms of action. This might also explain why symptomatic epilepsies 
(with structural lesions) are more drug-resistant than idiopathic epilepsies (usually genetic 
with presumably more diffuse changes).
Changes in mechanisms governing the access of AEDs to the seizure focus may potentially 
provide a unifying biological basis for pharmacoresistant, or "multidrug resistant", epilepsy. 
One such candidate mechanism is a family of dmg transporters (Twentyman, 1997), the 
prototype of which is P-glycoprotein (P-gp) which is found in cerebral capillary 
endothelium and functions as a dmg efflux pump, contributing to the integrity of the BBB 
(Van Asperen et al, 1997). The importance of the BBB and the potential role of P-gp in
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the pathogenesis of pharmacoresistance in epilepsy will be further discussed and explored 
by a series of animal and human studies in Part III.
Diversity in an individual’s response to drugs is well recognised not only in epileptology, 
but also across all medical disciplines. Much of this variation is now thought to be due to 
genetic differences (polymorphisms) which are studied under the heading of 
“pharmacogenetics” (Nebert, 1999). Traditionally, pharmacogenetics has focused on drug- 
metabolising genes as a determinant of individual susceptibility to drug toxicity (Ball and 
Borman, 1998; Evans and Relling, 1999). However, genetic polymorphisms may also 
influence a drug’s efficacy in a given patient, a phenomenon now recognised in many 
fields of medicine, including asthma, Alzheimer’s disease and coronary heart disease 
(Evans and Relling, 1999; Roses, 2000a). Pharmacogenetics has gained ever greater 
momentum with the completion of a “working draft” of the human genome (Macilwain,
2000). Pharmacogenetic profiling by DNA chips to personalise treatment so that the “right 
drug is given to the right patient” may soon be realised (Marshall, 1998; Wolf et al, 2000; 
Roses, 2000b). The potential impact of pharmacogenetics on epileptology is already being 
felt by the demonstration of greater sensitivity of mutated nicotinic acetylcholine receptors 
(which underlie autosomal dominant nocturnal frontal lobe epilepsy) to CBZ compared to 
wild type in vitro (Picard et al, 1999). Polymorphisms of the multidrug resistance (MDR) 
gene, which codes for P-gp, with functional changes affecting drug accumulation and 
metabolism in vivo have recently been reported (Hoffmeyer et al, 2000). It is possible that 
such genetic variation may explain in part the heterogeneous response to AED therapy, 
further underlining the importance to study whether P-gp plays a role in epilepsy.
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6 Overall aims
The aims of the current project were:
(1) To ascertain the prognosis of epilepsy in newly diagnosed patients.
(2) To identify clinical features that allow early prediction of refractory epilepsy.
(3) To document progress in the response to AED therapy among patients with newly 
diagnosed epilepsy.
(4) To determine whether underlying pathology influences outcome.
(5) To determine whether GAD autoantibodies are associated with AED-resistance.
(6 ) To determine whether commonly used AEDs are substrates of P-gp.
(7) To determine what role, if any, P-gp plays in the genesis of AED-resistance.
Clinical studies carried out to examine (1) to (5) are described in Part II, while laboratory- 
based experiments exploring (6 ) and (7) are reported in Part III.
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PART II
CLINICAL STUDIES
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1 Natural history of treated epilepsy — Early identification of refractory epilepsy
1.1 Introduction and aim
As discussed in Part I, Section 4, the major dilemma inherent to the sequential 
management approach of epilepsy lies in the imprecise understanding and definition of 
pharmacoresistance (Perucca, 1998). Although the recent improvement of surgical 
outcome and the dramatic expansion of AED therapy have substantially increased the 
chance of better seizure control, how to target the new treatment modalities is unclear. The 
introduction of 9 new AEDs since 1989 with more to come means that drug choice has 
been dramatically widened and the number of possible combinations is now almost 
limitless. How many trials of single AEDs should be employed before the patient is 
treated with duotherapy? How many AEDs, either singly or in combination (and in how 
many combinations), have to fail before the seizure disorder can be recognised as 
"refractory" and surgery considered? At what stage during the course of the disease does 
epilepsy become "pharmacoresistant" to AED treatment? Perhaps more importantly, are 
there clinical features that allow prediction of subsequent "refractoriness"?
To address these questions, a longitudinal outcome study was conducted to delineate the 
“natural history” of treated epilepsy. In particular, this study aimed to identify clinical 
features associated with poor response to therapy. Early identification of subsequent 
refractoriness may enable better targeting of combination AED therapy or surgery to “high 
risk” patients.
1.2 Methods
1.2.1 Patients
The study included consecutive unselected patients in whom epilepsy was diagnosed and 
AED therapy begun at the Epilepsy Unit, Western Infirmary, Glasgow, Scotland between 1
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January 1984 and 31 December 1997. Patients were enrolled into the study when they 
fulfilled the inclusion criteria and followed up prospectively at the Epilepsy Unit. The 
Epilepsy Unit is one of the major referral centres for the management of patients with 
epilepsy in Glasgow. Most of the patients were referred to the Epilepsy Unit by general 
practitioners with a minority (8 %) from the hospital’s accident and emergency department 
(McKee et al, 1990). The majority of patients reside in Glasgow, although some patients 
travel to the clinic from other parts of the west of Scotland.
A case file was created for each patient and stored on-site at the Epilepsy Unit, allowing 
instant access when required. At the first visit, demographic and clinical information was 
collected from the patient, and any witness, using a structured questionnaire. A general 
physical and neurological examination was performed. Additional investigations were 
carried out as clinically indicated. Surface EEG, either routine or sleep-deprived, was 
performed and reported by neurophysiologists and neuroimaging, particularly CT or MRI, 
was carried out by radiologists with interest in neuroradiology. Information obtained from 
the history, examination and investigations was used to classify the patient’s seizure and 
epilepsy type according to the guidelines of the ILAE (Part I; Sections 1.1 and 1.2).
During subsequent visits, the degree of seizure control, any side effects of medication, 
serum drug levels, and other relevant information were recorded in an ongoing database for 
subsequent analysis.
1.2.2 Approach to treatment
For each patient diagnosed to have epilepsy, the appropriate AED was chosen taking into 
account such factors as the types of seizure and epilepsy, patient characteristics, side 
effects, and interaction profiles of the available drugs (Part I; Section 3.3). Some patients 
volunteered to participate in randomised AED trials, in which case the drug remained
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unknown to both the clinician and the patient during the study period. Protocols for all 
drug trials were approved by the Ethics Committee of the Western Infirmary, and all 
patients or their parents or legal guardians provided written informed consent.
Patients were subsequently evaluated at the clinic every 4 to 6  weeks for the first 6  months 
and at least every 4 months thereafter. If medical attention was necessary between the 
scheduled appointments, the patients or their general practitioners could call the Epilepsy 
Unit by a dedicated telephone line. At each follow up visit, clinical information and the 
response to AED therapy were recorded in an ongoing prospective database (Tobias et al, 
1994). Compliance was monitored at the clinic with the help of on-site measurement of 
serum drug levels (McKee et al, 1993).
Drug dosage was titrated according to recommended schedules (Brodie and Dichter, 1996; 
Dichter and Brodie, 1996) and adjusted as clinical circumstances dictated, with particular 
attention paid to efficacy and tolerability. Monotherapy was used where possible, as is 
recommended practice (Part I; Section 3.3.2). Treatment was changed to another drug if 
seizures remained uncontrolled or if the patient developed an idiosyncratic reaction or 
intolerable side effects. Patients whose epilepsy was the result of a possibly removable 
structural abnormality, such as MTS, tumour, or AVM, were referred for surgical 
evaluation (Part I; Section 3.4) at another centre.
1.2.3 Definitions and statistical analysis
For the purpose of assessing any potential correlation between various clinical factors and 
outcome, patients were divided into two groups according to whether or not they were 
seizure-free during follow-up. The extent of seizure control was assessed at the time of the 
patient's last clinic visit. Patients were considered seizure-free if they had not had seizures
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of any type for at least one year (i.e. terminal remission). Response to treatment was 
classified as seizure-free, failure due to inadequate seizure control (lack of efficacy) or 
adverse events (idiocyncratic reactions such as rash and hepatotoxicity, or intolerable side- 
effects), or withdrawal of treatment due to reasons unrelated to efficacy or tolerability such 
as concern about potential adverse effects, planning a pregnancy, and a change of mind. A 
change of treatment regimen was defined as substitution of an existing drug or addition of 
a new drug.
The Chi-square test was used for comparisons of categorical data and the Mann-Whitney 
test for non-parametric continuous data. Non-parametric analyses were performed because 
the variables (e.g. age) were not normally distributed in the two groups and not equal in 
variance. Relative risks and their 95% confidence intervals for both significant and non­
significant differences were calculated (Altman, 1991). The Chi-square test for trend was 
used to assess the effect of pre-treatment seizure number on outcome. Potential interaction 
between factors was examined by logistic regression analysis. All statistics tests were two- 
tailed. Statistical calculations were performed with use of Minitab for Windows (Release
1 1 .2 1 ) software.
1.3 Results
1.3.1 Patient demographics
Overall, 629 of the 3,209 patients who were referred to the clinic between 1st January 1984 
and 31 st December 1997 were not being treated at the time of referral. They included 
patients who had not previously been diagnosed to have epilepsy and those in whom AED 
treatment had been withdrawn. Eight patients died from a variety of causes during 
treatment, 74 did not return for follow-up after the first AED was started, and 22 were 
excluded because of uncertainty about the diagnosis or persistent non-compliance with
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treatment. The remaining 525 patients (52% male) constituted the study group. Among 
them, 470 patients had never received AED therapy. The median duration of follow-up 
was 5 years (range, 2 to 15 years), and 90% of the patients attended the clinic for at least 3 
years. The median age at referral was 29 years (range, 9 to 93 years), and the median age 
at onset of epilepsy was 26 years (range, <1 to 92 years). There was no significant 
difference in sex (relative risk [RR] 0.92, 95% confidence interval [Cl] 0.80 to 1.04), age 
at referral (p=0.63) or the onset of seizures (p=0.56), prevalence of a family history of 
epilepsy (RR 0.98, 95% Cl 0.84 to 1.15), or history of febrile convulsions (RR 0.97, 95% 
Cl 0.72 to 1.35) between the group that became seizure-free and the group with 
uncontrolled epilepsy (Table 10).
1.3.2 Effects of previous treatment
At the last clinic visit, 333 (63%) patients were seizure-free (Figure 4). There was no 
significant difference (RR 0.87, 95% Cl 0.69 to 1.11) in eventual seizure-free rate between 
the 55 patients who had previously received one or more AEDs (56%) and those not 
previously treated (64%). The 55 patients who had previously received AED treatment 
were included in the analysis for other factors associated with refractory epilepsy with the 
exception of the analysis exploring response to first AED.
1.3.3 Epilepsy classification
One hundred and forty patients (27%) were classified as having idiopathic epilepsy, 150 
(28%) as symptomatic epilepsy and 235 (45%) as cryptogenic epilepsy. The proportion of 
patients with symptomatic or cryptogenic epilepsy who continued to have seizures during 
treatment was higher than in the patients with idiopathic epilepsy (40% vs. 26%, p=0.004; 
relative risk 1.5; 95% Cl 1.1 to 2.1). There was no difference in the proportions of
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Table 10. Clinical characteristics of 525 patients with epilepsy who became seizure-free or 
had persistent seizures while receiving antiepileptic drug therapy.
Characteristics Seizure-free 
n (%)
Uncontrolled 
n (%)
Total number All patients 333 (63) 192 (37)
Sex Male 157 (47) 102 (53)
Female 176 (53) 90 (47)
Age at onset (years) Median 25 26
Range < 1 - 9 2 1 - 7 5
Age at referral (years) Median 27 31
Range 9 -93 1 3 -7 6
Family history Positive 74 (22) 44 (23)
Negative 259 (78) 148 (77)
Febrile convulsion Positive 16(5) 10(5)
Negative 317(95) 182 (95)
Type of epilepsy Idiopathic 103 (31) 37 (19)
Symptomatic 8 6  (26) 64 (33)
Cryptogenic 145 (43) 90 (47)
Number of seizures at 2 0  or fewer 242 (73) 98 (51)
baseline Over 20 91 (27) 94 (49)
78
o
co
Q C O G O
H
u o
< II o  ^ C O
< N a w
79
Fi
gu
re 
4. 
Ou
tco
m
e 
in 
52
5 
pa
tie
nt
s 
aft
er 
co
m
m
en
ce
m
en
t 
on 
an
tie
pi
lep
tic
 
dru
g 
(A
ED
) 
the
rap
y 
re
ce
iv
in
g 
va
rio
us
 n
um
be
r 
of
 
dr
ug
s. 
Th
e 
sta
tus
 o
f 
the
 
pa
tie
nt
 a
t 
the
 t
im
e 
of 
the
 
las
t 
cli
nic
 
vis
it 
is 
giv
en
 
in 
pa
re
nt
he
se
s. 
SF 
= 
se
iz
ur
e-
fre
e.
patients with symptomatic and cryptogenic epilepsy who continued to have seizures (43% 
vs. 38%; RR 1.11, 95% Cl 0.27 to 1.42, respectively).
1.3.4 Pre-treatment seizure number
There was a significant linear trend in the proportion of patients with uncontrolled epilepsy
'y
in relation to the number of pre-treatment seizures (% =32.7, p<0.001; Figure 5), even after 
excluding patients with only one seizure (% =35.2, p<0.001). Epilepsy was uncontrolled in 
94 of the 185 patients (51%) who reported more than 20 seizures before initiation of 
therapy (p<0.001; relative risk 1.8, 95% Cl 1.4 to 2.2) as compared with 98 of the 340 
patients (29%) who had 20 seizures or less. Logistic regression analysis revealed no 
significant interaction between type of epilepsy and number of seizures before treatment.
1.3.5 Antiepileptic drug therapy
Four hundred and twenty-three patients (81%) were being treated with a single AED at the 
last clinic visit, with 289 receiving an established drug (CBZ 155, VPA 125, PHT 8 , ESM 
1) and 134 taking one of the newer AEDs (LTG 99, GBP 15, OXC 7, TGB 9, TPM 3,
VGB 1). There was no significant difference in seizure-free rates between the groups 
(67% vs. 69%; RR 0.98, 95% Cl 0.85 to 1.12). Fifty-three patients were being treated with 
2 AEDs, of whom only 12 (23%) were seizure-free (Figure 4). None of the 5 patients 
receiving 3 AEDs were seizure-free. Forty-four patients had chosen not to continue AED 
therapy, some after a period of remission (39%), some due to side-effects (48%) and the 
remainder for personal reasons (13%). Thirty-four (77%) of these patients had been 
seizure-free for more than a year.
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One hundred and ninety-five patients were enrolled in double-blind trials comparing an 
established AED with a new drug. In the 104 patients (53%) who completed such a study 
(established drugs: CBZ 38, VP A 13; new drugs: LTG 30, GBP 5, OXC 5, TGB 12, FBM 
1 ), there was no significant difference in seizure-free rate between the patients receiving 
the established and new drugs (established drug 71%, new drug 6 6 %; RR 1.07, 95% Cl 0.8 
to 1.4). All but four of the patients who received a new drug continued to be seizure-free 
while receiving the same drug after the study ended. Ninety-one patients (47%) did not 
complete the study, the majority (59%) because of side-effects. One hundred and twenty 
(62%) of the 195 patients who participated in single-drug trials became seizure-free, a 
figure which was similar to the rest of the cohort, suggesting no bias in the patient 
selection for these studies.
1.3.6 Response to the first drug and subsequent outcome
Among the 470 patients who had never received an AED, 301 (64%) became seizure-free. 
Two hundred and twenty-two (47%) were controlled with their first AED which was an 
established drug in 151 patients and a new drug in 71 patients (Figure 6 ), of whom 15 
remained seizure-free after discontinuation of the drug. The seizure-free rates were the 
same in both drug groups (RR 1.01, 95% Cl 0.82 to 1.23). Sixty-seven patients (14%) 
became seizure-free during treatment with a second or third drug. Only 12 patients (3% of 
total) were controlled with two drugs (Table 11). The probability of attaining seizure- 
freedom decreased progressively with successive AED regimens, and rapidly so after the 
first two regimens (Figure 7).
Treatment with the first AED was unsuccessful in 113 patients due to poor seizure control, 
69 because of intolerable side-effects, 29 because of idiosyncratic reactions, and 37 due to 
other reasons. Only 79 of these 248 patients (32%) in whom the first drug was ineffective
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Table 11. Success of antiepileptic drug regimens in 470 patients with previously untreated 
epilepsy.
Variable No. (%)
Seizure-free on the first drug 2 2 2 (47)
Seizure-free during continued therapy with first drug 207 (44)
Remained seizure-free after discontinuation of first drug 15 (3)
Seizure-free on the second drug 61 (13)
Seizure-free during monotherapy with second drug 41 (9)
Remained seizure-free after discontinuation of second drug 2 0 (4)
Seizure-free on the third drug 6 ( 1 )
Seizure-free during therapy with two drugs 1 2 (3)
Total 301 (64)
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subsequently became seizure-free. The outcome among these patients was strongly 
associated with the reason for initial failure (% =57.0, p<0.001; Figure 6). Fifty-five 
percent of the patients with an idiosyncratic reaction became seizure-free, as did 41% of 
the patients with intolerable side effects, but only 11% of those with inadequate seizure 
control subsequently became seizure-free.
1.4 Discussion
The overall remission rate of epilepsy in this study of 63% was comparable to that in 
several recent hospital-based studies (Table 7). Consistent with previous reports 
(Annegers et al, 1979; Shafer et al, 1988; Sillanpaa, 1993; Berg et al, 1996; Sillanpaa et al, 
1998), patients with a known or probable structural cerebral abnormality were 1.5 times 
more likely to have uncontrolled epilepsy. The reason for this is unclear. Potential 
differences in response pattern to AED treatment between patients with idiopathic and 
symptomatic/cryptogenic epilepsy will be further examined in Part II; Section 2. Whether 
limitation of AED access to the epileptogenic lesion contributes to the genesis of 
pharmacoresistance in symptomatic epilepsy will be explored in Part III.
A high number of seizures before treatment was a poor prognostic indicator, an 
observation that has also been made previously (Collaborative Group, 1992; Sillanpaa, 
1993). Whether high pretreatment seizure number is the cause of or merely a marker for 
severe seizure disorders is hotly debated (Part I; Section 5.1). Although a causal 
relationship between a high number of pre-treatment seizures and later intractibility may be 
supported by the experimental phenomenon of kindling, whereby an animal subsequently 
develops seizures after initially subconvulsive electrical stimulation (Reynolds, 1995), 
clinical studies have failed to suggest significant relevance of kindling in human epilepsy 
(Shinnar and Berg, 1996). Studies comparing outcome between early and delayed
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initiation of AED treatment (Camfield et al, 1996; Musicco et al, 1997), and reports from 
developing countries on long-term prognosis of patients newly commenced on therapy 
after a long history of untreated seizures (Feski et al, 1991; Watts, 1992), do not support 
the notion of "seizures beget seizures" (Gowers, 1881). Many authors, therefore, believe 
that a high number of seizures before treatment is the result, rather than the cause, of the 
pathophysiological changes that later manifest as refractory epilepsy (Berg and Shinnar, 
1997). However, it remains to be tested whether kindling occurs in specific epilepsy 
syndromes, for example MTLE on which the experimental model is based, and which is 
suggested by a growing body of evidence to be progressive in nature (Engel, 1999).
From a more practical point of view, the finding that many patients were seizure-free while 
taking a single AED is in agreement with the consensus that monotherapy is a realistic goal 
for most patients (Brodie and Dichter, 1996; Brodie and French, 2000) and, indeed, that the 
overall prognosis of epilepsy is good (Anonymous, 1997). This is reinforced by the 
observations that 47% of patients became seizure-free during treatment with their first drug 
and that 77% of those who stopped treatment remained seizure-free. Epilepsy may run a 
benign course and remit spontaneously in some patients (Keranen and Riekkinen, 1993).
The rates of remission were similar in patients treated with an established AED and those 
treated with a new drug. In randomised, double-blind trials comparing CBZ with LTG, 
there was no difference in efficacy between the two drugs, although fewer side effects and 
lower drop-out rates were reported among patients treated with LTG (Brodie et al, 1995; 
Brodie et al, 1999a).
An early response to drug therapy confers a favorable prognosis (Annegers et al, 1979; 
Elwes et al, 1984; Collaborative Group, 1992; Sillanpaa et al, 1998). Results from this
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study suggest that the response to the first AED is also a powerful prognostic factor. This 
factor was particularly useful among patients in whom treatment failure was due to 
inadequate efficacy: only 11% of such patients later became seizure-free, as compared with 
41% of the patients who had intolerable side-effects and 55% of those with an 
idiosyncratic reaction. The probability of attaining seizure-freedom declined progressively 
with successive AED regimens, and few became seizure-free after failure of two regimens. 
For all patients in whom treatment with the first AED was unsuccessful, 14% became 
seizure-free when changed to another drug but only 3% became seizure-free while taking a 
combination of two drugs.
These observations support the hypothesis that difficult-to-control epilepsy may be present 
de novo rather than evolve over time, since the clinical characteristics are apparent early in 
the course of disease. These patients are more likely to have underlying structural cerebral 
abnormalities, to present with more than 20 seizures, and to not respond to their first AED. 
Such theoretical considerations have practical implications for devising a more strategic 
approach to the management of epilepsy. From a pragmatic point of view, these data 
suggest that patients may be considered to have difficult-to-control epilepsy after failure of 
two first-line AEDs. It may be argued that this may be the case even as soon as the first 
AED fails due to inadequate efficacy (as opposed to intolerable side effects) since only 1 in 
9 of such patients became seizure-free in the long-term.
This consideration reinforces the assertion that for patients with correctable structural 
abnormalities, epilepsy surgery should be considered as soon as two first-line drugs fail 
(Engel, 1996; 1999). In selected groups of patients, this approach can render up to 90% of 
patients seizure-free (Part I; Section 3.4). For the majority of patients not suitable for 
“curative” resective surgery, AEDs remain the mainstay of treatment. The finding that
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only 3% of patients became seizure-free on more than one drug highlights the need to 
combine drugs more effectively. There is accumulating evidence to suggest that certain 
combinations, such as VPA and LTG (Brodie et al, 1997b), have additive or even 
synergistic effects, raising the possibility of a mechanistic approach to "rational 
polytherapy" (Part I; Section 3.3.3).
1.5 Conclusion
In conclusion, subsequent "refractoriness" may be predicted from clinical characteristics 
early in the course of the disease, allowing strategic targeting of surgery or effective 
polytherapy. Whether early performance of surgery or institution of "rational" polytherapy 
prevents the development of refractory epilepsy remains to be tested. A multicentre 
randomised trial to compare early and late surgery for patients with MTLE is soon to start 
(Engel, 1999), and a study comparing substitution and combination therapy after failure of 
the first AED is already underway in Glasgow.
From a management standpoint, many crucial questions remain. For instance, when 
should treatment with the first AED be deemed to have failed and alternative therapy, 
either substitution or polytherapy, be considered? Secondly, in patients without 
correctable structural abnormality, when and how should combination of AEDs be used? 
These issues are addressed in Part II; Sections 2 and 3 respectively.
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2 Natural history of treated epilepsy — Effectiveness of first ever antiepileptic drug
2.1 Introduction and aim
The natural history of newly diagnosed epilepsy in response to treatment has not been well 
documented (Part I; Section 4.2). Long-term outcome studies (Part II; Section 1) and 
randomised comparative trials (Mattson et al, 1992; Richens et al, 1994; Brodie et al, 1995; 
Beydoun, 1997) suggest that fewer than 50% of patients become seizure-free on the first 
AED. As shown in Part II; Section 1, failure on the first AED due to lack of efficacy is 
associated with poor subsequent outcome. Effectiveness encompasses both efficacy and 
tolerability (ILAE, 1998), but the importance of the latter is often inadequately assessed in 
randomised, particularly regulatory, studies which are not designed to address the everyday 
practical use of the drug (Chadwick, 1997). In patients with persistent seizures, it is 
unclear at what dosage the drug should be deemed non-efficacious and when alternative 
treatment, such as a second drug or a combination of 2 drugs, should be considered (Part I; 
Section 3.3.3). The usual recommendation of escalating the dose to near-toxic levels in 
patients with persistent seizures (Perucca, 1996) assumes a positive dose-response 
relationship. Direct evidence supporting this is lacking.
Although randomised controlled trials are essential to establish the efficacy of a new AED 
for regulatory purposes, whether their results can be extrapolated to clinical practice has 
been questioned (Walker and Sander, 1997). Observational studies may assist the 
translation of trial data into everyday usage (Mant, 1999; Pocock and Elboume, 2000; 
Stephen et al, 2000). This study aimed to explore the interaction among efficacy, 
tolerability and overall effectiveness of the first ever AED in patients with newly 
diagnosed epilepsy. These data facilitated observations on dose-response relationships 
with the commonly used first choice AEDs in this setting.
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2.2 Methods
2.2.1 Patients
The study included patients in whom epilepsy was diagnosed and treatment initiated at the 
Epilepsy Unit in the Western Infirmary in Glasgow, Scotland between 1st January 1984 and 
31st December 1997. Only those who had never received AED therapy were included in 
the analysis. During the first visit, a structured questionnaire was used to collect clinical 
information from the patients and any witnesses to the seizure. Investigations, in particular 
surface EEG and neuroimaging (Part I; Section 2.2), were carried out as clinically 
indicated. Epileptic seizures and syndromes were classified using information obtained 
from the history, physical examination and investigations according to the ILAE guidelines 
(Part I; Sections 1.2 and 1.3). The classification for each patient represented the final 
status at the time of analysis.
Treatment principles and follow-up arrangements were as described in Part II; Section 
1.2 .2 .
2.2.2 Statistical analysis
Patients were divided into 2 groups for purposes of analysis according to whether or not 
they became and remained seizure-free on their first ever AED. They were considered to 
be seizure-free if they had no auras or seizures of any type for at least one year. Response 
to medication was classified as: seizure-free; able to tolerate the medication but with 
persistent seizures (inadequate seizure control); change of treatment due to adverse events 
(including side-effects and idiosyncratic reactions); or withdrawal of treatment for reasons 
unrelated to efficacy or tolerability such as concern about potential adverse events, 
planning a pregnancy, and a change of mind.
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The Chi-square test and Fisher’s exact test were used for comparisons of categorical data, 
and the Mann-Whitney test for non-parametric continuous data. Multiple nominal logistic 
regression was employed to examine the potential interaction between factors such as the 
type of epilepsy and the antiepileptic drug prescribed, and to assess the difference between 
individual drugs in terms of treatment response. All statistical tests were two-tailed. 
Calculations were made using Minitab for Windows (Release 11.21) software.
2.3 Results
2.3.1 Patient demographics
Four hundred and seventy (51% male) previously untreated patients with newly diagnosed 
epilepsy entered the study. The median follow-up period was 5 years (range, 2 to 15 years), 
with 91% of patients attending the clinic for at least three years. The median age at referral 
was 29 years (range, 9 to 93 years), and the median age at onset of epilepsy was 26 years 
(range, 1 to 92 years). One hundred and nineteen patients (25.3%) were classified as 
having idiopathic epilepsy, 138 (29.4%) as having symptomatic epilepsy, and 213 (45.3%) 
as having cryptogenic epilepsy (Table 12).
2.3.2 Epilepsy type
Overall, 47% patients became seizure-free on the first ever AED. A higher proportion of 
patients with localisation-related epilepsy (symptomatic or cryptogenic) came off their first 
drug due to intolerable side-effects (17% compared to 8.5% in patients with idiopathic 
epilepsy; p=0.025; relative risk 2.00; 95% confidence interval (Cl) 1.06 to 3.78) and a 
lower proportion became seizure-free (43.5% compared to 58% in patients with idiopathic 
epilepsy; p=0.007; relative risk 0.75; 95% Cl 0.62 to 0.91). There was no significant 
difference in other outcome parameters between the two patient groups (Figure 8 ). There
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Table 12. Classification and aetiologies of epilepsy in newly diagnosed patients according 
to whether their epilepsy was controlled or uncontrolled by the first ever antiepileptic drug.
Aetiology/syndrome Controlled Uncontrolled Total (%)
Idiopathic 69 50 119 (25.3)
Tonic-clonic seizures 48 37 85 (18)
Juvenile myoclonic epilepsy 18 4 22 (5)
Juvenile absence epilepsy 1 2 3 (<1)
Childhood absence epilepsy 0 1 1 (<1)
Unclassified 2 6 8 (2)
Symptomatic 60 78 138 (29.4)
Post-stroke 17 22 39 (8)
Post-traumatic 18 17 35 (7)
Cerebral atrophy 8 14 22 (5)
Tumour 4 6 10 (5)
Perinatal insult 3 4 7 (1)
Mesial temporal sclerosis 2 2 4 (1)
Cortical dysplasia 1 2 3 (1)
CNS infection 2 0 2 (<D
Arteriovenous malformation 0 1 1 (<1)
Congenital malformation 0 1 1 (<D
Demyelination 0 1 1 (<1)
Multiple causes 5 8 13 (3)
Cryptogenic 93 120 213 (45.3)
Total 222 248 470 (100)
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was no difference in response to the first AED between the symptomatic and cryptogenic 
patient groups, and among the major specific aetiological categories (Table 12).
2.3.3 Dose-response relationship
The most frequently prescribed first AEDs were CBZ (n=212), VP A (n=101) and LTG 
(n=78), which accounted for treatment in 83% of the patient population. Twenty-seven 
patients received TGB, 19 GBP, 17 OXC, and 10 FBM, all within randomised double­
blind comparative trials. The remaining 6  patients were treated with PHT. Among 
patients treated with CBZ, VPA or LTG, those who became seizure-free (CBZ, p<0.0001; 
VPA, p<0.01; LTG, p<0.001), and those who had to change treatment due to intolerable 
side-effects (CBZ, p<0.0001; VPA, p<0.01) took lower doses than those with inadequate 
seizure control (Table 13). For all 3 drugs (Figure 9), over 90% of seizure-free patients 
required only a moderate daily dose (800mg CBZ or less, 1500mg VPA or less, 300mg 
LTG or less). Little additional seizure control was achieved as the dose was further 
increased. The majority of withdrawals due to adverse events also occurred at or below 
these doses (Figure 10; CBZ: 98%, VPA: 100%, LTG: 75%).
Patients with idiopathic and symptomatic/cryptogenic epilepsy took similar mean/median 
daily doses of VPA (n=56, 1040mg/1000mg and n=45, 1202mg/1000mg, respectively). 
There was also no significant difference in LTG doses between the 2 groups (idiopathic: 
n=20, 207.5mg/200mg; symptomatic/cryptogenic: n=58, 234.9mg/200mg), but the former 
group was receiving lower doses of CBZ (n=29, 469mg/400mg) compared to the latter 
group (n=183, 568mg/600mg; p=0.05). However, for all 3 drugs, there was no significant 
difference in drug dosages between the 2  patient groups within each response category.
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Table 13. Median (interquartile range) final daily doses (mg/day) of first antiepileptic drug 
in different response groups.
Response Carbamazepine Sodium valproate Lamotrigine
Seizure-free 600 (400-600)* 1 0 0 0  (800-1000)t 187.5 (150-200)K
Inadequate seizure control 800 (600-800) 1500(1000-2000) 300 (200-400)
Intolerable side-effects 400 (275-600)* 800 (500-1200)f 300(150-375)
Idiosyncratic reaction 2 0 0  (2 0 0 ) — 100 (50-150)
Withdrew for other reasons 600 (400-800) 1250 (1000-1875) 175 (150-200)
All patients 600 (400-600) 1000 (825-1500) 200(150-300)
*p<0 . 0 0 0 1  compared to patients on carbamazepine with inadequate seizure control. 
fp< 0 . 0 1  compared to patients on sodium valproate with inadequate seizure control. 
U p<0 . 0 0 1  compared to patients on lamotrigine with inadequate seizure control.
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2.3.4 Individual drugs
There was no significant difference in the proportion of patients able to tolerate each of the 
3 major AEDs but who had inadequate seizure control, suggesting similar efficacy (Table 
14). However, more patients treated with CBZ changed medication due to adverse events 
compared to those given VPA or LTG and, consequently, fewer became seizure-free (CBZ 
vs. VPA: p=0.02, odds ratio 0.43, 95% Cl 0.20 to 0.89; CBZ vs. LTG: p=0.002, odds ratio 
0.27, 95% Cl 0.12 to 0.62). There was no difference in outcome between patients treated 
with VPA and LTG.
Although the proportions of patients receiving the drugs were different among the 
idiopathic and localisation-related groups, nominal logistic regression analysis revealed no 
significant interaction in terms of treatment outcome between epilepsy type and the AED 
prescribed, suggesting that they acted as independent factors. Nevertheless, separate sub­
analyses were undertaken for the two patient groups. A lower proportion of patients with 
idiopathic epilepsy (all with GTCS as the only seizure type) given CBZ became seizure- 
free than those treated with VPA or LTG (CBZ vs. VPA: 41% vs. 64%, p=0.04; CBZ vs. 
LTG: 41% vs. 80%, p=0.007), again largely because they had a higher withdrawal rate due 
to adverse events (CBZ vs. VPA: 28% vs. 11%, p=0.05; CBZ vs. LTG: 28% vs. 0%, 
p=0.01). Among patients with localisation-related epilepsy, a higher proportion of patients 
treated with CBZ changed treatment due to adverse events than those prescribed LTG 
(CBZ vs. LTG: 27% vs. 14%, p=0.04), although the difference in seizure-free rates did not 
reach statistical significance (CBZ vs. LTG: 41.5% vs. 55%, p=0.07). Among patients 
with symptomatic/cryptogenic epilepsy, there was no significant difference in seizure-free 
rate between those treated with CBZ and VPA (41.5% vs 49%).
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Table 14. Response to the first antiepileptic drug in newly diagnosed epilepsy.
Carbamazepine Sodium valproate Lamotrigine 
No. (%) No. (%) No. (%)
Seizure-free* 8 8 (41.5) 58 (57) 48 (61.5)
Inadequate seizure control 53 (25) 26 (26) 2 0 (26)
Changed due to adverse events* 57 (27) 13 (13) 8 ( 1 0 )
Withdrew due to other reasons 14 (6.5) 4 (4) 2 (2.5)
Total 2 1 2 ( 1 0 0 ) 1 0 1 ( 1 0 0 ) 78 ( 1 0 0 )
* Carbamazepine vs. sodium valproate, p=0.02; carbamazepine vs. lamotrigine, p=0.002.
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The most common adverse event necessitating drug withdrawal was rash (Table 15), which 
developed more often with CBZ than VPA (p=0.001). The differences in rash rate, 
however, between CBZ and LTG and between VPA and LTG were not statistically 
significant. Patients not tolerating CBZ often complained of more than one symptom. For 
VPA and LTG, the most frequent side effect leading to drug withdrawal was headache. 
Non-neurological side effects were uncommon with both these AEDs (Table 15).
2.4 Discussion
This study aimed to assess the response to the first AED. Newly diagnosed patients, 
mostly adults, were followed up prospectively as per standard clinical practice. Nearly 
50% became seizure-free on the first ever AED, and over 90% did so at moderate doses. 
The marginal benefits in terms of additional seizure control by increasing the dose further 
were relatively small. The majority of withdrawals due to adverse events also occurred at 
low doses.
Examination of response to AEDs at different dose levels had not been conducted in 
randomised studies employing flexible dosing (Richens et al, 1994; Brodie et al, 1995; 
Heller et al, 1995; De Silva et al, 1996; Brodie et al, 1999a). A similar pattern emerged for 
CBZ, VPA and LTG. Although “standard” maintenance daily doses as monotherapy up to 
2000mg for CBZ, 3000mg for VPA, and 500mg for LTG are recommended (Brodie et al, 
1996; BNF, 2000), over 90% of seizure-free patients in this study required only a moderate 
amount of AED, beyond which few more became controlled. This lack of a positive dose- 
response relationship beyond the “placebo dose” has been noted in randomised 
monotherapy studies with other new AEDs employing 2 or 3 fixed doses (Beydoun, 1997; 
Chadwick et al, 1998).
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Table 15. Adverse events among patients not tolerating the first antiepileptic drug.
Adverse events Carbamazepine Sodium valproate Lamotrigine
(n=2 1 2 ) (n=1 0 1 ) (n=78)
No. (%) No. (%) No. (%)
Rash 2 2 ( 1 0 ) 0 (0 ) 3 (4)
Headache 1 2 (6 ) 4 (4) 2 (3)
Dizziness 1 0 (5) 1 (1 ) 0 (0 )
Nausea/vomiting 9 (4) 2 (2 ) 0 (0 )
Dysphoria 6 (3) 2 (2 ) 1 ( 1 )
Somnolence 6 (3) 1 (1 ) 1 ( 1 )
Fatigue 4 (2 ) 0 (0 ) 0 (0 )
Ataxia 2 ( 1) 0 (0 ) 0 (0 )
Cognitive disturbance 1 (<1 ) 1 (1 ) 0 (0 )
Change in mood 1 (<1 ) 0 (0 ) 2 (3)
Tremor 0 (0 ) 2 (2 ) 0 (0 )
Visual disturbance 1 (<D 1 ( 1 ) 0 (0 )
Insomnia 1 (<1 ) 0 (0 ) 0 (0 )
Itch 1 (<1 ) 1 0 ) 0 (0 )
Impotence 1 (<1 ) 0 (0 ) 0 (0 )
Hyponatraemia 1 (<D 0 (0 ) 0 (0 )
Total adverse events* 78 15 9
Patients withdrawn+ 57 (27) 13 (13) 8 ( 1 0 )
* Some patients reported more than one adverse event.
+ Carbamazepine vs. sodium valproate, p=0.02; vs. lamotrigine, p=0.002.
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Since AED doses are often progressively increased in patients with uncontrolled seizures, 
it is perhaps not surprising that these patients received a higher average dose compared to 
the seizure-free patients. Patients intolerant of AED treatment also took a lower average 
dose compared to the responding patients, and the majority of withdrawals due to adverse 
events occurred at low doses. The reasons for such extreme difference in response 
(seizure-freedom to intolerability at relatively low doses) is poorly understood, but may 
reflect underlying neuropathologies and pharmacogenetic factors (Part I; Section 5.2). 
Effectiveness (efficacy and tolerability) of an AED may, therefore, be determined in most 
patients when a moderate dose is reached. Escalating the dose to potentially toxic levels 
will improve seizure control in only a few more patients, while many more may have been 
delayed or even denied the opportunity of more effective treatment with alternative or 
combination therapy (Part I; Section 3.3.3) or epilepsy surgery (Part I; Section 3.4).
Patients with symptomatic/cryptogenic epilepsy were less able to tolerate AED treatment 
compared to those with idiopathic epilepsy. CBZ was less well tolerated than VPA or 
LTG. Although more patients with localisation-related epilepsy were given CBZ than the 
other 2 AEDs, as would be expected in routine practice, the differences in tolerability 
among the 3 drugs were more marked for patients with idiopathic epilepsy. This suggests 
that epilepsy type and choice of AEDs affected outcome independently, as was also 
supported by the multiple logistic regression analysis.
Tolerability of individual AEDs appeared to be an important factor in determining overall 
effectiveness. VPA and LTG were better tolerated than CBZ in this cohort of newly 
diagnosed patients. Similar findings have been reported in randomised trials comparing 
CBZ and VPA, and CBZ and LTG, involving previously untreated patients (Part I, Section 
3.3.4.3; Richens et al, 1994; Brodie et al, 1995; Heller et al, 1995; De Silva et al, 1996;
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Brodie et al, 1999a). The Veterans Affairs study (Mattson et al, 1992), which concluded 
superior control of complex partial seizures for CBZ compared to VPA, had many different 
patient and study characteristics from the present study population, including the enrolment 
of previously treated and mainly older males and the usage of high VPA doses (Reynolds 
et al, 1993).
Comparisons between the 3 drugs in this observational study inevitably suffer from 
potential confounding factors, including bias in selection of AEDs for individual patients. 
In addition, although CBZ is effective against primary generalised tonic-clonic seizures 
(Part I; Section 3.3.4), it is possible that it was prescribed to some patients with absence or 
myoclonic seizures which it may exacerbate (Brodie and Dichter, 1996) and which might 
not have been apparent at initial presentation. This may have contributed to its lower 
seizure-control rate compared to VPA and LTG which have a wider range of activity (Part 
I; Sections 3.3.4.4 and 3.3.5.1), and highlights the advantage of broad-spectrum AEDs for 
newly diagnosed patients (Brodie, 1999). A randomised trial in patients with well-defined 
seizure types is required to confirm the differences in seizure-free rate among the 3 drugs 
observed in this study.
The study described in Part II; Section 1 suggested that patients with a known or probable 
structural cerebral abnormality are more likely to have refractory epilepsy compared to 
those with idiopathic epilepsy which is presumed to have a genetic origin. This study 
suggests that a reduction in their ability to tolerate AED therapy may contribute to this 
difference in prognosis. Although these patients received a higher average dose of CBZ 
compared to those with idiopathic epilepsy, the majority of adverse events necessitating 
drug withdrawal occurred at low doses. Therefore, difference in doses, and the 
disproportionate distribution of the drugs across the patient groups, could not wholly
104
account for the difference in tolerability between them. Variation in tolerability of AEDs 
between patients with different seizure types has also been noted in randomised studies 
(Richens et al, 1994). Why this should be the case is unclear.
2.5 Conclusion
Approximately 50% of newly diagnosed patients will become seizure-free on the first AED. 
Over 90% will do so at modest doses. Effectiveness (efficacy and tolerability) of an AED 
may be determined in most patients when a moderate dose is reached. Alternative or 
combination therapy should be considered early. Tolerability is as important a factor as 
efficacy in determining drug choice (Mattson et al, 1985; Brodie et al, 1995; Beydoun,
1997; Chadwick, 1997; Brodie et al, 1999a; Brodie and Kwan, 2001).
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3 Natural history of treated epilepsy — Substitution or add-on after the first drug 
fails?
3.1 Introduction and aim
When and how combination of AEDs should be used in patients unresponsive to 
monotherapy is not known. Results from long-term outcome studies, including that carried 
out at the Epilepsy Unit described in Part II; Sections 2, as well as randomised trials 
(Mattson et al, 1992; Richens et al, 1994; Brodie et al, 1995; Beydoun, 1997) suggest that 
fewer than 50% of newly diagnosed patients will become seizure-free on the first AED.
An alternative drug is unavoidable when the patient develops intolerable adverse events, 
but when seizures persist despite a sufficient dose being tolerated, it is unclear whether or 
not substitution should be tried before a combination of two drugs is used (Schmidt and 
Gram, 1995).
This controversy arises largely because the natural history of newly diagnosed epilepsy in 
response to treatment is not well understood (Part I; Section 4). Since the advantages of 
single- over multiple-drug treatment, particularly in terms of side effect profile, were 
demonstrated by a series of studies in the late 1970s and early 1980s (Part I; Section 3.3.2), 
monotherapy has rightly become the established principle for managing new onset epilepsy. 
However, the explosion of new AEDs in the past decade with their different mechanisms 
of action and generally better tolerability, has raised the possibility of effective and safe 
combinations for patients unresponsive to monotherapy (Part I; Section 3.3.3). The 
effectiveness of substitution and add-on therapy after treatment with the first AED has 
failed was examined in a cohort of newly diagnosed patients.
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3.2 Methods
3.2.1 Patients
The study included unselected patients in whom epilepsy was diagnosed and treatment 
initiated at the Epilepsy Unit in the Western Infirmary in Glasgow, Scotland between 1st 
January 1984 and 31st December 1997. No patients had received AED therapy prior to 
enrolment. Patients in whom treatment with the first AED was unsuccessful entered the 
study. The choice of initial treatment took into account the type of seizures and epilepsy 
syndrome and other clinical characteristics (Brodie and French, 2000; Brodie and Kwan, 
2001). After commencement of medication, patients were reviewed as described in 
Section 1.2.2 (Part II). Dosages were titrated according to recommended schedules 
(Brodie and Dichter, 1996; Dichter and Brodie, 1996) and adjusted during follow up as 
clinical circumstances dictated paying particular attention to efficacy and tolerability.
Each patient's clinical information and progress to treatment were recorded in a prospective 
database (Tobias et al, 1994).
3.2.2 Definitions
Response to medication was classified as seizure-free (absence of any type of seizures or 
auras for at least one year); failure of treatment due to inadequate seizure control despite 
able to tolerate the medication (lack of efficacy) or due to adverse events (including 
intolerable side-effects and idiosyncratic reactions); or withdrawal of treatment for reasons 
unrelated to efficacy or tolerability such as concern about potential adverse events, 
planning a pregnancy, and a change of mind. A change of drug regimen was defined as 
either substitution of an existing AED or addition of a different drug. Patients who 
developed idiosyncratic reactions or intolerable side effects were treated with an 
alternative drug (substitution). When seizure control was inadequate, either substitution or 
an additional drug (add-on) was prescribed.
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3.2.3 Statistical analysis
Patients who had to replace the first AED with a second one were analysed according to 
the reason for substitution. In order to address the clinical question of appropriate 
treatment strategy for patients who experience persistent seizures despite being able to 
tolerable the medication, response to substitution was compared to add-on therapy in those 
with inadequate seizure control on the first AED they were able to tolerate. AEDs were 
classified according to their putative primary mode of action (Part I; Section 3.2). Drugs 
that primarily act on voltage-gated sodium channels include CBZ, PHT and LTG. VGB 
and TGB enhance the inhibitory function of GABA. VPA, GBP and TPM are classified as 
having multiple mechanisms of action. The Chi-square test and Fisher’s exact test were 
used for comparisons of categorical data. All statistical tests were two-tailed. Calculations 
were made using Minitab for Windows (Release 11.2) software.
3.3 Results
3.3.1 Patient demographics
Among 470 previously untreated newly diagnosed patients referred to the clinic between 1 
January 1984 and 31 December 1997, treatment with the first AED was unsuccessful in 
248 patients (53%), who constituted the present study cohort. One hundred and thirteen 
patients had inadequate seizure control on the first drug, 98 withdrew treatment due to 
adverse events (69 intolerable side effects, 29 idiosyncratic reactions), and 37 due to other 
reasons (also described in Part II; Section 1.3.6). Fifty-two percent were male. The 
median follow-up period was 5 years (range 2-15 years). The median age at referral was 
31 years (range 9-89 years), and the median age at onset of epilepsy was 28 years (range 1- 
87 years).
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3.3.2 Substitution vs. add-on
The percentage of successful treatment declined in each successive drug regimen 
(monotherapy or polytherapy), while that of patients with inadequate seizure control rose 
progressively (Figure 11). Among the 248 patients whose epilepsy was not controlled on 
the first AED, 166 received a substituted drug, 61 (37%) of whom became seizure-free on 
this second choice. Among the 113 patients with inadequate seizure control on the first 
AED, 58 opted to continue on the same drug, 24 received add-on treatment, and 31 were 
treated with a substituted drug, only five (16%) of whom became seizure-free (Figure 12). 
Eighteen patients were not able to tolerate trials of two different AEDs, five patients three 
AEDs, and one was not able to tolerate even the fourth choice.
When a tolerable AED was eventually identified, it was still ineffective in 56 patients, 18 
of whom then received add-on treatment and four substitution, while 34 opted to continue 
on the same tolerated drug. Thus, among all patients with inadequate seizure control on 
the first AED they were able to tolerate, 42 (24 after the first drug and 18 after subsequent 
drugs lacked efficacy) received add-on therapy and 35 (31 after the first drug and four after 
subsequent drugs) received substitution. There was no significant difference (p=0.25, RR 
1.5, 95% Cl 0.63 to 3.71) in seizure-free rates (add-on: 11 out of 42, 26%; substitution: 6  
out of 35, 17%) or incidence of adverse events necessitating withdrawal (add-on: 5 out of 
42, 12%; substitution: 9 out of 35, 26%; p=0.12, RR 0.46, 95% Cl 0.17 to 1.25) between 
the two treatment strategies (Figure 13).
3.3.3 Timing and choice of combinations
Eleven patients received add-on therapy at a later stage after the substituted drug failed to 
control the seizures. None of them became seizure-free, compared to a seizure-free rate of
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Figure 11. Response to successive antiepileptic drug regimens. Numbers of patients at risk 
given on top of bars.
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Figure 13. Response to add-on or substitution in patients with inadequate seizure 
control on the first well tolerated antiepileptic drug.
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26% (n=42) among those who received add-on as soon as the first tolerated AED failed 
(p=0.05).
A variety of AED combinations were employed (Table 16). Based on the drugs’ perceived 
primary mechanisms of action, more patients became seizure-free (Figure 14) when the 
combination involved a sodium channel blocker and an AED with multiple mechanisms of 
action (36%) compared to other combinations (7%, p<0.05). None of the patients who 
received a combination of a sodium channel blocker and a “pure” GABA-ergic agent 
(VGB or TGB) became seizure-free.
3.4 Discussion
Among patients with inadequate seizure control on the first well tolerated AED, those who 
received a substituted drug and those who received add-on had similar seizure-free rates 
and incidence of intolerable side effects. Based on the drugs' perceived primary mode of 
action, more patients became seizure-free when the combination involved a sodium 
channel blocker and a drug with multiple mechanisms of action compared to other 
combinations. Combination therapy rendered more patients seizure-free when prescribed 
immediately after the first drug failed due to lack of efficacy than when it was delayed 
until treatment with a substitution also proved unsuccessful.
The argument against add-on therapy traditionally has been its propensity to cause greater 
toxicity without substantial improvement in outcome (Schmidt and Gram, 1995). However, 
adverse events due to pharmacokinetic and pharmacodynamic interactions between AEDs 
can be equally problematic during the substitution phase (Brodie et al, 1997b; Brodie et al, 
1999b). Only 12% of our patients given combination therapy had to withdraw treatment 
due to side effects, which was lower, although not significantly so,
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Table 16. Combinations of antiepileptic drugs prescribed to patients receiving add-on 
therapy with inadequate seizure control on first well-tolerated drug.
Combinations No. of patients
Sodium channel blocker + multiple actions 28
LTG + VPA 12
CBZ + GBP 6
CBZ + TPM 3
CBZ + VPA 2
LTG + TPM 3
LTG + GBP 1
PHT + VPA 1
Two sodium channel blockers 5
CBZ + LTG 3
CBZ + PHT 1
PHT + OXC 1
Sodium channel blocker + GABA-ergic drug 5
CBZ + VGB 2
LTG + VGB 2
CBZ + TGB 1
Two drugs with multiple actions 2
VPA + TPM 1
VPA + GBP 1
GABA-ergic + multiple actions 1
VGB + VPA 1
Sodium channel blocker + glutamate antagonist 1
PHT + REM 1
Total 42
CBZ=carbamazepine, GBP=gabapentin, LTG=lamotrigine, OXC=oxcarbazepine, PHT=phenytoin, REM=remacemide, 
TGB=tiagabine, TPM=topiramate, VGB=vigabatrin, VPA=sodium valproate, GABA=y-aminobutyric acid
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than those who changed to a second drug (26%). Ninety percent of the combinations 
employed the newer drugs, some of which are better tolerated than their older counterparts 
(Marson et al, 1997; Brodie, in press).
Although no significant difference in efficacy was observed between alternative 
monotherapy and duotherapy in our cohort, synergistic (supra-additive) effects have been 
demonstrated for certain specific combinations in comparative studies, notably VPA and 
LTG (Brodie et al, 1997b; Pisani et al, 1999). This discrepancy is likely to be due to the 
inclusion of a relatively small number of patients taking a large number of different 
combinations in the present study. Indeed, when the various combinations were grouped 
together according to the AEDs' primary mode of action, significantly more patients given 
a sodium channel blocker and a drug with multiple mechanisms became seizure-free than 
those treated with other combinations. As the mechanisms of action of the AEDs become 
better understood, it may be possible to adopt a more mechanistic approach to polytherapy 
(Deckers et al, 2000).
Combination therapy was more effective when prescribed immediately after the first drug 
failed due to lack of efficacy than when it was delayed until treatment with a substitution 
also proved unsuccessful. This difference in efficacy might reflect the severity of the 
underlying disease -- patients unresponsive to two successive AEDs might have more 
"drug resistant" epilepsy than those uncontrolled with a trial of just one drug. This 
observation again raises the question of whether pharmacoresistance is present de novo or 
evolves over time (Part I; Section 5.1). Although its clinical characteristics may be 
apparent early in the course of disease (Part II; Section 1), the self-perpetuating nature of 
seizures in some patients may account for the progressive decline in the likelihood of 
seizure-ffeedom achieved with successive treatment regimens. It is possible that some
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patients have "difficult-to-control" (but still "controllable") epilepsy at the outset, which 
with time progresses to become "uncontrollable" or "intractable", with attendant 
pharmacoresistance, neuronal changes, and cognitive and psychosocial dysfunction that 
characterise refractory epilepsy.
Findings from this observational study may have relevance to the formulation of a more 
strategic approach in managing patients with newly diagnosed epilepsy. When the first 
AED failed due to lack of efficacy, the successful rate of an alternative monotherapy was 
only 16%, compared to 47% in drug-naive patients. The chance of seizure-freedom with 
pharmacological treatment after failure of two consecutive AEDs due to inadequate 
efficacy (as opposed to poor tolerability) is slim. These patients should be assessed for 
epilepsy surgery if they have an operable structural abnormality. For the majority of 
patients not suitable for “curative” resective surgery, these preliminary observations 
suggest that effective rational polytherapy should be employed early since its delay, like 
delayed surgical intervention (Engel, 1998; 1999), might risk irreversible psychosocial 
consequences and reduce the chance of eliminating disabling seizures.
3.5 Conclusion
The comparisons between substitution and add-on, and between the different AED 
combinations inevitably suffer from confounding factors, including possible bias in patient 
selection and non-uniformity of drug regimen. Nevertheless, observations from this study 
have generated verifiable hypotheses regarding the management of epilepsy after the first 
AED fails. Randomised trials to evaluate the effectiveness of different AED mechanistic 
combinations and that of early versus late combination therapy are needed. Such a study 
involving newly diagnosed patients is underway in Glasgow.
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4 Influence of aetiology on response to antiepileptic drug treatment
4.1 Introduction and aim
Recent advances in brain imaging, in particular MRI, have allowed better identification of 
the structural abnormalities underlying localisation-related epilepsy (Duncan, 1997; 
Spencer, 1998; Part I, Section 2.2.2). These commonly include MTS, CD, cortical gliosis, 
atrophy and infarction, primary neoplasm and vascular malformations such as AVM (see 
Part I; Sections 1.4.2 and 1.4.3). Epilepsy caused by structural abnormalities is less easy to 
control with AEDs than the primary generalised (idiopathic) epilepsies (Part II, Section 1). 
Many affected patients develop refractory partial-onset seizures which may be abolished or 
better controlled following resective surgery (Part I; Section 3.4). Patients with MTS- 
induced seizures are particularly likely to have hippocampal excision (Part I; Section 1.4.2) 
because of a perceived resistance to AED treatment (van Paesschen et al, 1997a; Semah et 
al, 1998; Briellmann et al, 1998; Kim et al, 1999). CDs are also widely thought to be 
associated with refractory seizures and also may be amenable to surgery (Palmini et al, 
1991)
Published data are thus often concerned with surgical outcome in patients with partial- 
onset seizures with only a handful of studies examining the response to AED therapy. This 
is despite the global introduction in the last decade of nine novel AEDs for this indication 
(Part I; Section 3.1). This study aimed to examine the outcome in pharmacologically 
treated patients with localisation-related epilepsy secondary to a range of structural 
abnormalities.
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4.2 Methods
4.2.1 Patients
The subjects consisted of adolescents and adults with localisation-related epilepsy referred 
to the epilepsy clinic at the Western Infirmary in Glasgow, Scotland, since 1st January 1984. 
At the first visit, demographic and clinical information was obtained from each patient and 
any witness to the seizures using a standardised structured questionnaire. Information 
collected included a detailed description of seizures, previous AED treatment, and risk 
factors for epilepsy such as febrile convulsions, head trauma, and family history of 
epilepsy. Seizure type and epilepsy syndromes were classified according to the guidelines 
of the ILAE (Part I; Sections 1.2 and 1.3). Patients in whom the clinical history or EEG 
results suggested localisation-related epilepsy underwent routine MRI of the brain in the 7 
years prior to analysis. Only patients with localisation-related epilepsy were included in 
this study. They were reviewed initially every 4-6 weeks for six months and subsequently 
at least every 4 months for a minimum of 2 years. Compliance was monitored with the aid 
of on-site measurement of plasma drug concentrations at the clinic (McKee et al, 1993). 
Demographic and clinical data, results of investigations and response to treatment for each 
patient were entered systematically into an ongoing prospective database (Tobias et al, 
1994).
4.2.2 Brain MRI protocol and classification of abnormalities
A standardised brain MRI protocol was employed using a 1.0-T Siemens Magnetom 
Scanner with a head coil. T2-weighted turbo-spin-echo sequences were obtained to cover 
the whole brain in the axial plane (repetition time [TR] = 4000 ms; echo time [TE] = 120 
ms; flip angle = 180°; section thickness = 5 mm; intersection gap = 0.2 mm; field of view 
[FOV] = 230 mm; echo train = 23). Ti-weighted MPRAGE sequences were acquired in 
the coronal plane (TR = 11.4 ms; TE = 4.4 ms; flip angle = 12 °; slab thickness = 250 mm;
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effective thickness = 1.98 mm; FOV = 250 mm). Further 4 mm-thick high resolution T2- 
weighted coronal images were acquired with TR = 4465 ms; TE = 120 ms; flip angle =
180 °; FOV = 230 mm; matrix size 300 x 512. The coronal planes were perpendicular to 
the longitudinal axis of the hippocampal body.
MRIs were assessed qualitatively (Part I; Section 2.2.2) and all films were reviewed blind 
by the same radiologist with special interest in neuroradiology to ensure the veracity of the 
original report. Abnormalities were classified as CD (abnormalities of gyration, 
heterotopia, tuberous sclerosis, focal cortical dysplasia, microdysgenesis, dysembryoplastic 
neuroepithelial tumour, megalencephaly / hemimegalencephaly); MTS; cortical gliosis 
(post-traumatic brain injury); cerebral infarction; tumours (glioma, meningioma); AVM; 
and cerebral atrophy (Part I; Section 1.4.3). Patients with dual pathology (MTS and 
another structural lesion) and those with surgically resectable tumours were excluded. The 
latter were referred to another centre for consideration of epilepsy surgery.
4.2.3 Statistical analysis
Patients were divided into two groups according to whether they were seizure-free or 
uncontrolled. Seizure-freedom was defined as the absence of any type of seizures or 
auras for a minimum of one continuous year. Seizure control was assessed at the time of 
the patient’s last clinic visit. The Chi-square test was used for comparisons of categorical 
data. All statistical tests were two-tailed. Calculations were computed using Minitab for 
Windows (version 11.21) software.
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4.3 Results
4.3.1 Patient demographics
Five hundred and fifty patients (50% male, 50% female) with localisation-related epilepsy 
entered the study. Of these, 165 (30%) were taking AED treatment at time of referral. The 
median age at onset of epilepsy was 21 years (range <1-92 years). The median age at 
referral was 30 years (range 12-93 years). The median follow-up period was five years 
(range 2-15 years).
4.3.2 Brain MRI findings
Structural abnormalities were identified on brain MRI in 361 patients (6 6 %), who were 
classified as having symptomatic epilepsy. Eighty-one patients (15%) had cortical gliosis, 
73 (13%) MTS, 63 (12%) CD, 49 (9%) cerebral atrophy, 46 (8 %) cerebral infarction, 35 
(6 %) primary tumour, and 14 (3%) AVM. Brain MRI was normal in the remaining 189 
patients (34%), who were classified as having cryptogenic epilepsy. No patient was 
classified as having idiopathic localisation-related epilepsy in this cohort of adolescent and 
adult patients.
4.3.3 Treatment outcome
Overall, 312 (57%) patients were seizure-free at the time of analysis. There was no 
difference in outcome between patients with symptomatic or cryptogenic epilepsy (56% 
versus 58% seizure-free, respectively; RR 0.96, 95% confidence interval (Cl) 0.8 to 1.1). 
Patients with MTS (n=73, 42% seizure-free) were less likely to be seizure-free (Figure 15; 
p<0.01, relative risk 1.4, 95% Cl 1.1 to 1.8), than those with other pathologies (AVM: 
n=14, 78%; cerebral infarction: n=46, 67%; primary neoplasm: n=35, 63%; cortical gliosis: 
n=81, 57%; cerebral atrophy: n=49, 55% and CD: n=63, 54%). There was no statistical
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difference in outcome among patients with other lesions. Of the 63 patients with CD, 34 
(54%) were seizure-free. Thirty-six categories of dysplastic lesion were identified on brain 
MRI, the commonest being right temporal heterotopia (n=7) and bilateral periventricular 
tubers (n=6 ). No specific dysplastic lesion was associated with a particularly poor 
prognosis.
4.3.4 Antiepileptic drug regimens
Of the 312 seizure-free patients, 187 patients (60%) were receiving treatment with a single 
AED (Table 17). Eighty-three patients (27%) required two AEDs, while 15 (4.7%) were 
controlled with three drugs, and one took four. Thirty-four patients elected not to take an 
AED, 26 having never been treated and eight having discontinued therapy due to 
intolerable side-effects. Of these 34 individuals, 26 experienced only sporadic seizures 
with none in the previous year, while the remaining eight had more frequent seizures. 
Among the seizure-free patients, 48% of patients with MTS required more than one AED 
(p<0.05, relative risk 1.6, 95% Cl 1.1 to 2.4) compared to 35% of those with other 
aetiologies (20% with CD, 23% with primary tumour, 27% with AVM, 29% with 
infarction, 30% with gliosis, 44% with atrophy and 31% with cryptogenic epilepsy). 
Patients with uncontrolled epilepsy also took a range of AEDs, varying from none to four 
(Table 18).
4.3.5 Family history and history of febrile convulsion
Family history of epilepsy (first or second degree) was more common (Table 19; p=0.02) 
in patients with MTS, CD and cryptogenic epilepsy (all 25%) and AVMs (28%) than in 
those with atrophy (20%), infarction (15%), gliosis (9%) and neoplasia (6 %). The presence 
of a family history tended to convey a better prognosis in the MTS patients (present: n=18,
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Table 17. Seizure-free patients on no treatment and on different antiepileptic drug (AED)
regimens.
Aetiology Patients 
n (%)
No AED 
n (%)
1 AED 
n (%)
2 AEDs 
n (%)
3 AEDs 
n (%)
4 AEDs 
n (%)
MTS 31 (1 0 0 ) 7(23) 9(29) 12 (39) 2 (6 ) 1(3)
CD 34(100) 5(15) 22 (65) 6(17) 1(3) 0 (0 )
Atrophy 27 (100) 1(4) 14 (52) 11 (40) 1(4) 0 (0 )
Gliosis 46 (100) 3(7) 29 (63) 1 2  (26) 2(4) 0 (0 )
Tumour 2 2  ( 1 0 0 ) 1(5) 16 (72) 4(18) 1(5) 0 (0 )
Infarction 31 (100) 1(3) 2 1  (6 8 ) 7(22) 2(7) 0 (0 )
AVM 1 1  ( 1 0 0 ) 1(9) 7(64) 2(18) 1(9) 0 (0 )
Cryptogenic 1 1 0 ( 1 0 0 ) 7(6) 69(63) 29 (27) 5(4) 0 (0 )
Total 312(100) 26 (8 ) 187(60) 83 (27) 15 (4.7) 1 (0.3)
MTS = mesial temporal sclerosis; CD = cortical dysgenesis; AVM = arteriovenous 
malformation
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Table 18. Patients uncontrolled on no treatment and on different antiepileptic drug (AED)
regimens.
Aetiology Patients 
n (%)
No AED 
n (%)
1 AED
n (%)
2 AEDs 
n (%)
3 AEDs 
n (%)
4 AEDs 
n (%)
MTS 42 (100) 1 (2 ) 7(17) 24 (57) 10 (24) 0 (0 )
CD 29(100) 2(7) 10 (34) 13 (45) 3(10) 1(4)
Atrophy 2 2  ( 1 0 0 ) 1(4) 9(41) 8(37) 3(14) 1(4)
Gliosis 35 (100) 1(3) 15 (43) 11(31) 8(23) 0 (0 )
Tumour 13(100) 0 (0 ) 2(15) 7(54) 4(31) 0 (0 )
Infarction 15 (100) 0 (0 ) 7(47) 6(40) 2(13) 0 (0 )
AVM 3 (100) 0 (0 ) 1(33) 2(67) 0  (0 ) 0 (0 )
Cryptogenic 79 (100) 3(4) 29 (36) 41 (52) 6  (8 ) 0 (0 )
Total 238 (100) 8(3) 80 (34) 112(47) 36(15) 2 ( 1)
MTS=mesial temporal sclerosis; CD=cortical dysplasia; AVM=arteriovenous 
malformation
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Table 19. Family history of epilepsy and history of febrile convulsions in different patient 
groups.
MTS CD Atrophy Gliosis Tumour Infarction AVM Normal MRI
No. o f patients 73 63 49 81 35 46 14 189
Family history (%) 18* (25) 16*(25) 10 (20) 8 (9 ) 2 (6 ) 7 (15 ) 4*(28) 48*(25)
Febrile convulsion (%) 27+ (37) 7(11) 8 (16) 3 (4 ) 0 (0 ) 2 (4 ) 0 (0 ) 23 (12)
MTS=mesial temporal sclerosis, CD=cortical dysplasia, AVM=arteriovenous 
malformation; MRI=magnetic resonance imaging 
* p<0 .0 2 ; + p<0 . 0 0 1  compared with other patient groups.
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61% seizure-free; absent: n=55, 36% seizure-free; p=0.065, RR 1.6, 95% Cl 1.0 to 2.8). 
MTS patients were more likely to have had febrile convulsions (Table 19) than those in the 
other groups (p<0.001, relative risk 4.1, 95% Cl 2.7 to 6.2), although this did not appear to 
affect outcome (present: n=27, 41% seizure-free; absent: n=46, 43% seizure-free).
4.4 Discussion
Over half of the patients with pharmacologically managed localisation-related epilepsy in 
this study become seizure-free. The majority were taking monotherapy. MTS patients were 
significantly more likely to be refractory and to require more than one AED to attain 
seizure-freedom. Within this pathological grouping, however, there was substantial 
variation in seizure control, ranging from seizure-freedom on no AEDs to refractory on 
four. This phenomenon was observed in patients with other diagnoses. Complete seizure 
control was achieved in the majority of patients with CD. No difference in outcome was 
found between patients with symptomatic or cryptogenic epilepsy. The latter had similar 
rates to patients with CD for seizure-freedom, and epilepsy risk factors. A family history of 
epilepsy was more common in patients with MTS, CD, cryptogenic epilepsy and AVM. 
This characteristic seemed to convey a better prognosis for patients with MTS. A history of 
febrile convulsions was statistically more prevalent in MTS patients compared to those 
with other pathologies.
Consistent with other reports (Part I; Section 1.4.2), patients with MTS had the poorest 
prognosis. There are few data, however, with which these outcomes can be compared. 
Semah and colleagues (1998) studied seizure frequency over one year in a cohort of 1369 
out-patients with localisation-related epilepsy. As in the present study, patients with 
infarcts, vascular malformations and tumours had the best prognosis with 54%, 50% and 
46% being seizure-free respectively. Their outcomes for MTS patients were poorer with
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only 11% being fully controlled. Only 8 % of the cohort were newly diagnosed, however, 
and the remaining pharmacoresistant patients contributed to the low seizure-freedom rates. 
Van Paesschen and co-workers (1997) examined for one year 63 out-patients with seizures 
who underwent brain MRI. Of these, all six with MTS remained refractory despite AED 
treatment, unlike 57 with other pathology, 30 of whom became seizure-free. Kim and 
colleagues (1999) reported that 25% of 104 out-patients taking AED treatment for MTS 
remained seizure-free during 2 years’ follow-up. Again, the majority were previously 
taking AEDs at time of referral with only 15% being newly diagnosed. Briellmann and 
colleagues (1998) also published a report on 47 patients with MTS being assessed for 
surgery. Not surprisingly, none was seizure-free.
The reason of the particular pharmacoresistant nature of MTS is unclear (Part I; Section
5.2). Over-expression of P-glycoprotein to limit AED access to the seizure focus has been 
suggested (Part I; Section 5.2.2). The potential role of P-glycoprotein in epilepsy will be 
discussed in detail in Part III.
Over half of the patients with CD in the present study attained complete seizure control. 
These patients fared much better than those studied by Semah and colleagues (1998) who 
observed that only 24% of patients with this diagnosis were seizure-free. Palmini and co­
workers (1991) examined 30 patients with CD-related refractory seizures. All but five had 
never experienced remission of their seizures. This study may have selected out a 
particularly pharmacoresistant population, however, since these patients were being 
considered for epilepsy surgery. The variability in outcomes within CD patients may 
reflect the wide range of lesions which comprise the condition (Kazee et al, 1991; 
Armstrong, 1996; Raymond et al, 1995; 1996).
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While patients with MTS and CD in this report had a more promising outlook than those 
previously studied, there was substantial heterogeneity among this group with some 
patients in remission off treatment while others continued to have seizures despite taking 
up to 4 AEDs. Murakami and colleagues (1996) observed this variability in children with 
MTS. The phenomenon may be a reflection of the natural history of the heterogeneous 
conditions, although this is difficult to explore given the low incidence and the fact that the 
course may be altered by AED therapy and/or surgery in most patients with seizures. The 
reporting at autopsy of MTS among non-epileptic subjects substantiates this theory (Crome, 
1955; Crystal et al, 1993; Dickson et al, 1994).
A family history of epilepsy was present in 25% patients with MTS. Interestingly, this 
seemed to convey a better prognosis, suggesting perhaps a hereditary component to the 
disease process in some patients (Fernandez et al, 1998). Such an association has been 
noted in patients who underwent temporal resection, although they had a variety of 
pathologies (Abou-Khalil et al, 1993). Febrile convulsions occurred in 37% patients with 
MTS, a higher figure than in all other groups. This is a well-recognised relationship 
(Fernandez et al, 1998). A history of febrile convulsions did not affect outcome in the 
present study. In previous studies, this has been associated with poorer response to AED 
treatment (Kim et al, 1999), but better outcome after temporal resection (Abou-Khalil et al, 
1993). It has been postulated that a pre-existing hippocampal lesion may predispose some 
individuals to febrile convulsions, MTS and a tendency towards refractory epilepsy, rather 
than febrile convulsions being the causative factor (Fernandez et al, 1998; Fisher et al,
1998; Hamati-Haddad and Abou-Khalil, 1998).
Patients with CD and AVM had a higher prevalence of family history of epilepsy than 
those with infarcts, gliosis and neoplasia. CD may be the result of familial disorders such
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as tuberous sclerosis or neurocutaneous syndromes (Shorvon, 1997). MTS with 
duplication / dispersion of the dentate fascia may be a form of CD (Raymond et al, 1994). 
The association of family history in patients with AVM may be explained by previous MRI 
findings that up to 75% sporadic cases of cavernous angiomas are familial (Labauge et al, 
1998).
Characteristics of patients with normal brain imaging were similar to those with CD, in 
terms of percentages of patients seizure-free (58% and 54% respectively), those with a 
family history of epilepsy (25% each), and those with a history of febrile convulsions (12% 
and 11% respectively). This lends credence to the suggestion that some patients with 
cryptogenic epilepsy may have cortical microdysplasia. Microdysgenesis can increasingly 
be identified by sophisticated neuroimaging techniques (Sisodiya et al, 1996).
4.5 Conclusion
In conclusion, outcome in patients pharmacologically treated for symptomatic or 
cryptogenic localisation-related epilepsy was highly variable. Whilst MTS was associated 
with the poorest prognosis, many more patients with the diagnosis were seizure-free than 
in previous studies. Encouraging results were also obtained for patients with CD.
Although many patients with MTS and some with CD will benefit from resective surgery, 
a considerable number will be controlled on AED therapy. Multicentre prospective studies 
are required to assess the clinical course in pharmacologically treated patients with newly 
diagnosed localisation-related epilepsy as a consequence of these pathologies.
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5 Glutamic acid decarboxylase autoantibodies in epilepsy
5.1 Introduction and aim
GAB A, the major inhibitory neurotransmitter in mammalian brain, is formed exclusively 
from L-glutamic acid via an irreversible reaction catalysed by GAD (Fariello et al, 1991; 
Part I; Section 3.2.4). Apart from GABA-ergic neurons in the central and peripheral 
nervous systems, GAD is present in pancreatic (3-cells, epithelial cells of the fallopian tube, 
and within the spermatozoa of the testes (Folli, 1998; Erdo and Wolff, 1990). GAD is a 
dominant autoantigen in insulin dependent diabetes mellitus (IDDM) and stiff man 
syndrome (SMS), a rare neurological disorder characterised by progressive and fluctuating 
muscle rigidity and painful spasms (Ellis and Atkinson, 1996; Atkinson, 2000). In IDDM, 
immune response to GAD and other islet-cell antigens is thought to be involved in the 
destruction of insulin-secreting cells (Lohmann et al, 2000) while GAD autoantibodies 
have been suggested to inhibit GAB A synthesis in SMS (Dinkel et al, 1998).
There have been recent case reports of elevated GAD autoantibodies in patients with 
refractory partial seizures (Part I; Section 5.2.2). Impairment of GAB A function is 
recognised to provoke seizures while glutamate is a pro-convulsant (Meldrum, 1995).
Many AEDs exert their anticonvulsant effect by facilitating GABA-ergic activities (Table 
4). Based on such theoretical consideration and anecdotal case reports, a causal 
relationship between GAD autoantibodies and refractory epilepsy has been postulated and 
immunotherapy has been advocated as treatment (Giometto et al, 1998). Whether GAD 
autoantibodies are associated with seizure disorders in general or with specific epilepsy 
syndromes, and perhaps more importantly, with refractoriness, has not been studied.
To explore the hypothesis that elevated GAD antoantibodies may be associated with 
therapy resistance, a pilot study was conducted to compare titres between patients with
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controlled and uncontrolled epilepsy. To maximise the applicability of the results to 
everyday clinical practice, common epilepsy types and aetiologies of both idiopathic and 
symptomatic nature were chosen.
5.2 Methods
5.2.1 Patients
One hundred and five patients (44% male) with a diagnosis of juvenile myoclonic epilepsy 
(an idiopathic syndrome), or with partial-onset seizures as a result of mesial temporal 
sclerosis, cortical dysplasia, or cortical gliosis were enrolled. Thirty one patients had been 
seizure-free for at least one year while the epilepsy had been refractory to AED treatment 
in the remaining 74 patients (Table 20). All were attending the Epilepsy Unit in Glasgow, 
Scotland. Median age was 37 years (range 17 to 71 years) and median duration of epilepsy 
was 13 years (range 2 to 59). None of the patients had a history of IDDM or SMS. The 
study was approved by the Western Ethics Committee and all patients gave written 
informed consent to their participation.
5.2.2 Measurement of serum GAD autoantibodies
GAD autoantibodies were measured in the serum by radioimmunoassay, which has been 
established as a sensitive and specific detection technique (Schranz and Lemmark, 1998). 
Aliquots of lOOp.1 of standards (human serum containing GAD antibodies supplied at 
different dilutions expressed in arbitrary units, U/mL) and serum samples were incubated 
with 200jxl of I125-labelled GAD antibodies complexed to GAD in tubes coated with GAD 
antibodies for 24 hours at room temperature (BRHAMS Diagnostic GmbH, Berlin, 
Germany). Extra tracer was washed off and radioactivity of each tube was measured in a 
gamma scintillation counter for 1 minute. The amount of radioactivity was inversely
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Table 20. Median glutamic acid decarboxylase autoantibody titres (confidence intervals) 
in patients with controlled and uncontrolled epilepsy.
Syndrome No.
Controlled 
Titre (95% Cl) No.
Uncontrolled 
Titre (95% Cl)
Mesial temporal sclerosis 9 0.48 (0.22-0.91) 31 0.56 (0.33-0.86)
Cortical gliosis 7 0.46 (0.08-1.12) 17 0.46 (0.16-0.65)
Cortical dysgenesis 7 0.57 (0.25-0.77) 15 0.63 (0.23-0.84)
Juvenile myoclonic epilepsy 8 0.68 (0.26-1.50) 1 1 0.40 (0.16-0.96)
Total 31 0.48 (0.36-0.78) 74 0.50 (0.37-0.65)
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proportional to the concentration of autoantibodies in the patient sample. The results were 
interpolated in the standard curve. All samples were tested in duplicate and the mean taken 
for presentation.
5.2.3 Other tests
Random blood glucose was measured in all patients to screen for undiagnosed diabetes 
mellitus. The sera of patients with elevated GAD autoantibody titres were tested for other 
autoantibodies, including pancreatic islet cell antibody, antinuclear antibody, extranuclear 
antibodies, anti-gastric parietal cell antibody, intrinsic factor antibody, anti-thyroid 
antibodies, and rheumatoid factor.
5.2.4 Statistical analysis
The Mann-Whitney test was used for comparisons of non-parametric continuous data. 
Correlation was employed to examine the possible association between GAD autoantibody 
titre and duration of epilepsy or seizure frequency. Statistical calculations were performed 
with use of Minitab for Windows software (version 11.21).
5.3 Results
There was no significant difference in serum GAD autoantibody titres between patients 
who were seizure-free and those with uncontrolled epilepsy, either analysing the 
syndromes in combination (Figure 16) or individually (Table 20). There was no significant 
association between the titre of GAD autoantibody and duration of epilepsy or seizure 
frequency. However, four female patients with uncontrolled epilepsy had GAD 
autoantibody levels at least three times above the highest titre measured in the seizure-free 
cohort (Table 21). Two of the four patients had mesial temporal sclerosis and one cortical 
dysplasia. The highest titre by far (170.4 U/ml) was found in the fourth patient (patient 1
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on Table 21) who had juvenile myoclonic epilepsy. She also tested positive for pancreatic 
islet cell antibody and antinuclear antibody (1 in 640). Pancreatic islet cell antibodies were 
detected in two other patients (patients 3 and 4 on Table 21). None had other systemic or 
organ-specific autoantibodies, or a family history of IDDM or autoimmune diseases. 
Random blood glucose levels were normal in all four. All had been treated unsuccessfully 
by a variety of AEDs with different mechanisms of action (Table 4), including facilitation 
of GABA-ergic activity.
5.4 Discussion
A causal relationship between GAD autoantibodies and epilepsy has been postulated based 
on anecdotal case reports, and immunotherapy, such as corticosteroids and intravenous 
immunoglobulins, has been advocated as treatment (Giometto et al, 1998). However, in 
these patients, additional features were present such as SMS (Solimena et al, 1988), 
diabetes mellitus (Saiz et al, 1997), impaired glucose tolerance (Nemni et al, 1994), or 
acute encephalitis (Giometto et al, 1998), all of which might explain the presence of GAD 
autoantibodies.
No difference in GAD autoantibody titres between seizure-free patients and those with 
refractory epilepsy was detected in this pilot study, or any relationship between GAD 
autoantibody titre and seizure frequency or duration. Four female patients with refractory 
epilepsy did appear to have higher antibody levels compared with the rest of the cohort. 
However, three of them also harboured pancreatic islet cell antibodies, which can be found 
in association with IDDM (Schranz and Lemmark, 1998), suggesting co-existing 
autoimmune damage to the pancreas and a possible pancreatic source of the GAD
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antoantibodies. There were no other shared clinical characteristics among these patients. 
Theoretically, they should be more responsive to AEDs that enhance GABA function, but all 
had failed treatment with GABAergic agents.
There has been recent renewed interest in the potential role of the immune system in the 
pathogenesis of epilepsy. Antibodies to glutamate receptor subtype GluR3 have been found 
in patients with Rasmussen’s encephalitis, but this is not always so and the condition often 
does not respond to immunotherapy (Dulac, 1996). Anti-GMl antibodies were detected in 4 
out of 64 patients with epilepsy in one study (Bartolomei et al, 1996) but whether the 
antibodies affect treatment outcome has not been examined. Likewise, the clinical 
significance of raised GAD autoantibodies in epilepsy remains to be determined. A recent 
Finnish study detected GAD autoantibodies in 8  out of 100 patients, but the two with highest 
levels had either a clinical history or serological evidence of autoimmune disease (Peltola et al, 
2000). Finding of elevated GAD autoantibody titre in a patient with drug-resistant epilepsy 
should, therefore, prompt a search for other autoantibodies, particularly those against the 
pancreas.
5.5 Conclusion
Although results from this pilot study do not suggest an association between elevated GAD 
autoantibodies and pharmacoresistance in common epilepsy types, studies in larger patient 
populations are required to confirm this. It is possible that their presence or influence on 
outcome is syndrome-specific, and was, therefore, not detected in the mixed patient sample
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studied. Any potential therapeutic role of immunotherapy needs to be evaluated in a double­
blind, placebo-controlled trial.
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6 General discussion and conclusion
Epidemiology can provide understanding about the incidence, prevalence, associated 
mortality and potential risk factors for a given condition. These aspects have been vigorously 
studied in epilepsy patients across continents in recent years (Part I; Section 1). However, it 
is the understanding of the natural history that potentially can have a direct impact on 
planning health services for people with epilepsy. Formulation of a more rational and 
strategic approach to the management of epilepsy thus formed the underlying objective of the 
series of prospective observational studies involving newly diagnosed patients described in 
this part of the thesis.
6.1 Methodological factors concerning study design and statistics
The series of outcome studies described in Part II, Sections 1-4, undoubtedly suffer from a 
number of methodological disadvantages, partly resulting from the setting in which they were 
carried out. The studies were conducted in a single centre. In order to maximise the study 
population and to document the long-term outcome of newly diagnosed patients, the study 
period stretched some 15 years. Such a long duration may be a weakness in itself in view of 
the many momentus changes in the management of epilepsy over this period of time, 
including classification, imaging technology and treatment.
To compensate for these possible confounding factors, the classification for each patient took 
into account all accumulated clinical and investigational information over the years and 
reflected the final classification at the follow up. Although many new AEDs have entered the 
market over the study period, they are still being prescribed to a minority of patients and there
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is no strong evidence that they have made a substantial impact on the prognosis of epilepsy, at 
least in the fashion they are presently utilised. In addition, the studies aimed to seek a 
“generic” understanding of patients’ reponse to AED treatment. Specific drugs were not 
compared except in an exploratory manner for the first AED prescribed in Part II, Section 2.
Conducting clinical studies in a single centre also risks the possibility of patient selection bias 
imposed by the characteristics of the centre and the setup of the health care service in which it 
operates. Apart from the Epilepsy Unit at the Western Infirmary, the other major epilepsy 
service in Glasgow is situated at a separate hospital specialising in the management of 
neurological diseases (the Institute of Neurological Sciences). It is possible that general 
practitioners might preferentially refer patients with associated neurological disorders to the 
latter. Since such patients in general have a poorer prognosis (Annegers et al, 1979), results 
from the Epilepsy Unit described in this thesis might have over-estimated the seizure-free rate.
Perhaps the most important limitation of the results relate to the nature of the studies. In the 
strictest sense, these studies were not “prospective” since it was not possible to define the 
exact parameters and variables to be analysed some 15 years ago. On the other hand, data 
were collected “longitudinally” and patients were unselected apart from the criteria that they 
were newly diagnosed or not on AED treatment at inclusion. This should have minimised the 
amount of missing data seen in the more typically “retrospective” or “case review” studies.
The parameters and statistical techniques employed to assess outcome in these studies also 
need discussion. Outcome definitions used in the literature are heterogeneous. Parameters
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such as number of seizures, seizure frequency, time to recurrence of seizures, time to 
remission, attainment of remission for a certain length (“remission ever” or “cumulative 
remission”), and length of “terminal remission” have all been used. The last two have been 
the favoured measurements in the more recent studies (Shafer et al, 1988; Cockerell et al, 
1995b). Measuring “remission ever” may not be relevant if the epilepsy subsequently 
becomes resistant to treatment after relapse. Terminal remission was chosen as the outcome 
measure in the studies described in this thesis. It has the practical advange of easy 
applicability and is probably most clinical relevant since it has a direct bearing on a patient’s 
present quality of life. Its main disadvantage is perhaps over-estimation of poor outcome 
since occurrence of only one seizure in the last year of follow-up would result in classification 
into the poor outcome group. A combination of terminal remission and longest cumulative 
remission period would probably be the best measurement.
Previous large-scale outcome studies (Shafer et al, 1988; Cockerell et al, 1995b) have tended 
to use the acturial, life-table approach to assess the probability of remission and compare risk 
factors, although the more straight-forward logistic regression analysis have also been used 
(Arts et al, 1999). The former has the clear advantage of describing outcome in relation to 
time, whereas the latter can only analyse predictors of outcome variables in a binary fashion. 
The main aim of the outcome studies described in this thesis was to document the course of 
epilepsy in relation to drug treatment instead of the traditional time factor (see Part I; Section
4.2.2). A “suvival curve” of seizure-freedom in relation to successive drug regimen was 
constructed for this purpose (Figure 7). Another important aim was to examine the predictive 
value of the response to the first AED for final outcome, which has not been attempted in
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previous studies. In view of the exploratory nature of this analysis, relatively simple binary 
analysis was adopted to generate results that would guide the design of future studies. It is 
acknowledged that in hindsight, the more sophisticated acturial approach would probably 
produce additional useful information, and should certainly be employed in more definitive 
prospective studies in the future (see Overall Discussion and Conclusion).
6.2 Newly diagnosed epilepsy -  a continuum or two populations?
The past decade has witnessed unprecedented advances in the understanding of the 
pathophysiology of seizures and epilepsy, diagnostic and investigational technologies (Part I; 
Section 2.2), coupled with a more realistic assessment of the long-term prognosis of the 
epilepsies (Part I; Section 4.2). Since effective treatment for epilepsy has been available for 
nearly a century, modem outcome studies (at least in developed countries where treatment is 
widely available) reflect the natural history of epilepsy in response to treatment. Yet in spite 
of the considerable number of such studies and their consistent finding of a remission rate of 
65-80% (Table 7), there is a paucity of documentation concerning the chronological progress 
from the point of diagnosis (or initiation of treatment) to the state of seizure-freedom or 
"refractoriness”. In other words, what is the likelihood of success or failure of each 
successive treatment regimen? The importance of such knowledge might not have been 
apparent when there were only limited therapeutic options of similar efficacy. However, this 
is no longer the case in epilepsy where there has been an exponential increase in the number 
of AEDs (Part I; Section 3.1) and a dramatic improvement in surgical outcome of selected 
patient groups since the 1980s (Part I; Section 3.4). For the (still) minority with surgically 
correctable lesions, a better understanding of the natural history of epilepsy in response to
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AED treatment is required to aid deciding the timing of operation. For the majority "non- 
surgical candidates", such knowledge can provide a framework to guide practical AED use, in 
terms of when, how and what monotherapy or polytherapy should be employed.
Central to this management template are the two seemingly antagonistic concepts concerning 
the development of "refractoriness" — is it a de novo, "predetermined", inevitable state, or an 
evolving, and thus potentially preventable process (Part I; Section 5.2)? Is it possible that 
they are both “correct”? Many hold that the outcome of most epilepsies is determined 
primarily by aetiology and syndromic classification (Perucca et al, 2000). This view is 
supported by findings of the study on newly diagnosed patients described in Part II; Section 1, 
that subsequent “refractoriness” may be predicted by clinical characteristics present early in 
the course of the disease. Such parameters included a structural cerebral abnormality, 20 or 
more seizures before starting treatment, and, most importantly, the reason for failure on the 
first AED. Only 11% of patients who had inadequate seizure control (as opposed to poor 
tolerability) on a sizeable dose of the first AED later became seizure-free (Figure 6 ).
When treatment outcome on the first ever AED was examined more closely in Part II; Section 
2, a similar response pattern to the most commonly prescribed drugs emerged. More than 
90% of the responding patients to the first AED required a moderate dose (CBZ up to 800mg, 
VPA up to 1500mg, LTG up to 300mg) with few more becoming seizure-free at higher 
dosage. Interestingly, poor tolerability largely occurred at doses lower than needed for good 
efficacy, and occurred more commonly in patients with symptomatic/cryptogenic epilepsies 
than idiopathic epilepsies. These results push the likely recognition of subsequent
144
“refractoriness” even further, to the point when a moderate dose of the first AED is tolerated 
but not wholly effective.
The outcome of localisation-related symptomatic/cryptogenic epilepsies was investigated 
more specifically in a separate study (Part II; Section 4). Even within this patient sub­
population, response to AED treatment was determined by the nature of the underlying lesion, 
with MTS-related seizures being the most pharmacoresistant. This finding may lend further 
support to the proposition that “refractory” epilepsy is present at the outset in some patients. 
However, marked variability in response to treatment was observed within any given 
underlying pathology, so that some patients remained seizure-free after withdrawal from AED 
therapy whereas others continued to have seizures despite taking polypharmacy with up to 
four AEDs. This suggests that factors other than aetiology also affect outcome.
On the other hand, the step-wise reduction in the probability of remission with successive 
treatment manipulations (Figure 7), the cellular changes associated with recurrent seizures 
recognised in both human epilepsy and animal models, and the psychosocial consequences of 
chronic epilepsy (see Overall Discussion and Conclusion) suggest the possible presence of a 
progressive deterioration, at least for those patients suffering from recurrent seizures despite 
AED treatment. Hence 60% of newly diagnosed patients became seizure-free on their first 
(47%) or second (13%) AED, but only 1% on the third monotherapy choice (Table 11). The 
seizure disorder in these patients, with time, had become resistant to multiple AEDs with a 
range of different mechanisms of action, a situation not dissimilar to multidrug resistant
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cancers (Part III; Section 1.2.1). The possibility of a progressive biochemical process 
associated with seizures is explored in laboratory-based studies in Part III.
6.3 A unifying hypothesis
A unifying hypothesis may be formulated from these seemingly opposing propositions. This 
series of observational studies suggest that patients with newly diagnosed epilepsy can be 
divided into two distinct populations. Around 60% will control on monotherapy. Some will 
remain in remission after withdrawal of AED therapy. This is supported by the consistently 
similar remission rate reported in outcome studies conducted in many different countries (Part 
I; Section 4.2) with distinctly different local preference of AED choice (e.g. PHT is widely 
used as the first drug in the US but much less favourable in Europe), and the similar 
effectiveness of the established first-line AEDs in comparative trials (Part I; Section 3.3.2).
Up to 40% have “difficult-to-control” epilepsy de novo, as determined by the underlying 
aetiology or syndrome. The challenge facing the clinician is to prevent these patients from 
developing the full-blown state of refractory epilepsy or “multidrug resistant” epilepsy with 
attendant pharmacoresistance, irreversible neuronal changes, cognitive deterioration and 
psychosocial dysfunction. Under this unifying hypothesis, such “refractory epilepsy” is an 
“irreversible”, but potentially preventable state by early employment of effective therapeutic 
interventions.
These interventions may include epilepsy surgery and rational AED combinations. In 
selected patient groups, the most well defined of which is MTLE associated with MTS, 
resective surgery can render up to 90% seizure-free (Part I; Section 3.4). There is now
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accumulating evidence that AED polytherapy based on mechanisms of action may improve 
effectiveness when seizures are not controlled on a single drug (Deckers et al, 2000). In the 
observational study described in Part II; Section 3, duotherapy was well tolerated, probably 
attributable to the use of the newer AEDs, some of which have a more favourable side effect 
profile than their older counterparts (Part I; Section 3.3). Data from this study are also 
consistent with the view that combinations involving a sodium channel blocker and a drug 
with multiple mechanisms of action were more effective than others, implying that a 
mechanistic approach to polytherapy has potential merits.
6.4 Conclusion
Patients with symptomatic epilepsies, particularly those with MTS, and those with inadequate 
response to initial treatment are likely to develop refractory epilepsy. Nearly 50% of newly 
diagnosed patients responded to the first AED, with 90% doing so at moderate dosing. 
Tolerability was as important as efficacy in determining the overall effectiveness of AED 
treatment. Whether early surgical intervention or rational polytherapy improves long-term 
outcome has formed the basis of testable hypotheses that are currently being actively pursued 
(Engel, 1999; Part II, Section 3.5).
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PART III
POTENTIAL ROLE OF MULTIDRUG RESISTANCE (MDR) GENE 
AND P-GLYCOPROTEIN IN EPILEPSY
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1 General introduction
1.1 The blood-brain barrier
To exert their antiepileptic effect, AEDs need to reach and maintain an adequate 
concentration at their site of action, i.e. the CNS. The steady state concentration of a drug in 
the CNS can be regarded as an equilibrium between its rate of influx and efflux (Table 22); 
(Saunders et al, 1999). The mechanisms that regulate entry at the interface between the 
systemic circulation and the brain are collectively known as the "blood-brain barrier" (BBB).
thThe concept of the BBB began to develop at the end of the 19 century, pioneered by the 
German pharmacologist and physiologist Paul Ehrlich who demonstrated that upon 
intravenous injection, acidic dyes spread throughout the rat but the CNS remained unstained 
(Ehrlich, 1885). Subsequent experiments by Goldmann (1909), Spatz (1933) and Walter 
(1930) further suggested the additional existence of a blood-cerebrospinal fluid (CSF) barrier 
formed by the endothelial and epithelial lining of the choroid plexus, while the ependyma, 
which lines the brain tissue, represents the brain-CSF barrier. Although substances that do 
not pass the BBB may nevertheless reach the CNS by extravasation in the choroid plexus, the
iL
surface area available for exchange at the blood-CSF barrier is only 1/5000 of that at the 
BBB. The BBB, therefore, constitutes the most important regulatory interface between the 
brain and systemic circulation (De Boer and Breimer, 1994).
The BBB is crucial for the protection of the brain against potentially toxic substances in the 
blood and the maintenance of a constant internal environment in which optimal neuronal 
functions can take place. For instance, blood concentrations of the excitatory
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Table 22. Main factors influencing drug accumulation in the brain (Van Bree et al, 1992; 
Saunders et al, 1999).
Influx Efflux
Passive diffusion Efflux drug pumps e.g. P-glycoprotein
Facilitated diffusion e.g. glucose The “sink” effect
Active transport e.g. amino acids, gabapentin Enzymatic metabolism and degradation
Transcytosis
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neurotransmitters glycine and glutamate are 1 0 0 0 -fold higher than in the extracellular space 
of the brain. At these concentrations both components would be neurotoxic, causing massive 
"electrical short circuits" and cell death (Schlosshauer, 1993).
Traditionally, the impermeability of the BBB is thought to be imposed by the unique 
morphological characteristics of the cerebral capillary endothelium (Johansson, 1990; Betz,
1992). Unlike non-neural ones, brain endothelial cells lack fenetrations and are joined by 
very tight junctions, blocking transport of large proteins and colloidal lanthanum. In addition, 
pinocytotic vesicles are almost absent in brain capillary endothelium (Van Bree et al, 1992;
De Boer and Breimer, 1994). The endothelial cells are completely engulfed by a basal lamina, 
which is further covered by endfeet of astrocytes, pericytes and microglia (Schlosshauer,
1993). These mechanisms effectively block the passive diffusion of large, lipid-insoluble 
compounds. In order to obtain nutrients essential for CNS cell metabolism, specific carrier 
systems are present at the blood-brain interface. The glucose transporter is the best 
characterised example of facilitated diffusion without energy consumption (Schlosshauer, 
1993). Many amino acids and some drugs, including baclofen and GBP, are actively 
transported by relatively specific systems (Van Bree et al, 1992). Transcytosis has been 
proposed as a transfer mechanism for various proteins through the BBB, including that of 
iron-loaded transferrin (Broadwell, 1989).
However, many molecules, including drugs, exhibit much lower BBB permeabilities than 
would be predicted on the basis of their small size or high lipid solubility, suggesting the 
presence of additional mechanism that restricts their entry into the brain. It is now realised
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that drug transporter proteins, the prototype of which is P-glycoprotein (P-gp), are 
constitutively expressed by cerebral endothelial cells (Figure 17) where they function as 
active efflux pumps to transport substrate compounds back into the capillary lumen (Cordon- 
Cardo et al, 1989; Saunders et al, 1999). Many hydrophobic but large (>500 Da) molecules 
are also recognised to be substrates of P-gp, providing another explanation for their inability 
to penetrate the BBB (Van Asperen et al, 1997).
1.2 P-glycoprotein and the MDR genes
1.2.1 P-glycoprotein and multidrug resistance in cancer
Much of the present knowledge about P-gp has been gained in cancer research due to its role 
in chemoresistance in cancer treatment (Gottesman and Pastan, 1993). The investigation of 
the phenomenon of multidrug resistance, in which cancer cells are resistant to multiple anti­
cancer drugs, may be traced to Burchenal’s initial observations some 50 years ago (Roepe, 
2000). Selection of cancer cell lines using a single cytotoxic compound leads to cross­
resistance to a broad spectrum of structurally and functionally unrelated agents. The Danish 
physicist Dano (1973) subsequently hypothesised the presence of an active outward directed 
drug pump in tumour cells resistant to multiple drugs but originally exposed to only 1 or 2  
anti-cancer agents. Juliano and Ling (1976) later identified a large (170 kD) membrane 
protein in drug resistant cells which they designated “P-glycoprotein”, attributing reduced 
drug accumulation in its presence to impaired permeability. The P-gp genes in human and 
rodents have subsequently been cloned and named the MDR genes (Ueda et al, 1987).
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Although other cellular mechanisms are now recognised to contribute to the multidrug 
resistant phenotype (Table 23), P-gp remains the most extensively investigated and best 
understood. Three classes of human cancers express P-gp: (a) those derived from tissues in 
which MDR1 gene is constitutively activated; (b) those that have acquired multidrug 
resistance after repeated exposure to chemotherapeutic agents; and (c) those in which the 
neoplastic transforming event per se leads to novel activation of the MDR1 gene (Gottesman 
and Pastan, 1993). The presence of P-gp in tumour cells correlates with poor 
chemotherapeutic response and poor prognosis, and its absence with good prognosis (Chan et 
al, 1991; Ling, 1997). The level of P-gp expression has been shown to be higher in 
subsequent relapses, and may be present in relapses if not detected at first presentation (Ling, 
1997). The most persuasive evidence of P-gp’s causative role in multidrug resistance comes 
from gene transfer experiments, in which transfection of murine or human MDR gene into 
drug-sensitive cells is sufficient to result in cross-resistance to multiple chemotherapeutics 
(Silverman, 1999). The level of drug resistance in MM-transfected cells correlates with the 
density of P-gp in the plasma membrane (Choi et al, 1991). P-gp is believed to confer the 
multidrug resistance phenotype by reducing intracellular drug accumulation through its 
function as an active efflux pump (see below).
Subsequent to the discovery of P-gp, it became apparent some multidrug-resistant tumours 
and cell lines do not express P-gp and that other drug transporters may be involved. This 
observation led to the identification and cloning of the multidrug resistance protein (MRP, 
also called multidrug resistance-related or associated protein); (Cole et al, 1992), which has 
since evolved into a family of at least six members (Borst et al, 1999). Although also capable
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Table 23. Cellular mechanisms contributing to multidrug resistance in cancer treatment (List, 
1997).
Action Mechanism
Extracellular drug reflux P-glycoprotein
Multidrug resistance protein
P95
Intracellular entrapment or redistribution Multidrug resistance-related protein
Lung-resistance protein
Transporter of antigenic peptides
Drug detoxification Glutathione-S transferase
Heat-shock proteins
Altered nuclear target Topoisomerase II
DNA repair enzymes
Altered apoptotic response P53
Bcl-2
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of conferring multidrug resistance, MRP1 differs from P-gp in substrate specificity (Seelig et 
al, 2000), structure, tissue distribution and possible physiological functions (Regina et al, 
1998; Cole and Deeley, 1998; Rappa et al, 1999). Studies to detect its presence in the BBB 
have yielded conflicting results (Regina et al, 1998; Seetharaman et al, 1998). It may well be 
that there are other transporter families responsible for drug resistance awaiting discovery.
1.2.2 P-glycoprotein as a member of a transporter superfamily
P-gp and MRP are now recognised to belong to a highly conserved protein superfamily, the 
ATP-binding cassette (ABC) proteins which form one of the largest protein families with over 
1 0 0  members found in every kind of organism examined so far, including bacteria, plants, 
fungi and animals (Van Veen and Konings, 1997). Thirty-nine human ABC proteins have 
been identified, half of which were discovered through progress of the Human Genome 
Project in the past several years (Klein et al, 1999). With few exceptions, the human ABC 
proteins function as active pumps at the cell membrane through hydrolysis of ATP to drive 
the flux of their substrate against a concentration gradient. The substrate range for these 
proteins is diverse and includes drugs, nutrients, amino acids, sugars, peptides, pigments, and 
metals (Silverman, 1999). These transporters share a common organisation and considerable 
amino acid homology around the nucleotide-binding domain (see below), suggesting 
evolutionary conservation. Examples of other ABC proteins include pfmr, which mediates 
resistance in the malarial parasite Plasmodium falciparum, and the antigenic peptide 
transporter involved in MHC antigen presentation (Higgins, 1992; Lepage and Gros, 1993). 
Mutations in these proteins are causative in a range of genetic disorders, such as the cystic
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fibrosis transmembrane conductance regulator (CFTR) in cystic fibrosis, MRP2 in Dubin- 
Johnson syndrome, and adrenoleukodystrophy protein (ALDP) in ALD (Klein et al, 1999).
1.2.3 Genetics, structure and mechanism of action of P-glycoprotein
P-gp is encoded by a small gene family, comprised of two genes in human, designated MDR1 
and MDR2, located near each other on chromosome 7q21.1 (Callen et al, 1987), and three 
genes in rodents, mdrla, mdrlb and mdr2 (Silverman, 1999; Table 24). Based on sequence 
identity and function, mammalian MDR genes are classified into two categories (Borst, 1997; 
Silverman, 1999). Class I genes (human MDR1, rodent mdrla and lb) encode the drug 
transporter associated with multidrug resistance, whereas the class II genes (MDR2, mdr2) do 
not confer the multidrug resistance phenotype but encode a phosphotidylcholine transporter in 
biliary canaliculi. The MDR genes are highly conserved. Sequence comparison shows 
considerable identity and homology amongst them (Brown et al, 1993). For example, the 
human MDR1 and MDR2 coding sequences are 75% identical despite different transport 
properties, and the human MDR1 and mouse mdrla genes, with similar function, are 82% 
identical, despite 50 million years or more of evolution. For the purpose of this thesis, unless 
otherwise specified, the term P-gp refers to that encoded by the class I MDR genes, which is 
used to include human MDR1 and both mdrla and mdrlb in rodents.
The molecular weight of P-gp varies slightly from species to species, and from gene to gene. 
Human P-gp encoded by the MDR1 gene is an integral membrane protein with 1280 amino 
acids and a molecular weight of approximately 170 kDa (Dicato et al, 1997). Similar to other 
ABC transporters, sequence analysis suggests it comprises two homologous halves, each
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Table 24a. The mammalian multidrug-resistance gene family. (Alternative nomenclature in 
parentheses.)
Species Class I Class II
Human MDR1 MDR2 (MDR3)
Rat mdrla, mdrlb mdr2
Mouse mdrla (mdrS), mdrlb (mdrl) mdr2
Hamster p g p l PSP2 PSP2
Table 24b. GenBank accession numbers of MDR cDNA sequences *
Gene Accession number References
Human MDR1 M14758 Chen et al, 1986
MDR2 M23234 Van der Bliek et al, 1988
Rat mdrla AF257746 Unpublished
mdrlb M62425 Silverman et al, 1991
Mdr2 L15079 Brown et al, 1993
Mouse mdrla M30697, M33581 Devault and Gros, 1990
mdrlb M14757 Gros et al, 1986
Mdr2 J03398 Gros et al, 1988
Hamster mdrla M60040 Endicott et al, 1991
mdrlb M60041 Endicott et al, 1991
Mdr2 M60042 Endicott et al, 1991
* Complete intron-exon structure known for human MDR1 (Chen et al, 1990) and MDR2 
(Lincke et al, 1991) only.
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consisting of one transmembrane domain containing six segments, and one nucleotide- 
binding domain or ABC unit (Figure 18; Gottesman and Pastan, 1993; Higgins et al, 1997; 
Klein et al, 1999). Recent analysis by high resolution electron microscopy suggests a three- 
dimensional structure as a monomer with a 5-nm central pore closed on the cytoplasmic 
surface of the plasma membrane forming an aqueous compartment (Rosenberg et al, 1997). 
The energy of ATP hydrolysis is utilised by a mechanism that involves positive cooperativity 
between the two ABC units and a tight molecular coupling of the transmembrane domains to 
the ABC units, so that conformational changes caused by substrate binding is transmitted to 
active transport (Klein et al, 1999).
The mechanism of action of P-gp remains hotly debated (Roepe, 2000). The initial 
hypothesis of altered plasma membrane permeability (Juliano and Ling, 1977) soon gave way 
to direct efflux pump activity (Willingham et al, 1986) whereby substrates are actively 
extruded from intracellular to extracellular space against the concentration gradient (Sharom, 
1997). Although such a classical pump model explains most of P-gp’s mechanisms of action, 
it cannot account for the protein’s unusually broad substrate specificity in contrast to other 
membrane transporters (Roepe, 2000). This led to the suggestion that hydrophobic drugs are 
removed directly from within the lipid bilayer of the plasma membrane rather than from the 
aqueous phase (Gottesman and Pastan, 1993; Shapiro and Ling, 1998). This “hydrophobic 
vacuum cleaner” model may account for P-gp’s wide range of substrates which are all 
hydrophobic and amphipathic. A further modified version of the pump model (the “flippase” 
model) which is gaining increasing support suggests that P-gp may interact with substrates in 
the inner leaflet of the lipid bilayer and “flip” them to the outer leaflet (Ueda et al, 1997; Borst
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and Schinkel, 1997). Suggestion of indirect secondary effects of P-gp on passive intracellular 
drug accumulation by altering intracellular pH or membrane potential (Roepe, 2000) has not 
been widely accepted (Borst and Schinkel, 1997). It remains unclear how many drug-binding 
sites or pores P-gp possesses.
1.2.4 Substrates and modulators of MDR1 P-glycoprotein
Unlike most energy-dependent pumps, P-gp appears to be highly promiscuous. Hundreds of 
structurally and chemically unrelated compounds, as diverse as anthracyclines (doxorubicin), 
alkaloids (vincristine), specific peptides (cyclosporin A), steroid hormones (hydrocortisone), 
local anaesthetics (dibucaine), dye molecules (rhodamine 123), to mention only a few, have 
been identified as substrates (Table 25). How P-gp recognises such a diverse range of 
compounds is still largely unexplained (Ueda et al, 1997). It has been said that a "typical" 
substrate is large (molecular weight > 400), hydrophobic, amphipathic, with a planar ring 
system and a weak positive charge at physiological pH (Sharom, 1997). However, 
transported compounds can range in size from 250 Da (cimetidine) to almost 1900 Da 
(gramicidin D), and apart from aromatic groups, non-aromatic linear or circular compounds 
can also be substrates, and some alkaline drugs (e.g. methotrexate) are transported (Schinkel,
1997). Amphipathy and hydrophobicity which allow intercalation into the membrane lipid 
bilayer appear to be the only common characteristics among the substrates (Gottesman and 
Pastan, 1993; Schinkel, 1997; Ueda et al, 1997). Although it has been suggested recently that 
the number of electron donor groups and spatial separation may be useful in predicting likely 
P-gp substrates (Seelig, 1998), the possibility of a compound being a substrate cannot be ruled 
out until adequately tested.
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Table 25. Examples of P-glycoprotein substrates and inhibitors (Ford et al, 1996; Sharom, 
1997; Seelig, 1998; Rodriguez et al, 1999).
P-gp substrates
A nticancer drugs O ther cytotoxic agents Steroids M iscellaneous
Doxorubicin Colchicine Aldosterone Digoxin
Daunorubicin Emetine Dexamethasone Protease inhibitors
Vinblastine Actinomycin D Loperamide
Vincristine Puromycin Peptides Rhodamine 123
Etoposide Mitoxantrone Leupeptin 99raTc-SESTAMIBI
Teniposide Pepstatin A Triton X-100
Paclitaxel Gramicidin D
Docetaxel Nonactin
P-gp inhibitors
C alcium  channel blockers C yclic peptides Steroids M iscellaneous
Verapamil Cyclosporin A Progesterone Dipyridamole
Nifedipine Valinomycin Tamoxifen Amiodarone
Diltiazem Tacrolimus Cortisol Quinidine
Nicardipine Propranolol
Phenothiazines A ntibiotics Chloroquine
Trifluoperazine Erythromycin Terfenadine
Chlorpromazine Ceftriaxone Reserpine
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Ever since the role of P-gp was recognised in drug resistance in cancer, modulators (also 
called chemosensitisers, inhibitors or reversal agents) to circumvent its functions as a means 
to overcome resistance have been sought (Ford and Hait, 1993). This has generated another 
bewildering list of compounds which increase the sensitivity of cells in vitro to cytotoxic 
substrate drugs (Table 25). Many of these modulators are themselves substrates for P-gp, 
suggesting they act by competitive inhibition (Ford et al, 1996). “First-generation” 
modulators include drugs already developed for other therapeutic indications, such as calcium 
channel blockers (verapamil), immunosuppresants (cyclosporin A), antiarrhythmic drugs 
(quinidine, amiodarone), and steroidal agents (progesterone, tamoxifen), some of which have 
been evaluated in phase II/III clinical trials as adjuctive agents in solid and haematological 
cancers (Ford and Hait, 1993; Ford et al, 1996; Silverman, 1999). Their results have so far 
been disappointing, partly because of dose-limiting side effects due to their low affinity 
(Dicato et al, 1997). In other instances, toxicity of the chemotherapeutic agent is increased 
due to pharmacokinetic interactions with the P-gp modulator (Dalton, 1994; Lum and 
Gosland, 1995), either through metabolism or absorption and disposition which are now 
recognised to be significantly influenced by P-gp. In addition, other drug transporters and 
cellular mechanisms may be responsible for the multidrug resistant phenomenon (Table 23), 
thus a P-gp reversing approach alone may not be sufficient to improve treatment outcome 
(Dicato et al, 1997). Less toxic, “purpose-made” second-generation inhibitors (e.g. PSC 833) 
which are effective at much lower concentrations as well as other more sophisticated ways to 
modulate P-gp functions are being developed (Sarkadi and Muller, 1997).
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1.2.5 Tissue distribution and physiological functions of P-glycoprotein
The tissue distribution of a protein can yield important clues to its function. Measurements of 
MDR1 RNA (Fojo et al, 1987) and P-gp protein levels (Sugawara et al, 1988; Cordon-Cardo 
et al, 1990) have reported high degree of expression in organs with excretory functions, such 
as the adrenal cortex, epithelial cells on the lumenal surface of biliary hepatocytes, pancreatic 
ductules, small and large intestine mucosal cells and proximal renal tubules (Table 26). 
Another group of anatomical sites with high level of MDR1 expression is the blood-tissue 
barriers, in particular the capillary endothelial cells of the brain (Cordon-Cardo et al, 1989; 
Beaulieu et al, 1997), testis and placenta (Sugawara et al, 1988). More recently, functional 
MDR1 P-gp has also been detected in the blood-CSF barrier across the choroid plexus 
epithelium (Rao et al, 1999) and in the blood-inner ear barrier in mice (Zhang et al, 2000b).
In addition, MDR1 is significantly expressed by cells in the haematopoietic system, 
particularly the progenitor cells and CD8 + cytotoxic T cells (Schinkel, 1997).
Investigation of P-gp in the human foetus using RNase protection assays suggested expression 
as early as 7 weeks (van Kalken et al, 1992). Immunohistochemical analysis showed staining 
in kidney by 1 1  weeks of gestation, liver, adrenal, heart, and smooth muscle by 13 weeks, and 
brain, stomach, intestine, and bile ducts by 28 weeks.
In mice (and probably also in rats), the two drug-transporting mdrla and mdrlb P-gps have 
overlapping but distinct substrate specificities (Devault and Gros, 1990) and tissue 
distributions (Croop et al, 1989), but together they cover the same tissues as the single MDR1
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in man (Table 27), suggesting that they fulfil the same physiological role(s) in the different 
species (Schinkel, 1997).
In view of its vectorial transport capacity and the pattern of tissue distribution, P-gp is 
widely believed to play an important role in the protection of the organism against 
xenobiotics, either by exclusion of the toxins, as in the intestine and blood-tissue barriers, 
or by active excretion in the liver, intestine and kidney (Schinkel, 1997). Its expression in 
the adrenal gland and reproductive organs, and the observation that several corticosteroid 
hormones are transported by P-gp while progesterone is an inhibitor, suggest that P-gp may 
be involved in steroid secretion (Chin and Liu, 1994; Schinkel, 1997). The more primitive 
the haematopoietic cells, the higher the level of P-gp function, implying a possible role in 
the maturation of bone marrow stem cells (Schinkel, 1997). The early foetal expression 
and wide tissue distribution also suggest an important role in transport of endogenous 
substrates and protection from xenobiotics during a critical phase of development.
From a pharmacological point of view, judging from its strategic distribution in organs of 
drug absorption, metabolism and elimination, P-gp can be expected to play a potentially 
pivotal role in the pharmacokinetics and disposition of its substrates (Fromm, 2000). 
Indeed, studies using mdrl gene knockout mice show that active excretion by intestinal P- 
gp limits the oral absorption of certain substrates such as HIV-proteases (Kim et al, 1998) 
and paclitaxel (Sparreboom et al, 1997). P-gp and the hepatic metabolising P-450 
isoenzymes, particularly CYP3A, share many common substrates and are simultaneously 
induced by many drugs, suggesting possible coordinate regulatory elements and that the 
two mechanisms may play complementary roles in drug resistance (Burt and Thorgeisson,
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Table 27. Relative expression level of mdrla and mdrlb in mouse tissues determined by 
RNA-DNA hybridisation (Croop et al, 1989).
Tissue mdrla Mdrlb
Pregnant uterus +++++
Adrenal ++++
Placenta +++
Uterus +
Kidney + ++
Liver + +
Muscle + +
Spleen + +
Heart ++ ++
Brain ++ +?
Lung ++ +
Intestine +++
Stomach +
Spinal cord ++
Testes ++
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1988; Wacher et al, 1995). Impaired P-gp function was associated with an exaggerated 
induction of CYP3A by rifampicin (Schuetz et al, 1996). P-gp in the intestine, renal 
tubules and the biliary tract is responsible for the elimination of many of its substrates 
(Silverman, 1999). For example, delayed elimination of digoxin from the blood stream in 
mdrl knockout mice is mainly due to reduced faecal excretion (Schinkel, 1998). Finally, 
using mdrl knockout mice, it has been shown that P-gp limits the penetration of its 
substrates across many blood-tissue barriers, including the blood-brain barrier (Schinkel et 
al, 1994; Schinkel et al, 1996; Schinkel et al, 1997; Kim et al, 1998), blood-CSF barrier 
(Rao et al, 1999), and the blood-inner ear barrier (Zhang et al, 2000b). The contribution of 
mdrl knockout mice to the understanding of P-gp functions will be further discussed in 
Part III; Section 2.1.
The influence of P-gp in all key kinetic stages means that any attempt to modulate its 
function in one step is likely to have knock-on effects on the others. Thus, administration 
of inhibitors aiming to enhance tissue penetration of a P-gp substrate may also lead to 
raised plasma concentration due to increased oral bioavailability, reduced hepatic 
metabolism, and reduced elimination, causing increased systemic toxicity (Lum and 
Gosland, 1995).
P-gp has also been demonstrated to enhance cell volume-activated chloride currents in 
vitro (Valverde et al, 1992; Mintenig et al, 1993; Higgins, 1995). Whether P-gp possesses 
an additional function as a chloride channel (unlikely), or it activates an endogenous and as 
yet unidentified chloride channel, is unclear (Borst and Schinkel, 1997).
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1.2.6 MDR1 expression at the blood-brain barrier
It is increasingly recognised that P-gp plays a vital role in maintaining the integrity of the 
BBB. P-gp substrates may reach almost 100-fold higher in the brains of mdrla knockout 
mice that are devoid of P-gp at cerebral capillary endothelium compared with their wild- 
type counterparts, sometimes with lethal consequence (Schinkel, 1997). Although some 
authors have suggested that P-gp is located at the astrocyte foot processes at the BBB 
(Pardridge et al, 1997), most studies report its expression at the luminal side of capillary 
endothelium, consistent with its presumed barrier function (Beaulieu et al, 1997; 
Seetharaman et al, 1998). P-gp is normally not expressed by brain parenchyma in man, but 
it has been detected in diseased astrocytes, e.g. in astrocytomas (Matsumoto et al, 1991), 
and in patients with phenylketonuria, tuberculous leptomeningitis, and encephalitis 
(Bietzmann et al, 1994). In addition, P-gp expression has been reported to disappear 
acutely following focal cerebral ischaemia in rats, but to reappear after several days 
(Samoto et al, 1994), indicating regulation in response to external factors.
Whether both drug-transporting mdrla and mdrlb are expressed in rodent brains has been 
investigated in few studies, often involving the whole brain and employing different 
techniques. In rats, it is generally agreed that only mdrla is present in cerebral 
microvessels in vivo (Barrand et al, 1995; Regina et al, 1998), but mdrlb has also been 
detected in brain parenchyma using reverse transcriptase-polymerase chain reaction which 
is more sensitive than immunohistochemistry (Regina et al, 1998). In mice, one study 
using DNA-RNA hybridisation found both mdrla and mdrlb in homogenised brain tissues, 
although the latter at lower level (Croop et al, 1998). In addition, brain levels of P-gp 
substrates (e.g. digoxin) can reach one to two orders of magnitude higher in mdrla 
knockout or mdrl a/lb  “double-knockout” mice compared to wild-type mice, whereas
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similar brain levels are found in mdrlb knockout mice and normal mice (Schinkel et al, 
1997). This also suggests that mdrla is the predominant functioning P-gp in mouse BBB. 
However, expression of mdrlb confined to certain discrete "at risk" region(s) in the rodent 
brain conferring “extra protection” cannot be ruled out.
1.2.7 Control of MDR1 gene expression
Although a consistent pattern of distribution has emerged from tissue studies, the exact 
level of P-gp expression was highly variable between different individuals in these studies, 
suggesting genetic or environmental influences (Van der Heyden et al, 1995; Silverman, 
1999). Recently, single nucleotide polymorphisms of the MDR1 gene have been described, 
some of which were preferentially expressed by multidrug resistant cell lines (Mickley et 
al, 1998). Sequence analyses covering the entire gene in 24 healthy volunteers identified a 
relatively common polymorphism in MDR1 (homozygous in 24% of test subjects) which 
was associated with changes in P-gp protein level and activity in vivo. In addition, another 
polymorphism was present just preceding the translation start codon and might influence 
initiation, while three were associated with amino acid changes with possible functional 
consequences (Hoffmeyer et al, 2000). Identification of nucleotide polymorphisms has 
raised the possibility of pharmacogenetic influence in individual response to treatment with 
P-gp substrates both in terms of efficacy and tolerability (see Part I; Section 5.2.2).
Expression of P-gp is highly inducible by environmental factors. Novel activation of the 
MDR1 gene can be found in neoplasms derived from tissues not normally expressing the 
gene, or in tumours during relapse but not on initial presentation (Gottesman and Pastan,
1993). Apart from its substrate drugs, MDR1 expression has been found to be induced by 
heat shock, arsenite, partial hepatectomy, extracellular matrix, growth factors, sodium
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butyrate, protein kinase C agonists, and even its inhibitors such as verapamil (Gottesman et 
al, 1995). The process of cell culture has been shown to lead to an increase in the 
expression of mdrlb in rat brain endothelial cells, with reduction in that of mdrla (Barrand 
et al, 1995).
Although drug resistant cell lines selected in vitro usually display an amplification of DNA, 
elevation of mRNA and P-gp is often observed in both human and animal tumours without 
concomitant amplification of the MDR1 gene (van der Heyden et al, 1995). The primary 
mode of regulation of expression in clinical conditions in vivo thus appears to be at the 
transcriptional level, either by increasing the amount of new RNA transcripts or by 
enhancing their stability (Thorgeirsson et al, 1994). Post-translational modifications by 
glycosylation and phosphorylation are not required for the basal transport activity of P-gp 
but may affect its functional properties such as substrate affinity and efflux velocity 
(Gottesman et al, 1995). In addition, the possibility of co-amplification of linked or non­
linked genes capable of altering drug response (e.g. MRP) needs to be considered. These 
factors may explain the variation in the pattern of drug resistance seen in different selection 
schemes of multidrug resistant cell lines, even under conditions in which the 
overexpression of MDR genes gives a wild-type phenotype.
1.2.8 Measurement of MDR1 gene expression
Since gene amplification is thought not to be relevant in the development of clinical drug 
resistance, the determination of MDR1 expression has centred primarily on the detection of 
messenger ribonucleic acid (mRNA) or P-gp, for which a number of methods have been 
developed (Van der Heyden et al, 1995). Techniques to detect mRNA include Northern 
blot, slot-blot analysis, in situ hybridisation, RNase protection assay, and reverse
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transcriptase-polymerase chain reaction (RT-PCR). Compared with the other techniques, 
RT-PCR is highly sensitive and requires much less tissue. In addition, by using an internal 
standard to compete with the target, the absolute amount of mRNA molecules can be 
measured, whereas only a relative comparison can be made with other methods. RT-PCR 
is, therefore, preferable when quantification is required but only a small sample is available 
(Zhang et al, 1996a; Zhang et al, 1996b). The theoretical basis of quantitative RT-PCR 
will be further discussed in Part III; Section 3.1.
One of the major drawbacks of all RNA detection techniques is their labour intensive 
nature. In addition, they do not allow localisation of gene expression or distinction 
between normal and abnormal tissues. In contrast, immunohistochemistry permits 
detection of P-gp at single cell level, which is not possible by Western blot (Friedlander et 
al, 1989). However, protein detection techniques are generally time-consuming and 
require large samples. The staining antibody may cross-react with other molecules and a 
panel of antibodies is needed to improve reliability and specificity (Van der Heyden et al,
1995). Sample preparation may also affect the detection rate of P-gp (Cordon-Cardo et al,
1990), and only semiquantitative measurement is possible by Western blot or 
immunohistochemical staining.
A third alternative to measure P-gp expression is functional assays, the most commonly 
employed of which is flow cytometry using monoclonal antibodies or specific dyes such as 
rhodamine-123 in selected cell lines (Davies et al, 1996). This technique can be applied in 
routine clinical screening as it is widely available, cheap, reproducible, and easy to perform, 
However, flow cytometry requires reliable cell suspensions, which often results in 
substantial cell damage. Another problem is the low specificity of the labelling techniques
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and factors other than drug efflux may contribute to the measured function (Van der 
Heyden et al, 1995). Recently, visualisation of P-gp using SPECT or PET has been 
developed, most commonly using [99mTc]SESTAMIBI or other radiolabelled substrates as 
ligands (Hendrikse et al, 1999). These techniques may offer a non-invasive way to monitor 
the dynamic function of the P-gp drug efflux pump in vivo.
1.3 P-glycoprotein and “multidrug resistant epilepsy” - the hypothesis
As eluded above, although the investigation of P-gp and its other drug transport members 
originated from research in oncology, it is increasingly recognised to significantly 
influence the safety and efficacy of many other non-cancer agents. It is conceivable that P- 
gp may also play a role in pharmacoresistance in epilepsy, analogous to drug resistance in 
cancer. Up to one third of patients with epilepsy continue to have seizures despite AED 
treatment, and the cause of this “refractoriness” is largely unknown (Part I; Section 5.2).
In these patients, the seizure disorder displays resistance to multiple agents, either singly or 
in combination, with a variety of modes of action, suggesting the operation of a universal 
mechanism affecting AEDs in a general fashion. One possible candidate mechanism might 
be limitation of access of AEDs to the brain due to the efflux action of P-gp at the BBB. 
AEDs, which require penetration across the BBB to exert their antiepileptic effect, might 
be prevented from accumulating to a sufficiently high concentration, either in the brain in 
general or specifically in the seizure focus, if they were extruded by P-gp located at the 
cerebral capillary endothelium. If the function of the BBB was enhanced around the 
epileptogenic focus by increased P-gp expression, AEDs might be prevented from entering 
their site of action, but could still penetrate the rest of the brain to cause neurotoxicity.
This might also explain why symptomatic epilepsies (with structural lesions) are more 
drug-resistant than idiopathic epilepsies (usually genetic with presumably more diffuse
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changes), and why certain lesions (e.g. MTS) are particularly so if such changes were more 
prominent in specific brain regions. Furthermore, if P-gp were induced by neuronal 
discharges, in much the same way as heat shock or other external factors, a vicious cycle 
might ensue whereby more P-gp leads to further uncontrolled seizures, ultimately resulting 
in “multidrug resistant epilepsy”. If so, P-gp inhibitors might potentially be given together 
with AEDs to increase their access to the desired site of action and improve efficacy, 
offering a truly "rational" approach to combination therapy.
Such a proposition is based on two separate but parallel hypotheses. First, and perhaps 
most importantly, some of the available AEDs must be substrates of P-gp. If not so, any 
elevation in P-gp expression would be unlikely to have clinical relevance. In vitro analysis 
(Tishler et al, 1995; Seling, 1998; Schinkel et al, 1996) suggest PHT is transported by P-gp. 
Other established and new AEDs have not been tested, but their hydrophobicity makes 
them candidate-P-gp substrates. Although they do not all conform to the "typical" planar 
ring structure, such possibility cannot be excluded until they are adequately tested (Part III; 
Section 1.2.4). If they were indeed P-gp substrates, the possibility that they are also 
inducers of P-gp would merit exploration.
Second, increased expression of MDR1 is associated with refractory epilepsy. Evidence to 
support this has come from examination of brain tissues resected from patients with 
refractory epilepsy. Tishler and colleagues (1995) studied MDR1 expression in 19 patients 
undergoing epilepsy surgery. The median time from seizure onset to surgery was 19 years 
(range 3-41 years). Treatment with PHT had been unsuccessful in all, CBZ in 18, PB in 15, 
and VPA in 12. Temporal lobe resections were performed in 15 of the 19 patients, 
sclerosis was observed in 13 specimens, tumours in 4, carvenous angioma in 1 and
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inflammation in the remaining patient. Using a semiquantitative RT-PCR technique,
MDR1 mRNA level was found to be over 10 times higher in 11 of the 19 resected samples 
compared with controls ("normal" brain tissues resected during removal of arteriovenous 
malformations). In addition, P-gp was detected by immunohistochemical staining in 
astrocytes where it is not normally present, suggesting novel expression similar to other 
conditions with diseased astrocytes (Part III; Section 1.2.6) and malignant tumours (Part III; 
Section 1.2.1). The small number of study subjects did not allow exploration of 
mechanisms controlling expression, such as seizures or underlying lesions or previous 
AED treatment.
Since this report, sporadic case series investigating the association between P-gp and 
epilepsy have trickled through the literature. Published as an abstract, D’Giano and 
colleagues (1997) examined P-gp by immunohistochemistry in patients undergoing 
epilepsy surgery for refractory TLE. P-gp was stained in neuronal and glial components in 
9 out of 12 resected temporal lobe specimens in the region of MTS but not in the lateral 
neocortex. Quantification or comparison with control tissues was not undertaken. The 
same group of investigators later reported a single case of detection of P-gp (again by 
antibody staining) in tuber cells removed from a 4-month-old infant with tuberous sclerosis 
and uncontrolled epilepsy (Lazarowski et al, 1999). Sisodiya and co-workers (1999) used 
two monoclonal antibodies to stain P-gp in post-mortem archival samples of a range of 
cortical dysplasias (CD). Positive perivascular glial labelling was noted in 10 of 16 CD 
samples but only 2 of 16 age-matched controls. Although none of the CD patients (aged 
20 weeks to 7 years at post-mortem) had suffered seizures, they were regarded as “pre­
epileptic” by the authors since most patients with CD are thought to develop epilepsy 
eventually.
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1.4 Summary
Over-expression of the drug transporter P-gp, encoded by the MDR1 gene, confers 
chemoresistance in certain cancers. P-gp extrudes a wide range of xenobiotics from cells 
and is present in cerebral capillaries where it contributes to the integrity of the BBB. Over­
expression of MDR1 has been reported in brain tissues removed from patients with 
refractory epilepsy. It is hypothesised that some AEDs are substrates of P-gp and 
increased P-gp expression is associated with drug resistance in epilepsy.
A series of laboratory studies were carried out to test these hypotheses. Mdrla knockout 
mice were used to determine whether any of the established and new AEDs are subject to 
transport by P-gp. To determine gene expression, cerebral mdrl mRNA concentrations in 
animal models of seizure and tissue damage as well as human specimens were measured 
with use of specifically constructed competitive internal standards. The specific aims of 
these studies and the rationale behind the various models will be discussed in detail in the 
individual sections.
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2 Pharmacokinetics of antiepileptic drugs in mdrla knockout mice
2.1 Introduction
M drla knockout {mdrla (-/-)) mice of FVB background were generated by Schinkel and 
colleagues using embryonic stem cell technology (Schinkel et al, 1994). Subsequently, 
mdrlb (-/-) mice and mice deficient in both mdrla and mdrlb genes (m drla/lb  (-/-) mice) 
have been produced and studied (Schinkel et al, 1997). Each of these strains has so far 
shown no difference in viability, health, weight, fertility and litter size from their wild-type 
(+/+) counterparts. Extensive analyses of serum biochemical and haematological 
parameters, and macroscopic and microscopic surveys of all major organs have revealed 
no abnormalities (Schinkel, 1997; Schinkel, 1998).
However, these mice exhibit major abnormalities in drug handling. The mdrla (-/-) mice 
have been most extensively studied. Drugs that are substrates of P-pg reach significantly 
higher levels in organs that normally express mdrla, particularly in the brain. The most 
dramatic example is with ivermectin, a generally safe pesticide routinely used to treat mite 
infestation. At 24 hours after oral administration, its level in the brain was nearly 90 fold 
higher in mdrla (-/-) mice than in mdrla  (+/+) mice with lethal consequence. A toxicity 
assay demonstrated that mdrla (-/-) mice were 50 to 100-fold more sensitive to the toxic 
effect of ivermectin than wild-type mice (Schinkel et al, 1994). Similar increased 
accumulation in the brains of mdrla (-/-) mice has been observed for a variety of drugs 
such as digoxin, vinblastine (Schinkel et al, 1994; Schinkel, 1998), loperamide, 
ondansetron (Schinkel et al, 1996), HIV-1 protease inhibitors (Kim et al, 1998), quinidine 
(Kusuhara et al, 1997), and amitriptyline (Uhr et al, 2000).
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The mdrla (-/-) mice are, therefore, gaining popularity as a useful tool for the screening of 
P-gp substrates, particularly at the BBB level. There are, however, several caveats to their 
use. Firstly, in addition to effects on drug passage across blood-tissue barriers, complex 
pharmacokinetic consequences can be anticipated in view of the wide tissue distribution of 
P-gp (Part III; Section 1.2.5). Higher plasma levels of P-gp substrates (e.g. digoxin, 
paclitaxel) have been observed in mdrla (-/-) mice, an effect attributed to increased 
intestinal absorption or reduced elimination. Changes in cytochrome P450, in particular 
CYP3 A, have also been reported in mdrl knockout mice (Schuetz et al, 2000), potentially 
affecting drug metabolism. Thus any increase in brain concentration needs to be 
interpreted in the light of changes in plasma and other organs.
The role of mdrlb has not been fully explored. The tissue levels of digoxin in mdrlb (-/-) 
were similar to those in the wild-type mice, whereas mdrl a/lb  (-/-) mice had higher levels 
comparable to mdrla (-/-) mice (Schinkel et al, 1997). Although such observation may be 
interpreted as consistent with the general view that mdrla is the only or predominant mdrl 
gene expressed in the mouse brain, P-gps encoded by the two isoforms do have distinct 
drug specificities (Devault and Gros, 1990), and localised expression of mdrlb in the brain 
cannot be ruled out (see Section 1.2.6). Substances that are not transported by P-gp in 
mdrla (-/-) mice should, therefore, be screened in mdrlb (-/-) mice before concluding that 
they are not substrates of murine P-gp. Such concern does not arise in man in whom there 
is only one drug-transporting P-gp encoded by MDRL
The mdrl knockout mice appear to be indistinguishable from their wild-type counterparts 
as long as they are not challenged with drugs. This might suggest that drug-transporting P- 
gps have no essential physiological functions. However, the absence of P-gps ab initio
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might allow the development of compensatory mechanisms that obfuscate the detection of 
essential P-gp functions. For instance, the expression of mdrlb is upregulated in the liver 
and kidney (but not in other tissues) of mdrla (-/-) mice (Schinkel et al, 1994). So far 
examination of other transporters such as mrp, Sister o f P-gp, octl and cftr has not 
revealed evidence of compensatory upregulation in mdrl a/lb  (-/-) mice (Schinkel et al, 
1997), although these represent only a very small fraction of possible candidate 
transporters.
2.2 Aims
The aim of this pilot study was to examine whether the established and new AEDs are 
substrates of mouse mdrla P-gp by comparing their pharmacokinetics in mdrla (-/-) mice 
and mdrla (+/+) mice. Based on previous observations of large difference in brain levels 
for other P-gp substrates, mdrla (-/-) mice would be particularly suited to examine whether 
P-gp at the BBB limits CNS penetration of AEDs which obviously require brain access to 
exert their desired pharmacological effects. AEDs that are substrates of P-gp can be 
expected to reach higher brain levels in mdrla (-/-) mice than in wild-type mice.
2.3 Methods
2.3.1 Materials
Female mdrla (-/-) mice and mdrla (+/+) FVB mice between 8  and 20 weeks of age (20- 
30g) were used. They were bred in-house by Dr Elizabeth CM de Lange at 
Leiden/Amsterdam Center for Drug Research and kept in a controlled temperature and 
humidity environment with day/night cycle conditions and access to food and water ad 
libitum.
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The established AEDs, PB, PHT, CBZ and VP A, were purchased from Sigma Chemical 
Company (Poole, UK). The new AEDs were obtained from the following companies: 
LTG from GlaxoWellcome Research and Development (Stevenage, UK), TPM from RW 
Johnson Pharmaceutical Research Institute (Spring House, PA, USA), GBP from Parke- 
Davis Pharmaceutical Research (Ann Arbor, MI, USA), and VGB from Hoechst Marion 
Roussel (Uxbridge, UK).
2.3.2 Drug administration
All drugs were prepared on the day of use. CBZ was dissolved in 30% (v/v) glycofurol 
(Tauboll et al, 1990), while the other seven drugs were all dissolved in 0.9% saline. The 
pH was adjusted to 9.0 with NaOH for PHT and TPM to improve solubility. Seventy-two 
mdrla (-/-) and 72 mdrla (+/+) mice were randomised into eight treatment groups (n = 
9/group/genetic type) and AEDs were administered subcutaneously. The following doses 
of drugs were injected: PB, 20mg/kg; PHT, 20mg/kg; CBZ, 20mg/kg; VP A, 200mg/kg; 
LTG, 5mg/kg; TPM, 50mg/kg; GBP, 50mg/kg; VGB, 500mg/kg. Drugs were formulated 
to ensure uniformity of injection volume.
Three mice from each treatment group of each genetic type were sacrificed by decapitation 
at 30 minutes, three at 60 minutes, and three at 240 minutes after drug administration. A 
truncal blood sample was obtained and the brain, liver, heart and skeletal muscle (thigh) 
removed. Tissues were rinsed with 0.9% saline and dried by blotting to remove excess 
blood. The samples were stored at -70°C until required.
180
2.3.3 Sample preparation
Blood samples were centrifuged at 800xg for 10 minutes to obtain serum. Tissue samples 
for CBZ, PHT, VPA and PB analysis were homogenised in 5 volumes (w/v) of 0.9% saline 
and centrifuged (800xg) for 5 minutes. Supernatants were decanted into glass tubes and 
5ml diethylether / dichlorormethane (3:1) was added. Tubes were vortex-mixed and 
centrifuged for a further 5 minutes (800xg). The organic layer was removed and 
evaporated to dryness. Residues were reconstituted in 120pl of synthetic plasma for 
analysis. TPM tissue samples were homogenised in 5 volumes (w/v) of EDTA buffer 
(Sills et al, 2000) and centrifuged (800xg) for 15 minutes. The supernatant was decanted, 
re-spun (800xg) for a further 15 minutes and the resulting supernatant analysed. GBP 
tissue samples were homogenised in 5 volumes (w/v) of 1% perchloric acid and LTG and 
VGB samples homogenised in 5 volumes (w/v) of 0.9% saline. All homogenates (GBP, 
LTG, VGB) were then centrifuged (800xg) for 15 minutes prior to analysis.
2.3.4 Drug assays
CBZ, PHT, VPA and PB samples (serum and extracted tissue) were analysed by enzyme 
mediated immunoassay technique (EMIT, Syva Company, Cupertino, CA, USA). Serum 
and tissue TPM concentrations were determined by fluorescence polarisation immunoassay 
(Innofluor Topiramate Assay System, OXIS International, Portland, OR, USA). LTG, 
VGB and GBP levels in serum and tissue extracts were analysed by established HPLC 
methods (Kilpatrick et al, 1996; Forrest et al, 1996; Ratnaraj and Patsalos, 1998).
2.3.5 Statistical analysis
Group results were expressed as mean values ± standard error of the mean. Drug 
concentrations between mdrla (-/-) and mdrla (+/+) mice were compared using Student’s
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two-sample t-test. Statistical calculations were made with use of Minitab for Windows 
software (version 1 1 .2 1 ).
2.4 Results
Serum and tissue concentrations of the new AEDs are shown in Figures 19-25. Results for 
VPA were not available due to technical problems with the assay.
Compared with wild-type mice, mdrla (-/-) mice had significantly higher brain 
concentrations of TPM at 30 minutes (p=0.04) and 60 minutes (p=0.01) after subcutaneous 
injection (Figure 23). PHT reached a higher level in the brains of mdrla (-/-) mice at 240 
minutes after injection (p=0.04) compared to mdrla (+/+) mice (Figure 20). CBZ (Figure 
21) concentrations were also higher in the brains of mdrla (-/-) mice at 240 minutes after 
injection, although the difference failed to reach statistical significance (p=0.07). There 
was no difference in brain concentrations of PB, LTG, GBP or VGB between mdrla (-/-) 
mice and mdrla (+/+) mice at any time points investigated.
Compare to wild-type mice, CBZ (Figure 21) concentrations were higher in the liver of 
mdrla (-/-) mice at 240 minutes after injection (p=0.02). However, liver concentrations of 
PHT (Figure 20) at 240 minutes (p=0.02) and of GBP (Figure 24) at 30 minutes (p=0.03) 
after injection were lower in the mdrla (-/-) mice. For all eight drugs, there was no 
difference in concentrations in serum, heart or skeletal muscles between the two genotypes.
2.5 Discussion
This study was designed to examine whether P-gp at the BBB limits entry of AEDs into 
the brain. Drugs were administered by subcutaneous injection to bypass intestinal
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absorption which might be increased in mdrla (-/-) mice in the absence of gut P-gp 
(Sparreboom et al, 1994). Single administration was employed to avoid the effect of 
hepatic enzyme induction or inhibition during chronic dosing of some AEDs (Part I; 
Section 3.3.4). In some cases drug concentrations were below the lower quantifiable limit 
of the assays, particularly in cardiac and skeletal muscles where drug penetration tends to 
be low. Blood and tissue concentrations were undetectable at 240 minutes after injection 
of some AEDs, particularly those with short elimination half-lives, such as GBP and VGB.
Higher brain levels of TPM, PHT, and possibly CBZ were found in the mdrla (-/-) mice 
compared with mdrla (+/+) mice, with no difference in serum levels, suggesting that these 
drugs are substrates of P-gp at the BBB. Maximal difference in drug concentration 
between the two genotypes was observed for TPM at 60 minutes after administration (78% 
higher in the knockout mice). Previous studies have reported up to 90-fold higher brain 
levels in the mdrla (-/-) mice for certain substrates (Schinkel et al, 1994), but these studies 
tended to employ radiolabelled drugs, the measurement of which do not distinguish 
metabolites from the parent compound. With the exception of GBP and VGB which are 
largely excreted unchanged by the kidney (Wilson and Brodie, 1996), all the AEDs 
investigated in this study undergo extensive metabolism. Measuring the parent 
pharmacoactive moieties as opposed to radiolabelled compounds, therefore, reflects more 
truly their pharmacokinetic profiles.
Liver concentrations were significantly higher in mdrla (-/-) mice than wild-type mice for 
CBZ, but lower for PHT and GBP. These differences need to be interpreted with caution. 
The liver is highly vascular and it was, therefore, not possible to completely remove excess 
blood from it. Homogenised liver samples could easily be contaminated by drug in the
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vascular compartment, which is possibly the case for CBZ and GBP since differences in 
serum concentrations in the same direction between the two genetic types were observed. 
Interpretation is further complicated by the co-expression of mdrlb in the liver (Table 27). 
Compensatory upregulation of mdrlb in liver and kidney (but not the brain) has been 
reported in mdrla (-/-) mice (Schinkel et al, 1994).
Comparison of the physical and chemical properties of the eight AEDs investigated might 
yield some clues as to why only TPM, PHT and CBZ were identified as P-gp substrates 
(Figure 26). Apart from hydrophobicity, a “typical” P-gp substrate is said to be large and 
positively charged at physiological pH (7.35-7.45) with a planar ring structure (Part III; 
Section 1.2.4). TPM is the heaviest (molecular weight 339) among the AEDs studied and 
the molecular weight of both PHT and CBZ are over 230. With pKa (the pH at which the 
compound is neutral) above 7.45, TPM and PHT are the only two that are positively 
charged at physiological pH. The two fused benzene rings afford CBZ a planar 
conformation (Faigle and Feldmann, 1995). Functionally, PHT and CBZ are both inducers 
of cytochrome P450 (CYP), which has been suggested to play a complementary role with 
P-gp in drug resistance (see Section 1.2.5). TPM increases the clearance of digoxin and 
the oestrogenic component of oral contraceptives (Garnett, 2000), also suggesting 
induction of CYP isozymes. However, PB, the archetypal CYP inducer, does not appear to 
be transported by mdrla according to results of this study.
These data suggest that among the eight AEDs studied, TPM is the strongest P-gp substrate 
at the BBB. Differences in brain levels were observed at 30 minutes and 60 minutes after 
injection for TPM, but only at 240 minutes for PHT and CBZ. This may reflect the shorter
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elimination half-life of TPM compared to the other two drugs observed clinically (Faigle 
and Feldmann, 1995; Trieman and Woodbury, 1995; Garnett, 2000).
PHT is the only AED that has been investigated previously for possible transport by P-gp. 
The finding of higher brain levels of PHT in mdrla (-/-) mice than mdrla (+/+) in our 
study provides in vivo evidence to support previous in vitro studies which have also 
identified PHT as a weak P-gp substrate (Tishler et al, 1995; Schinkel et al, 1996). An 
earlier study in mdrla (-/-) mice found no difference in the tissue distribution of [14C]PHT 
compared to wild-type mice (Schinkel et al, 1996), but the use of radiolabelled compound 
might not have reflected the drug's true pharmacokinetics. If the majority of the PHT 
metabolites (also radiolabelled) were not P-gp substrates and penetrated the brain easily, 
their presence might completely mask any potential differences for the parent drug.
These results also suggest CBZ to be a possible weak substrate of P-gp. Since the major 
metabolite of CBZ, 10,11-epoxide, also possesses antiepileptic activity, in hindsight, its 
tissue concentrations should have been analysed in addition to those of CBZ itself.
In conclusion, results from this pilot study suggest that TPM, PHT, and possibly CBZ are 
substrates of mdrla P-gp. These findings need to be confirmed in larger scale experiments 
A larger number of animals analysed across a wider range of doses and time points would 
allow more detailed profiling of the drugs’ pharmacokinetics. The effect of chronic dosing 
should also be investigated to mimic their clinical usage more closely, and to examine 
whether these AEDs, similar to many other substrates, also induce the expression of P-gp. 
Since experiments in rats suggest that mdrlb is only expressed in the hippocampus in the 
brain (data presented in Part III, Section 4), hippocampal concentrations of AEDs may be
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compared between mdrlb (-/-) mice and mdrlb (+/+) mice to investigate whether they are 
substrates of mdrlb P-gp. Finally, studies to determine whether co-administration of 
substrate AEDs with a P-gp inhibitor may enhance their access to the brain would aid 
assessment of the feasibility of such “rational polytherapy” in the clinical setting.
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3 Recurrent materials and methods for the quantification of MDR1 expression
3.1 Quantitative reverse transcriptase-ploymerase chain reaction -  the theories
As discussed in Part III; Sections 1.2.7 and 1.2.8, the control of MDR1 expression is at the 
transcriptional level and the amount of mRNA is generally regarded as a reliable reflection 
of the level of gene expression. A number of procedures are widely employed for 
determining the abundance of a particular mRNA in a sample of total RNA, including 
northern blot, slot-blot analysis, in situ hybridisation, RNAase protection assay, and 
reverse transcriptase-polymerase chain reaction (RT-PCR). Since the subsequent 
experiments (Part III, Sections 4 to 7) involved analysis of small discrete regions of rat 
brain in which the level of mdrl expression had not been previously studied, an assay that 
is both selective and sensitive was required. In addition, clinical epileptic brain tissues 
acquired during resective surgery (Part III, Section 8 ) can be poorly preserved, thus some 
tolerance to degradation was also necessary.
3.1.1 Drawbacks of common techniques to measure mRNA
Northern analysis is straightforward and versatile, but is very vulnerable to RNA 
degradation and relatively insensitive. Although RNAase protection assay is more 
sensitive than northern analysis, it still requires p,g quantities of RNA and is subject to 
RNA degradation. Slot-blotting is prone to error through nonspecific hybridisation. A 
further common problem with these assays is the need to compare the results with a control 
as they generate an arbitrary number. In order to correct for assay variations, it is also 
necessary to compare the signal from the assay RNA to that of another gene whose 
expression is assumed to be unchanged in the experimental system. Such an assumption 
might not be valid in this case.
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3.1.2 RT-PCR
In RT-PCR, a retroviral reverse transcriptase enzyme, e.g. Moloney-murine leukaemia 
virus (MMLV) or Avian Myoblastosis virus (AMV), uses random hexamers or oligo 
deoxythymidine [oligo(dT)i5] to prime the synthesis of cDNA transcripts from mRNA. 
The cDNA is then specifically amplified exponentially using sequence specific 
oligonucleotide primers in the PCR. Compared to AMV, MMLV has higher stability and 
lower intrinsic RNase H activity, while the use of random hexamers, unlike oligo(dT) 
primers, has the flexibility of acting on mRNA without a poly(A)+ tail (Promega, 1996).
RT-PCR can detect the RNA transcript irrespective of the paucity of starting material or 
relative abundance of the specific mRNA. Compared to other RNA detection techniques, 
RT-PCR is specific, sensitive, and tolerant to low level RNA degradation and suitable for 
use on clinical and other small tissue samples (Noonan et al, 1990; Tishler et al, 1995; 
Zhang et al, 1996a; 1996b). In addition, when combined with a competitive internal 
standard, RT-PCR generates an absolute quantification without reference to a control 
sample or comparison gene, making it suitable for ongoing day-to-day analysis (Zhang et 
al, 1996a).
3.1.3 Competitive quantitative RT-PCR
Theoretically, the abundance of an individual mRNA transcript can be determined by 
knowledge of the amount of total RNA used in the initial cDNA synthesis reaction, the 
amount of cDNA used in the PCR reaction, and the number of PCR cycles necessary to 
generate sufficient detectable products. In practice, it is much more complicated. A major 
drawback to exponential amplification is that small sample to sample differences in 
amplification translate to large differences in product yield. In addition, there may be
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confounding factors influencing the final amount of the detectable product, such as 
temperature variation across the thermal cycler block resulting in variable reaction 
efficiencies, or even variation in loading the final products to the agarose gel which is often 
not prepared with uniform quality. Accurate determination of the absolute abundance of a 
specific transcript by RT-PCR requires the use of competitive RT-PCR techniques.
Competitive quantitative RT-PCR uses a single set of primers to amplify both the target 
mRNA of interest and an exogenously added competitor RNA (internal standard) of known 
concentration, but is distinguishable from the gene of interest. A serial dilution of the 
internal standard is added to replica samples of tissue RNA in amounts that span the target 
mRNA level at the reaction outset (the RT step). Any confounding variations between 
samples discussed above are thus accounted for. At the concentration of internal standard 
where the yield of competitor product matches that of the endogenous target, the two 
templates are presumed to have been present in equal amounts at the start of the reaction. 
Competitive RT-PCR requires the construction of a template as internal standard which 
undergoes RT and PCR at the same efficiency as the target mRNA. A method of 
discriminating the products from each other is also required. The internal standard usually 
consists of the target mRNA with a small, but significant, insertion or deletion in order that 
its RT-PCR products can be separated electrophoretically from those of the target mRNA 
on an agarose gel.
The major disadvantage of the use of competitive RT-PCR to quantify target mRNA is that 
it is technically laborious and costly, as multiple RT and PCRs are required for each 
sample. Nevertheless, its superior specificity and sensitivity makes it the technique-of- 
choice for quantifying mdrl mRNA in the experimental models described in this thesis.
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3.2 Isolation of total RNA
Solutions used in RNA analysis were treated with 0.01% v/v diethylpyrocarbonate (DEPC) 
overnight at room temperature to inactivate ribonucleases (RNases), then autoclaved to 
remove any remaining DEPC. Sterile, disposable deoxyribonuclease (DNase)- and RNase- 
free plasticware was used throughout. All re-used reaction tubes or instruments in direct 
contact with tissues were washed thoroughly in 3% v/v hydrogen peroxide followed by 
0.1% DEPC treated distilled water (dH20). To avoid cross contamination all pipetting 
was carried out using DNase- and RNase-ffee filter tips and a fresh aliquot of water was 
used each time. Reagents and tissues were kept on ice at all times during manipulation to 
prevent degradation of RNA.
Total RNA was extracted from brain tissues using a commercial kit (RNAgent Total RNA 
Isolation System, Promega, Southampton, UK). The volumes of reagents used were 
adjusted according to the weight of the tissue as recommended in the protocol. Brain 
tissue was dropped into ice cold denaturing solution ( 1 .2 ml per 1 0 0 p,g tissue) supplied with 
the kit and homogenised using a Kinematica polytron homogeniser (Philip Harris 
Scientific, Aberdeen, UK) on maximum setting for 30 seconds. A 600pl aliquot of the 
homogenised solution was removed into a clean 2 ml microtube, while the remainder was 
stored at -80°C for future use if required. A 60jnl aliquot of sodium acetate (2M; pH 4.0) 
was added to the microtube and mixed thoroughly by inverting the tube 4-5 times. 
Phenol:chloroform:isoamyl alcohol (125:24:1; 600pl) was removed from the lower organic 
phase of the bottle supplied and added to the tissue sample tube. The mixture was shaken 
vigorously for 10-15 seconds and left to chill on ice for 15 minutes. The mixture was 
centrifuged at 10,000xg for 20 minutes at 4°C in a pre-chilled centrifuge (Heraeus
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Sepatech). The top aqueous layer was carefully removed to a fresh tube, avoiding the 
interface, which contains genomic DNA. An equal volume of isopropanol was added, the 
sample was inverted several times to mix and finally stored at -20°C for 3 to 6 hours to 
precipitate the RNA.
The RNA was pelleted by centrifuging the sample at 10,000xg for 20 minutes at 4°C. The 
supernatant was poured off and the pellet washed in 75:25 ethanol/DEPC treated dfbO. 
The sample was centrifuged again at 10,000xg for 20 minutes at 4°C. The supernatant was 
aspirated and the pellet allowed to dry on ice for 15 minutes. The RNA pellet was 
resuspended in 15-20pl DEPC-treated dP^O. The total RNA concentration was 
determined by measuring the OD260, in duplicate, on a spectrophotometer (UV1101 
Biotech Photometer, WPA, Cambridge, UK), where 1 optical density unit (OD) 
corresponds to approximately 40pg RNA/ml. The purity of the RNA was determined by 
the ratio of OD260/OD280, where pure RNA has a ratio of 2.0 (Sambrook et al, 1989). In 
practice, ratios of between 1.7 and 2.2 were considered acceptable. The integrity of the 
extracted RNA was confirmed by running 300ng on an ethidium bromide-stained 1% w/v 
agarose gel. The 28S and 18S and ribosomal RNA bands were identified under ultraviolet 
light and the RNA was stored at -80°C until required. The procedures of gel preparation 
and electrophoresis are described in Part III; Section 3.5.3.
3.3 Removal of contaminating DNA
Genomic DNA contamination of the RNA would interfere with the subsequent RT-PCR 
quantification as DNA absorbs light at the same wavelength as RNA. In addition, genomic 
DNA would compete with the target and internal standard cDNA during PCR. To remove 
contaminating genomic DNA, RNA was treated with a DNase (RQ1 deoxyribonuclease,
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Promega, Southampton, UK) which digests double stranded DNA but has no RNase 
activity, thus leaving the RNA intact.
The reaction mixture was as follows
RNA (200ng/jLil) lOOpl
MgCb (25mM; Promega) 40pl
1 Ox Mg2+ free PCR buffer (Promega) 20pl
RQ1 DNase (lU/pl) 40pl
Total volume 200pl
The mixture was incubated at 37°C for 1 hour and the reaction terminated by adding an 
equal volume (2 0 0 |il) of phenol/chloroform, vortexing for 1 0  seconds, then centrifuging at 
10,000xg for 5 minutes at 4°C in a pre-chilled centrifuge. The upper aqueous layer was 
removed into a clean tube and an equal volume of chloroform was added. The sample was 
vortexed for 10 seconds and then centrifuged at 10,000xg for 5 minutes at 4°C. The upper 
aqueous layer was again removed into a clean tube and 3 volumes of 100% ethanol and 0.1 
volumes of DEPC treated sodium acetate (3M; pH 5.5) was added. The tube was inverted 
several times and stored at -20°C for 3 hours to precipitate the RNA. Thereafter, the 
sample was centrifuged at 10,000xg for 30 minutes at 4°C. The supernatant was poured 
off and the pellet washed in 75:25 ethanol/ DEPC treated dH2 0 . It was centrifuged again 
at 10,000xg for 30 minutes at 4°C. The supernatant was aspirated and the pellet dried on 
ice for 15 minutes. The RNA pellet was re-dissolved in lOpl DEPC-treated dH2 0 . The 
concentration, purity, and integrity were determined by spectrophotometry and agarose gel 
electrophoresis as described above. The RNA was stored at -80°C until required.
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3.4 Preparation of internal standard control RNA
Internal standard control (ISC) RNAs were prepared from DNA plasmids as previously 
described (Zhang et al, 1996a). The same protocol was used for the internal standards of 
rat mdrla and mdrlb, and human MDR1. Aliquots of DNA plasmids of rat mdrla and 
mdrlb and human MDR1 ISC were kindly gifted by Dr T.W. Gant (MRC Toxicology Unit, 
Leicester, UK). They were constructed by insertion of an extra sequence into the 
corresponding genes (Zhang et al, 1996a). The RT-PCR products of an ISC were, 
therefore, visualised as a heavier band than those of the tissue RNA on the agarose gel.
3.4.1 Transformation of competent cells with ISC plasmid DNA
A commercial kit (AdvanTAge PCR Cloning Kit, CLONTECH Laboratories UK Ltd, 
Basingstoke, UK) was used to transform competent cells with ISC plamids. For each 
plasmid, a tube of frozen TOPI OF’ E. coli cells and p-mercaptoethanol were thawed on ice 
and SOC medium was allowed to defrost to room temperature. A 2pi aliquot of p- 
mercaptoethanol was pipetted into the cells and stirred gently. Thereafter, 2|nl of plasmid 
was added and the mixture was again stirred gently. The mixture was kept on ice for 30 
minutes before heating to 42°C for exactly 30 seconds in a water bath. The mixture was 
left on ice for a further 2 minutes. A 250fil aliquot of SOC medium was added and the 
mixture incubated in a shaking incubator (37°C) at 225 r.p.m. for 1 hour. Therefore, 50pl 
of mixture was spread onto an L-amp agar plate (Appendix 2) and 200 jll1 to another plate. 
The plates were left upright at room temperature for 30 minutes, then inverted and 
incubated at 37°C overnight. Normal TOPI OF’ cells are sensitive to the ampicillin in the 
plate and, therefore, do not grow. MDR ISC plasmids confer ampicillin resistance, thereby 
allowing transformed cells to multiply into colonies.
201
3.4.2 Large scale preparation and purification of ISC plasmid DNA
Large quantities of the transformed cells were grown and the plasmid isolated by alkali 
lysis as described (Sambrook et al, 1989). The plasmid was then purified using a 
commercial kit (QIAfilter Maxi, QIAGEN, Crawley, UK).
Using a sterile pipette tip, one of the colonies containing the plasmid was picked from the 
L-amp agar plate and dropped into 2ml LB-amp medium (Appendix 2) in a 25ml sterile 
tube. The culture was placed in a shaking incubator (37°C) at 225 r.p.m. overnight. The 
culture plate was discarded.
A 500pl aliquot of the overnight culture was added to 250ml freshly prepared LB-medium. 
This was again incubated (37°C) at 225 r.p.m. overnight. A glycerol stock of the 
transformed cells was prepared by adding 150pl of the culture solution to 850pl 100% 
glycerol (autoclaved), which was stored at -70°C and from which colonies could be re­
grown by re-spreading on an agar plate if required.
The following day the culture medium was poured into a clean bottle and centrifuged at 
6000xg  for 15 minutes at 4°C. The supernatant was decanted and the bacterial pellet 
resuspended completely in 10ml Buffer PI provided in the kit (resuspension buffer). A 
10ml aliquot of Buffer P2 (lysis buffer) was added, mixed gently by inverting 4-6 times, 
and incubated at room temperature for exactly 5 minutes. A 10ml aliquot of Buffer C 
(neutralisation buffer) was added to the lysate and mixed by inverting 4-6 times. The 
lysate was poured into the barrel of the QIAfilter cartridge immediately and left to incubate 
at room temperature for 10 minutes. During this period of time, a QIAGEN-tip 500
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column was equilibrated by applying 10ml Buffer QBT, which was allowed to pass 
through the resin in the column by gravity flow. The cap was removed from the cartridge 
nozzle and the plunger was inserted into the cartridge to filter the cell lysate. The filtered 
lysate was then allowed to enter the previously equilibrated resin by gravity flow. The 
resin column was washed twice with 30ml Buffer QC; again the wash buffer was allowed 
to move through the resin by gravity flow. A 15ml aliquot Buffer QF was poured into the 
resin column to elute the DNA, which was collected in a clean 30ml polypropylene tube. 
DNA was precipitated by adding 10.5ml isopropanol (room temperature). The tube was 
inverted several times and centrifuged at 15,000xg at 4°C for 30 minutes. The supernatant 
was decanted and the DNA pellet washed with 5ml 70% ethanol (room temperature) and 
centrifuged again at 15,000xg for 10 minutes. The resulting supernatant was carefully 
decanted. After air-drying the pellet for 10 minutes, the DNA was redissolved in 250pl TE 
buffer (pH 8.0). The concentration of the DNA plasmid was determined by measuring the 
OD260 on a spectrophotometer (UV1101 Biotech Photometer, WPA, Cambridge, UK), 
where 1 absorbance unit is equivalent to 50pg DNA/ml.
3.4.3 Linearisation of plasmid DNA
Each of the rat mdrla , mdrlb and human MDR1 ISC plasmids was linearised as follows:-
Plasmid DNA (10pg) x pi (where x is concentration-dependent)
1 Ox Buffer 5 pi
Restriction enzyme (1 OU/ml) 1 Opl
DEPC-treated dH2<3 y pi (where y is dependent on x)
Total volume 50pl
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MDR1 was linearised with PstI (Buffer H), and mdrla and mdrlb with Ncol (Buffer D). 
The reaction was incubated at 37°C for 4 hours. The quality of the DNA was assessed and 
the absence of RNA confirmed by running 2jxl of the digest mix on a 1% agarose gel with 
~500ng of uncut plasmid in an adjacent lane to ensure that the digest was complete. The 
uncut plasmids, due to supercoiling, were visible as several bands of various lengths, while 
only single bands were seen with linearised plasmids.
3.4.4 Purification of linearised plasmid DNA
Each linearised plasmid DNA was purified using a commercial clean-up kit (Wizard DNA 
Clean-up System, Promega, Southampton, UK). A 40jnl aliquot of DEPC-treated dJUO 
was added to 1 OjliI (~2pg) of the linearised plasmid mix. Thereafter, 1ml of Clean-Up 
resin was added and mixed by inversion. The resin/DNA mix was pipetted into the 
supplied syringe barrel. Vacuum was applied using a manifold (Vac-Man Jr. Laboratory 
Vacuum Manifold, Promega) to draw the solution through the minicolumn supplied. To 
wash the column, 2  ml of 80% isopropanol (v/v) was added to the syringe barrel and drawn 
through the minicolumn by vacuum. The resin was dried by applying vacuum for a further 
30 seconds after the solution had been pulled through the column. The minicolumn was 
centrifuged at 10,000xg for 2 minutes to remove any residual isopropanol. The 
minicolumn was then transferred to a new microcentrifuge tube. A 50pl aliquot of 
prewarmed (65-70°C) DEPC-treated dJUO was applied to the Minicolumn. After 1 minute, 
the minicolumn was centrifuged at 10,000xg for 20 seconds to elute the bound DNA.
3.4.5 In vitro transcription of ISC RNA
A 25|li1 aliquot of the purified DNA was transcribed by SP6  RNA polymerase as follows:-
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5x transcription buffer 14pl
lOOmM dithiothreitol 7 pi
Rnasin (40U/ml) 2 pi
rNTP mix (2.5mM) 20pl
ISC DNA template 25pl
SP6  RNA polymerase (20U/ml) 2pl
Total volume 70pl
The reaction was incubated at 37°C for 1 hour. A 2pl (2U) aliquot of RNase-free RQ1 
DNase (Promega) was then added and the incubation continued for a further 30 minutes to 
remove the DNA template. Thereafter, 80pl DEPC-treated dP^O was added, followed by 
150pl of phenol/chloroform and the mixture vortexed for 10 seconds. It was then 
centrifuged at 10,000xg for 5 minutes at 4°C. The upper aqueous layer was removed to 
which an equal volume of chloroform was added. The mixture was again vortexed for 10 
seconds and centrifuged at 10,000xg for 5 minutes at 4°C. The upper layer was again 
removed, to which 3 volumes of ethanol and 0.1 volumes of DEPC treated sodium acetate 
(3M; pH 5.5) was added. The tube was inverted several times and stored at -20°C 
overnight. The next day the tube was centrifuged at 10,000xg for 30 minutes at 4°C. The 
supernatant was decanted and the pellet washed in 75:25 ethanol/ DEPC dH2 0 . It was 
centrifuged again at 10,000xg for 30 minutes at 4°C. The supernatant was aspirated and 
the pellet dried on ice for 15 minutes. The RNA pellet was redissolved in lOpl DEPC- 
treated dH2<3 and the concentration and purity was determined by spectrophotometry as 
described above.
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A lpg aliquot of the transcribed RNA was passed through a purification column (NucTrap 
probe Purification Column, Stratagene, Amsterdam, The Netherlands) to remove the 
unincorporated nucleotides following the manufacturer’s instructions. The purified ISC 
RNA retrieved was quantified on a spectrophotometer as described above. To avoid 
degradation through thawing and re-freezing, dilutions of ISC RNAs were prepared fresh 
on the day of each RT-PCR experiment from an aliquot of the stock solution. Unused 
dilutions were discarded.
3.5 Reverse transcriptase-polymerase chain reaction
The methodology of qualitative and quantitative RT-PCR closely followed that developed 
by Zhang and colleagues (1996a), using the same primer sequences, reaction compositions 
and conditions. Each set of primers was designed such that they spanned an intron. This 
ensured that any products arising from amplification of contaminating genomic DNA 
(containing introns) would be longer than those from the RNA (without introns) and could 
be differentiated by electrophoretic separation. Primers were chosen from regions that 
bore the least homology amongst the genes to ensure specificity (Zhang et al, 1996a). The 
sequences of the primers, expected product size for rat mdrla , lb  and human MDR1, and 
the molecular weight of the ISCs are given in Table 28.
3.5.1 Reverse transcription
For each sample of rat brain RNA, qualitative RT-PCR for both mdrla and mdrlb was 
performed. RT-PCR for MDR1 was performed for human tissues. Individual reaction 
mixtures consisted of the following:
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1 Ox Mg2+-free PCR buffer 1.00
MgCl2 (50mM) 0.50
dNTP mix (lOOmM) 0.40
Random hexamers (90OD/ml) 0.10
Dithiothreitol (1 OOmM) 0.10
Rnasin (40U/ml) 0.25
MMLV RT(200U/pl) 0.50
Tissue RNA (1OOng/pl) 1.00
dH20  (DEPC treated) 6.15
Total volume 10.00
In practice, since multiple reactions were carried out at any one time, a reaction mixture 
containing the reagents was prepared on the day of the experiment. A 9 pi aliquot of the 
mixture was pipetted into each reaction tube, to which 1 pi of tissue RNA was added. The 
reaction was carried out in a thermal cycler (Perkin Elmer DNA Thermal Cycler 480, PE 
Biosystems, Norwalk CT, USA):
Hexamer annealing 23°C 1 0  minutes
Product extension 42°C 45 minutes
Reaction termination 99°C 1 0  minutes
Inactivation of RT 4°C stand (at least 1 0  minutes)
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3.5.2 Polymerase chain reaction
All the cDNA produced in the RT was used for the subsequent PCR which contained:
liL
lOx Mg2+-ffee PCR buffer 1 . 0
MgCl2 (50mM) 0.5
Sense primer (4 pmol/pl) 1 . 0
Antisense primer (4 pmol/pl) 1 . 0
W-1 detergent (1 %) 1 . 0
Taq DNA polymerase (5U/pl) 0 . 2
cDNA (from RT above) 1 0 . 0
dH20 5.3
Total volume 2 0 . 0
Again, in practice, since multiple reactions were carried out at any one time, a reaction 
mixture containing the reagents was prepared on the day of the experiment. A lOpil aliquot 
of the mixture was pipetted into each reaction tube. The reaction was carried out in a 
thermal cycler (Perkin Elmer DNA Thermal Cycler 480, PE Biosystems, Norwalk CT, 
USA):
Denaturation 
Primer annealing 
Primer extension
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95 C 5 minutes
56°C 2 minutes
72°C 1 minute
x 1 cycle
95°C 1 minute
55°C 1 minute
72°C 1 minute
x 28 cycles
95°C
55°C
72°C
1 minute
2  minutes 
5 minutes
x 1 cycle
4°C stand
3.5.3 Visualisation of PCR products
A 2% (w/v) agarose gel was prepared by adding 2g agarose (BioGene, Kimbolton, UK) to 
100ml electrophoresis buffer (Appendix 2) which was heated to boiling in a volumetric 
flask. Approximately 3 pi of ethidium bromide (lOmg/ml) was added to the agarose 
solution and mixed thoroughly by swirling. The solution was poured onto an 
electrophoresis tray (Bio-Rad Laboratories Ltd, Hemel Hempstead, UK) and allowed to 
stand at room temperature to form a gel. "Wells" were formed by placing a "comb" on the 
tray during cooling. The tray containing the gel (without the comb) was then immersed in 
electrophoresis buffer in a horizontal tank (Bio-Rad). A 15pl aliquot of the products in 
each PCR tube was added to 5pi of DNA loading buffer (Appendix 2) and the mixture was 
loaded to a single well on the gel. Electrophoresis was carried out at 110V for 1.5 hours. 
The PCR products were visualised under ultraviolet light (see below).
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3.5.4 Quantitative RT-PCR
If mRNA was detected by qualitative RT-PCR, quantitative RT-PCR was performed to 
measure the absolute level of gene expression. During the RT step, lpl of internal 
standard RNA was added and the volume of dH2C) was reduced accordingly. For each 
sample of tissue RNA, 7 reverse transcription reactions were set up with increasing amount 
of internal standard RNA competing with the same amount of target RNA. For example,
Reaction Target RNA (ng) ISC RNA (pg) RT enzyme
1 1 0 0 0 . 0 1 +
2 1 0 0 0.05 +
3 1 0 0 0 . 1 +
4 1 0 0 0.5 +
5 1 0 0 1 . 0 +
6 1 0 0 0 -
7 dH20  (DEPC-treated) 0 +
Reactions 6  and 7 acted as negative controls. PCR and gel electrophoresis were then 
carried out as described above. The concentration range of ISC was chosen such that it 
spanned the target mRNA concentration in the tissue. This ensured that the ratios of band 
volume of ISC/target across the ISC dilutions spanned across 1 during subsequent image 
analysis (see below).
3.5.5 Calculation of target mRNA concentration
When electrophoresis was finished, the agarose gel was placed directly under a digital 
densitometer (GelDoc, Bio-Rad Laboratories Ltd, Hemel Hempstead, UK) for scanning. A
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typical image is shown in Figure 27a. The top band corresponded to the heavier ISC 
which travelled slower than the target (tissue) RNA due to the extra inserted sequence. 
The intensity (volume) of each individual band was measured against a local background 
using Multi-Analyst 1.1 software (Bio-Rad Laboratories Ltd). In the example shown in 
Figure 27a, the following results were yielded:
Lane Band
position
RNA Amount of ISC 
in weight (pg)
Amount of ISC in 
molecules (xlO6)
Band
volume
Ratio of 
ISC/target
1 Upper ISC 0 . 0 1 0.04 26.84 0.05
Lower Target 1109.82
2 Upper ISC 0.05 0 . 2 0 171.31 0 . 2 0
Lower Target 868.49
3 Upper ISC 0 . 1 0.39 251.96 0.44
Lower Target 571.72
4 Upper ISC 0.5 1.97 888.19 1.80
Lower Target 492.85
5 Upper ISC 1 3.93 1850.41 4.69
Lower Target 394.66
Knowledge of the molecular weight of the ISC (Table 28) allowed calculation of the 
number of ISC molecules employed in each reaction. A double-logio plot of the amount of 
ISC RNA (x-axis) against the ratio of ISC intensity/target intensity (y-axis) yielded a 
straight line (Figure 27b). Only graphs with a correlation coefficient (r2) of at least 0.95 
were used to ensure validity of the results.
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Lane 1 2  3 4 5
Figure 27a. Typical quantitative RT-PCR image after electrophoretic separation 
on an agarose gel. ISC=internal standard control
P <  0.001 
R2 = 0.995
X
0.01
0.01 100.1
No. o f  ISC molecules x 106
Figure 27b. Calculation o f the number o f target mdrl mRNA molecules by plotting the 
ratio o f the band volume o f internal standard control (ISC)/target against the known 
amount o f ISC in the reactions.
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When the ratio of internal standard intensity / target intensity = 1, the number of molecules 
of target mRNA is equivalent to that of ISC. The straight line equation could thus be used 
to calculate the absolute number of molecules of mdrl mRNA per ng of total RNA:
y = ax + b
where y is the logio ratio of band volume of ISC over that of target, x is the logio number of 
molecules of ISC, a is the gradient of the slope and b is the y-axis intercept. In this 
example, the concentration of target mdrla mRNA was 0.93 x 106 molecules per lOOng 
total RNA extracted from the tissue, or 9.3 x 10 molecules per ng total RNA. Statistical 
calculation was performed with use of Minitab for Windows (version 11.21).
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4 Validation of RT-PCR assay and physiological expression of mdrl genes in rat 
brain
4.1 Introduction
Whereas the drug-transporting (Class I) P-gp is encoded by a single gene (MDR1) in man, 
two isoforms exist in rodents (Table 24a). Their tissue distribution in rats has not been 
well investigated. In mice, mdrla and mdrlb P-gps have overlapping but distinct tissue 
distributions (Croop et al, 1989). Together they cover the same tissues as the single MDR1 
in man (Table 27), suggesting that they fulfil the same physiological role(s) in the different 
species (Schinkel, 1997).
4.1.1 Which isoform is expressed in which region?
Although genetically engineered mice deficient in mdrla and / or mdrlb are increasingly 
employed to screen drugs as possible substrates of P-gp at the BBB level, the expression 
pattern of mdrla and mdrlb in rodent brains has been investigated in few studies. These 
have often involved the whole brain and employed different techniques. No studies 
specifically examining the regional distribution of the two isoforms in the brain have been 
reported. In mice, one study using DNA-RNA hybridisation found both mdrla  and mdrlb 
in homogenised whole brain tissues, although the latter at lower level (Croop et al, 1989). 
In rats, only mdrla is thought to be present in the cerebral micro vessels in vivo (Barrand et 
al, 1995; Regina et al, 1998), although mdrlb has also been detected at very low level in 
whole brain tissues using RT-PCR, a more sensitive method than immunohistochemistry 
(Regina et al, 1998). In addition, brain levels of P-gp substrates can reach one to two 
orders of magnitude higher in mdrla knockout or mdrl a/lb  “double-knockout” mice 
compared to wild-type mice, whereas similar brain levels are found in mdrlb knockout 
mice and normal mice (Schinkel et al, 1997). This may suggest that mdrla is the
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predominant functioning P-gp in mouse BBB. However, expression of mdrlb confined to 
certain discrete at risk region(s) in the rodent brain conferring “extra protection” cannot be 
ruled out by results from these studies in which the whole brain was examined.
4.1.2 Cellular location of expression
The cellular location of P-gp in the brain has been the subject of much debate. If cerebral 
P-gp is expressed by cells other than the capillary endothelium, attempts to inhibit its 
action pharmacologically might have knock-on effects on neuronal and glial functions.
The use of different methodologies has made comparison of findings across published 
studies problematic. With few exceptions (Pardridge et al, 1997), most authors report 
detection of P-gp by autoantibody staining or Western blotting on capillary endothelium 
and not on normal brain parenchymal cells (Cordon-Cardo et al, 1989; Seetharaman et al, 
1998). Diseased astrocytes are the only exception to this observation (Bietzmann et al, 
1994; Tishler et al, 1995). The highly conserved nature of the mdr genes between human 
and rodents suggests that they may have a similar distribution in rats. Western 
immunoblotting has demonstrated the presence of P-gp in isolated microvessels from rat 
brain cortex (Barrand et al, 1995; Beaulieu et al, 1997; Regina et al, 1998). However, 
using RT-PCR, Regina and co-workers (1998) found a very low level of mdrlb (but not 
mdrla) expression in whole cerebral cortex homogenates but not in isolated cortical 
micro vessels. This led the authors to conclude that the mdrlb isoform is expressed by 
brain parenchymal cells. In addition, mdrlb mRNA can be detected in primary culture of 
brain endothelial cells grown from capillary fragments isolated from rat cortical grey 
matter (Barrand et al, 1995; Regina et al, 1998). Whether it is also expressed in other 
cultured brain cells, such as astrocytes or neurones, has not been investigated.
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4.2 Aims
The aims of this study were threefold. Firstly, the technique of quantitative RT-PCR 
developed for measuring mRNA concentrations was validated by testing the inter-assay 
variation. Secondly, regional expression of mdrla and mdrlb genes, both qualitative and 
quantitative, in the rat brain was determined. Finally, RT-PCR was employed to determine 
the expression of mdrla and mdrlb in primary cultures of rat cortical astrocytes and 
neurones. The rat was chosen instead of the mouse since its relatively larger brain allows 
dissection into regions of adequate size for reliable mRNA measurement.
4.3 Methods
4.3.1 Animals
Adults rats were obtained from Harlan Olac (Bicester, UK). Neonates and embryos for 
cell culture studies were obtained from a colony of Sprague-Dawley rats at the Central 
Research Facility at the University of Glasgow. All animals were housed in a controlled 
temperature/humidity environment with day/night cycle and access to food and water ad 
libitum. All experimental work was governed by the Animals (Scientific Procedures) Act, 
1986 (UK).
4.3.2 Regional analysis
Four male Sprague-Dawley rats at 12 weeks of age were studied. They were sacrificed by 
cervical dislocation followed by decapitation. Each brain was quickly removed and 
dissected into seven regions, namely frontal cortex, dorsal cortex, cerebellum, pons, 
midbrain, hippocampus, and olfactory bulbs as previously described (Glowinski and 
Iversen, 1966). Each region was washed in ice cold saline, blotted dry, and immediately 
snap frozen in liquid nitrogen. Frozen tissues were stored at -70°C until required.
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4.3.3 Primary culture of cerebral cortical astrocytes
Primary culture of cortical astrocytes was performed as previously described (Leach et al, 
1996). The cerebral cortices of one day-old rat pups were removed under aseptic 
conditions and cleared of attached olfactory bulbs, basal ganglia, hippocampal formations 
and meningeal membranes. The dissected neopallia were then cut into small cubes (0.5 
mm3) by two passes (at 90°) in a Mcllwain tissue chopper (Mickle Laboratory Engineering 
Company Ltd, Gomshall, UK). The chopped tissue was transferred to a sterile glass filter 
(80 pm nylon mesh; Lockertex Ltd., Warrington, UK) and the filtrate collected in a sterile 
beaker. The chopped material was washed through the filter with culture medium 
(Dulbecco’s modified Eagle medium (DMEM) supplemented with 20% (v/v) horse serum,
2.5 mM L-glutamine, 100 I.U./ml penicillin, and 100 pg/ml streptomycin, all obtained 
from Gibco BRL, Paisley, UK) to give a final volume of 3 ml per brain. The filtrate was 
then passed through a sterile needle (BD Microlance 21G 0.8 x 40) three times. The 
volume of the resulting suspension was adjusted with culture medium to allow a 3 ml 
aliquot per culture dish in a ratio of 1 brain to 3 dishes. A 3-ml volume of the final cell 
suspension was plated onto 60 x 15 mm Falcon Primaria culture dishes (A+J Beveridge, 
Edinburgh, UK). The cultures were maintained at 37°C in an environment of 95% air / 5% 
CO2 with a humidity of > 90%. The culture medium (3 ml) was replaced every 3 - 4  days 
throughout. The horse serum concentration was reduced to 10% at the first medium change 
with a final reduction to 5% at the second change. After 14 days in culture the medium was 
supplemented with 0.25 mM 3'5'-dibutyryl cyclic adenosine monophosphate (cAMP; 
Sigma, Poole, UK) to induce cell differentiation. Expression of mdrl genes in the cultures 
was determined by RT-PCR 7 days after supplementation with cAMP.
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4.3.4 Primary culture of cerebral cortical neurones
This method was devised from modifications of the methods of Larsson and co-workers 
(1981), Yu and co-workers (1984), and Courtney and colleagues (1990).
4.3.4.1 Reagents
Poly-D-lysine solution was prepared by dissolving 1.5 mg poly-D-lysine in 100 ml borate 
buffer (pH 8.4). Solution B consisted of 0.25% D-glucose, 0.3% bovine serum albumin 
(BSA), and 0.0382% MgSC>4 in phosphate buffered saline (PBS). Trypsin solution was 
prepared by dissolving 50mg of trypsin in 20ml of solution B. Concentrated DNase/soya 
bean trypsin inhibitor (SBTI) solution consisted of 2.8% DNase I, 5% SBTI, and 0.0382% 
MgSC>4 in Solution B. A weak DNase solution was prepared by diluting 3.2ml of the 
concentrated DNase/SBTI solution to 20ml with Solution B. The borate buffer was 
prepared by adjusting the pH of 15 pM boric acid to 8.4 with 1 M NaOH. The culture 
medium consisted of minimal essential medium (MEM) supplemented with 20% (v/v) 
horse serum, 2 mM L-glutamine, 7 pM para-aminobenzoic acid (PABA), 100 pl.U./litre 
insulin, 0.6% D-glucose, and 0.14% KC1. The culture medium was further supplemented 
with 40 pM cytosine arabinoside (ARA-C), where indicated, to remove all replicating, 
non-neuronal cells. All solutions were prepared under sterile conditions, using sterile water 
where required and filter sterilised through a 0 . 2  pm pore filter prior to use and/or storage. 
Solutions were stored sterile at 4°C for up to 5 days. Liquid reagents were obtained from 
Gibco BRL (Paisley, UK) while solid ingredients were bought from Sigma (Poole, UK).
4.3.4.2 Tissue preparation
Tissue for cell isolation was removed under aseptic conditions. Pregnant female rats, at 15- 
17 days post-conception, were sacrificed by a blow to the head followed by cervical
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dislocation. The abdomen was opened and all foetuses removed into a culture dish 
containing MEM. The membraneous-like skull surface was removed with forceps and the 
cerebral cortices resected with a delicate pinch between the points of a pair of curved 
watchmaker’s forceps. The dissected cortices were transferred to a sterile universal tube 
containing 6  ml of MEM prior to cell isolation.
4.3.4.3 Cell isolation
Isolated cerebral cortices were chopped into small cubes (0.375 mm3) by two passes (at 90°) 
in a Mcllwain tissue chopper. Chopped tissue was transferred to a sterile 50 ml Falcon tube 
containing 20 ml trypsin solution and gently agitated to reduce clumping. A sterile plastic 
pipette was used to aid this process. Tubes were capped, shaken gently, and incubated for 20 
minutes at 37°C. After incubation, 20 ml of weak DNAse/SBTI solution was added and 
tubes mixed gently. Cells were pelleted by gentle centrifugation (2000 rpm for 1 minute). 
The supernatant was discarded and 1 ml concentrated DNAse/SBTI solution added. Cells 
were resuspended by trituration of the cell pellet suspension through a sterile glass pipette. 
The cell suspension was transferred to a 15 ml Falcon tube, a further 1ml of concentrated 
DNAse/SBTI solution added and trituration repeated through a sterile glass pipette with a 
narrowed end. Underlying the cell suspension with 2ml of 4% BSA using a “kwill” filling 
tube facilitated decontamination of the cells. Cells were again pelleted by centrifugation at 
2000 rpm for 5 minutes. The supernatant was discarded and the cells resuspended in 2ml 
culture medium. A ten-fold dilution of this cell suspension (90 jil culture medium + 10 pi 
cell suspension) was prepared and lOpl employed for cell counting in a haemocytometer. 
The total number of cells was calculated and the volume of the cell suspension adjusted with 
culture medium to give 1.25 million cells per ml. Falcon Primaria culture dishes (35 mm ) 
had been pre-coated with 2 ml poly-D-lysine solution for 1 hour at room temperature and
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allowed to air dry. A 2 ml volume of cell suspension was plated on each dish and plates were 
incubated at 37°C for 30 minutes. Thereafter the medium was replaced with a further 2 ml of 
culture medium to remove all non-attached cells.
4.3.4.4 Culture maintenance
The cultures were maintained at 37°C in an environment of 95% air / 5% CO2 with a 
humidity of > 90%. After 48 hours in culture the medium was replaced with 2 ml culture 
medium containing 40 |iM ARA-C to eliminate all non-neuronal cells. At this point the 
horse serum concentration was reduced to 10%. The horse serum concentration remained 
at 10% thereafter. Twenty-four hours later (day 3) and again on day 6  the medium was 
again replaced with 2 ml culture medium without ARA-C. Cultures were seen to be fully 
mature and ready for use between day 8  and day 1 0  and were viable for up to 15 days.
4.3.5 Qualitative and quantitative determination of mdrl mRNA
Total RNA was extracted from brain tissues and cell cultures and cleaned as described in 
Part III; Sections 3.2 and 3.3. Qualitative RT-PCR was performed to determine whether 
mdrla and mdrlb were expressed in the various brain regions. If so, concentrations of the 
mRNA were measured by quantitative RT-PCR as described in Part III; Section 3.5.
4.3.6 Inter-assay variation of quantitative RT-PCR
To measure inter-assay variation, one of the samples homogenised in RNA Denaturing 
Solution was split into four specimens, which were then processed individually on separate 
days for the remaining RNA extraction procedure and to the final analysis of quantitative 
RT-PCR results.
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4.3.7 Statistical analysis
The inter-assay and inter-individual variability of mdrla and mdrlb mRNA levels was 
assessed by calculating the standard error of the mean values. The mRNA concentrations 
in different regions of the brain were expressed as the mean values ± standard error, and 
compared by one-way analysis of variance with Dunnet’s correction for multiple 
comparisons. Statistical calculation was performed using Minitab for Windows (version
11.21).
4.4 Results
4.4.1 Qualitative regional expression of mdrl genes
The same pattern of expression was observed in all four rats. Using primers specific for 
mdrla , a fragment corresponding to the expected size (351 bp) was amplified from total 
RNA prepared from all seven brain regions dissected. However, use of primers specific 
for mdrlb resulted in the amplification of an expected 326-bp fragment to a significant 
level with RNA prepared from the hippocampus only (Figure 28). The level of expression 
of mdrlb in the other regions was below the quantifiable lower limit of the assay.
Attempts to increase the RT-PCR products of mdrlb to fall within the quantifiable range 
were unsuccessful.
4.4.2 Inter-assay variation
Inter-assay variation of mdrla mRNA level was assessed using a homogenised sample of 
cortex. Since mdrlb was only expressed at quantifiable level in the hippocampus, inter­
assay variation of mdrlb mRNA level was assessed using homogenised hippocampi from 
one of the rats.
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la  (351bp) lb  (326bp)
Blank
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DNA
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Figure 28. Regional expression o f mdrla  and mdrlb in the rat brain. 
M B=midbrain, FC=frontal cortex, DC=dorsal cortex, CE=cerebellum, PO=pons 
OF=olfactory bulb, FIC=hippocampus
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The mean concentration of mdrla mRNA measured in four separate analyses of the same 
cortical sample was 12320 molecules/ng total RNA, with a standard error of 301 
molecules/ng total RNA (2.4%). The mean concentration of mdrlb measured in four 
separate analyses of the same hippocampal sample was 2223 molecules/ng total RNA, 
standard error 101 molecules/ng total RNA (4.6%).
4.4.3 Regional expression of mdrla and mdrlb genes
Figure 29 shows the level of mdrla expression as measured by concentration of mRNA. 
This did not differ significantly among the different brain regions. Mdrlb mRNA level 
was only high enough to be quantified in the hippocampus (Figure 30).
4.4.4 Expression of mdrla and mdrlb genes in cortical astrocytes and neurones
Using primers specific for mdrla , a fragment corresponding to the expected size (351 bp) 
was amplified from total RNA prepared from primary cultures of both cortical astrocytes 
and neurones (Figure 31a). Similarly, use of primers specific for mdrlb resulted in the 
amplification of an expected 325-bp fragment with RNA prepared from cultures of both 
cell types (Figure 31b).
4.5 Discussion
The narrow inter-assay variations (standard error <5% of mean values) in mRNA levels 
measured suggest the technique of quantitative RT-PCR developed for this purpose is 
reproducible for the determination of rat mdrla and mdrlb mRNA. Marked inter­
individual variation in mdrla expression level was noted in some regions, particularly the 
cerebellum (standard error = 29% of mean values). Wide variation in expression level has 
also been noted in human studies (Part III; Section 1.2.7).
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Figure 31a. Expression o f mdrla  in primary cell cultures. 
Expected band size = 351 bp.
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Figure 31b. Expression o f mdrlb in primary cell cultures. 
Expected band size = 326bp.
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Although mdrl P-gp is increasingly recognised to play an important role in maintaining the 
mammalian BBB (Part III; Section 1.2.5), differential regional expression of the mdrl 
genes in the brain has not been reported. Results from the present study suggest that while 
mdrl a is expressed throughout the rat brain at comparable levels, mdrlb is only expressed 
to an appreciable amount by the hippocampus. Although the cellular location of mdrlb 
mRNA in the hippocampus could not be determined, a reasonable extrapolation of findings 
from the literature suggests that it is likely also to be present in capillary endothelium, 
serving similar functions as mdrl a P-gp (Part III; Section 1.2.5).
Why both mdrl isoforms should be expressed to a significant level in the hippocampus 
alone is unclear. The hippocampus is recognised to play a crucial role in higher cognitive 
functions, including memory, learning and spatial orientation, as well as emotion in 
mammals (Sutula et al, 1994; Parent, 1996). Virtually all aspects of memory processed by 
the hippocampal system can be referred to its function as a temporary memory store, 
believed to be effected via its exquisite anatomical and physiological plasticity (Lynch et al, 
1990; Akhondzakeh, 1999). Both long-term potentiation and depression, which produce 
long-lasting changes in the efficacy of information processing at the synaptic site, are 
prominent in the hippocampus (Lynch et al, 1990; Bliss and Lomo, 1973; Akhondzakeh, 
1999; Nayak and Browning, 1999). Lesions to the hippocampus produce memory deficits 
(Squire, 1992), as exemplified by the classic report of patient H.M. who developed 
profound anterograde amnesia with little change in other cognitive functions following 
bilateral medial temporal lobe resection (Scoville and Milner, 1957). HS is a common 
finding in elderly people with dementia (26% in one series; Dickson et al, 1994). HS/MTS 
is the most common pathological finding in refractory temporal lobe epilepsy (Part I;
Section 1.4.2). The presence of HS is associated with generalised cognitive impairment in
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intelligence, language, visuospatial functions and material-specific memory when 
compared to patients with temporal lobe epilepsy without HS (Hermann et al, 1997).
The presence of both mdrl a and mdrlb P-gp in the mammalian hippocampus might, 
therefore, have evolutionary significance by their enhanced ability to extrude xenobiotics 
from this particularly important but plastic brain structure. However, this "extra 
protection" might hinder pharmaceutical efficacy by limiting drug access when the 
hippocampus becomes diseased. This mechanism might conceivably contribute to the 
particularly pharmacoresistant nature of MTS-related epilepsy compared with other 
cerebral lesions (Part II; Section 4).
Such near-exclusive expression of mdrlb in the hippocampus might help to explain why 
mdrlb was not detected in micro vessels isolated from the cortex (Barrand et al, 1995; 
Regina et al, 1998), but was present in “whole brain” (Croop et al, 1989). In addition, this 
distribution pattern of the mdrl P-gps might account for the similar level of digoxin, a 
strong P-gp substrate, measured in the brains of mdrlb (-/-) mice and mdrlb (+/+) mice 
(Schinkel et al, 1997), assuming the mouse displays the same expression pattern as the rat. 
Comparing the hippocampal levels of the drug in the two mouse genotypes might have 
yielded different results.
In cell culture, both mdrl isoforms were expressed at similar levels by astrocytes and 
neurones. However, P-gp has not been visualised in normal brain parenchyma in man 
(Cordon-Cardo et al, 1989; Tishler et al, 1995). It has been shown that whereas only 
mdrl a is expressed in vivo in rat brain micro vessels, mdrlb is also expressed in cultured 
endothelial cells (Barrand et al, 1995). In view of the highly inducible nature of P-gp (Part
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Ill; Section 1.2.7), it is likely that the expression of mdrlb in astrocytes and neurones is 
largely, if not entirely, induced by the culturing process itself.
In summary, while these data do not rule out expression of mdrl in normal brain 
parenchyma (proof would require analysis of brain tissues without the intricate 
microvessels which is not technically feasible), together with most literature reports, they 
suggest that P-gp is likely to be located primarily, if not exclusively, on the capillary 
endothelium of the BBB. It is possible that the additional expression of mdrlb in the 
hippocampus provides an enhanced protection of this sensitive and important brain region. 
This would have implications for those therapeutic agents, such as AEDs, which often 
require access to the hippocampus to exert their effects.
Further studies should include confirmation of mdrlb P-gp in the hippocampus by 
immunocytochemistry employing specific antibodies (Barrand and Twentyman, 1992). 
Determination of any differential regional expression of P-gp in man may only be 
practically and reliably investigated by non-invasive functional in vivo assays (Part III; 
Section 1.2.8). If the hippocampus were armed with extra functioning P-gp, AEDs that are 
substrates would be expected to reach lower level in this structure than other regions. 
Testing of this hypothesis requires measuring drug levels within specific brain regions by 
sensitive techniques, which have been attempted for a few drugs in very few studies 
(Rambeck et al, 1993; Comford et al, 1996; Darius et al, 1999).
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5 Effects of seizures in genetically epilepsy-prone rats
5.1 Introduction
5.1.1 Phenotype
Genetically epilepsy-prone rats (GEPRs) were developed originally from a colony of 
Sprague-Dawley rats in the late 1950s by selective breeding based on their susceptibility to 
sound-induced seizures (Laird and Jobe, 1987). These animals possess an inborn 
vulnerability to audiogenically induced seizures, which is usually displayed from around 2  
to 4 weeks after birth and continues through adulthood (Thompson et al, 1991). Two 
distinct colonies have been developed based on the severity of the audiogenic seizures 
(AGS). The moderate seizure GEPRs (GEPR-3) exhibit a running, bouncing fit which 
terminates in generalised clonus with loss of righting reflex. The most commonly studied 
strain is GEPR-9 which displays the most severe form of AGS beginning with a very brief 
running phase, followed by a discrete clonic phase, terminating in tonic hind limb 
extension and post-ictal depression (Dailey et al, 1996; Faingold, 1999). Although the 
original GEPR breeding stock was selected for its sensitivity to acoustic stimulation, 
subsequent work suggests that these animals can exhibit spontaneous seizures and have 
increased susceptibility to a variety of other physical and chemical seizure stimuli (Laird 
and Jobe, 1987; Buchhalter, 1993).
All major established AEDs have been shown to be effective in preventing AGS in GEPRs 
(Reigel et al, 1986), although sensitivity varies with the strain (Dailey and Jobe, 1985). 
GEPR-9s are more sensitive than GEPR-3 s to the anticonvulsant effect of PHT and CBZ. 
ESM is equally effective in both strains. VPA is more effective in GEPR-3s than GEPR-9s 
It has been suggested such response patterns may be useful in identifying agents with 
different clinical indications, corresponding to tonic-clonic seizures, absence seizures, and
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broad seizure spectrum, respectively (Laird and Jobe, 1987). Some compounds (e.g. 
chlorpromazine, haloperidol, baclofen) that possess anticonvulsant effects in other animal 
models (e.g. MES, scPTZ), but not in man, are devoid of activity in GEPRs (Dailey et al, 
1996). Notwithstanding breeding difficulties (Consroe et al, 1979), GEPRs have, therefore, 
proven to be one of the most useful animal models of inherited epilepsy, with behavioural, 
electrographic and pharmacological features similar to primary GTCS (Coffey et al, 1996).
5.1.2 Neuronal networks
The pathway that underlies AGS in GEPR-9s principally involves neuronal networks in the 
brainstem (Faingold, 1999). It is generally believed that AGS are initiated by high 
intensity acoustic input to the cochlea, which is damaged in GEPR-9s. The output of the 
lower auditory nuclei is projected via glutamate receptor-mediated excitation to the inferior 
colliculus in the midbrain. This region has been shown to play a critical role in AGS 
initiation. Bilateral lesions of the inferior colliculus inhibit seizures whereas electrical 
stimulation produces seizures (Buchhalter, 1993). Recordings from this region 
demonstrate spike-wave discharges immediately prior to (Faingold, 1999), and during the 
initiation of AGS (Ludvig and Moshe, 1989). Cortical spikes are observed after discharges 
in the inferior colliculus, although cortical ablation does not eliminate seizures (Ribak et al, 
1988).
The deep layers of the superior colliculus develop rapid tonic firing 1 to 2 seconds prior to 
wild running, suggesting a role in the generation of convulsive behaviour. Firing ceases in 
the post-ictal period with eventual recovery. Just prior to tonic hind limb extension and 
throughout this phase, discharges can be seen in the pontine reticular nucleus and
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periaqueductal gray, implying a critical role of these regions in the manifestation of the 
tonic-clonic seizure (Faingold, 1999).
The genetic basis of AGS in the GEPR is unknown, but inheritance is likely to be 
polygenic and autosomal dominant (Buchhalter, 1993). Neurochemically, extensive data 
suggest that GEPRs have widespread deficiencies in noradrenergic and serotonergic 
functions in the CNS, both presynaptically and postsynaptically (Buchhalter, 1993; Dailey 
et al, 1996; Hosford et al, 1997). Recent observations of reduced effectiveness of 
GABAergic inhibition and an excess of glutamate availability in the inferior colliculus 
suggest altered GABA function may also play a role (Faingold, 1999).
5.1.3 Aims
This study aimed to examine whether the expression of mdrla and mdrlb genes may be 
induced by a single seizure in GEPRs. The main advantage of using GEPRs for this 
purpose is the ability to generate seizures without administration of chemoconvulsive 
agents, which themselves might be substrates and/or inducers of P-gp. Since the neuronal 
network of the GEPR is relatively well-delineated, any potential effect of seizures on mdrl 
expression can be compared between the brain regions that are involved in seizure 
generation with those that are not. It can be hypothesised that if mdrl expression could 
indeed be induced by seizure, the effect would be most marked in the midbrain and cortex 
which are involved in the seizure pathway with relative sparing of other areas.
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5.2 Methods
5.2.1 Materials
Twenty adult male rats (8-10 weeks of age) were taken from an established colony of 
GEPRs bred in-house at the Institute of Psychiatry, London, under the supervision of 
Professor Brian S Meldrum. None had been exposed to audiogenic stimulation prior to the 
experiment.
The rats were randomised into four groups. Five rats remained naive and served as the 
control group while the remaining 15 were exposed individually to a single audiogenic 
stimulation (110-120 dB; 12-16 Hz; maximum 60 s or until seizures began) as previously 
described (Smith et al, 1993). Five rats were sacrificed at 4 hours, five at 24 hours, and the 
remaining five at 7 days post-stimulation. All rats were kept in a controlled temperature 
and humidity environment with day/night cycle conditions and access to food and water ad 
libitum until sacrificed by decapitation. Their brains were removed and quickly dissected 
into four regions, namely midbrain, cortex, pons/medulla, and hippocampus (Glowinski 
and Iversen, 1966). The brain regions were placed individually in microcentrifiige tubes 
and immediately snap frozen in liquid nitrogen before being transferred to storage at -70°C 
until required.
5.2.2 Measurement of mdrl mRNA
Total RNA was extracted from brain tissues and cleaned as described in Part III; Sections
3.2 and 3.3. M drla and mdrlb mRNA concentrations were measured by quantitative RT- 
PCR (Part III; Section 3.5).
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5.2.3 Statistical analysis
Group results were expressed as the mean of absolute values ± standard error of the mean. 
Groups sacrificed at different time points after stimulation were compared to the control 
animals using one-way analysis of variance with Dunnet’s correction for multiple 
comparisons. Statistical calculation was performed using Minitab for Windows (version
11.21).
5.3 Results
All but one of the stimulated GEPRs displayed motor seizures of either moderate (GEPR-3) 
or severe (GEPR-9) form in response to acoustic stimulation. Mdrla  mRNA was present 
in all regions of all stimulated and control rats, whereas mdrlb mRNA was detected at 
quantifiable levels in the hippocampus only.
Compared with controls, mdrla mRNA concentration in the cerebral cortex rose at 4 hours 
after a single audiogenic stimulation (Figure 32). There was a further rise at 24 hours 
(p<0.05), after which the concentration declined, although it remained elevated at 7 days 
post-stimulation. A similar time-dependent response in mdrla mRNA level was observed 
in the midbrain (Figure 33), although the increase did not reach statistical significance. 
Audiogenic stimulation did not significantly alter the mRNA levels of mdrla in the 
pons/medulla (Figure 34) or hippocampus (Figure 35), or of mdrlb in the latter (Figure 36) 
at any of the time points investigated.
5.4 Discussion
Results from this pilot study suggest that seizures may induce changes in P-gp expression.
A rise in mdrla expression was observed at 4 hours after a seizure in brain regions that are
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Figure 32. Concentration of mdrla mRNA in cerebral cortex of GEPRs at various time 
points after a single audiogenic seizure. *p<0.05. Bars indicate standard error of mean.
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Figure 33. Concentration of mdrla mRNA in midbrain of GEPRs at various time points 
after a single audiogenic seizure. Bars indicate standard error of mean.
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Figure 34. Concentration of mdrla mRNA in pons/medulla of GEPRs at various time 
points after a single audiogenic seizure. Bars indicate standard error of mean.
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Figure 35. Concentration of mdrla mRNA in hippocampus of GEPRs at various time 
points after a single audiogenic seizure. Bars indicate standard error of mean.
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Figure 36. Concentration of mdrlb mRNA in hippocampus of GEPRs sacrificed at 
various time points after a single audiogenic seizure. Bars indicate standard error of mean.
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known to be involved in the seizure propagating pathway. The maximum increase in 
expression in this study was observed at 24 hours. The temporal pattern suggests that the 
peak expression may be observed at some point between 4 hours and 7 days post­
stimulation. Significant changes were observed in the cortex, a structure to which seizure 
activity originating in the midbrain (inferior colliculus) projects. Since chemoconvulsants 
(which might be P-gp substrates or inducers) were not used, these changes most likely 
represent response to the sound-induced neuronal discharges.
Adaptive changes of the BBB to various insults, including seizures, have long been 
recognised (Comford and Oldendorf, 1986). Both animal and human data have 
traditionally suggested a non-specific transient increase in permeability of the BBB ictally 
(Comford and Oldenforf, 1986; Duncan and Todd, 1991). More recently, activities of 
certain components of the BBB, for instance the glucose transporter Glutl, have been 
shown to be specifically up-regulated acutely during seizures (Comford, 1999). Such 
transient up-regulation of glucose transport has been suggested to account partly for the 
ictal hypermetabolic state of a seizure focus detected by positron emission tomography
1 Susing [ F]-fluorodeoxyglucose (Comford, 1999).
On the other hand, relatively little is known about the long-term changes at the BBB in 
epilepsy. Down-regulation of the Glutl glucose transporter activity has been observed in 
the epileptogenic focus of patients with chronic partial epilepsy (Comford, 1999). 
Thickening of the cerebral capillary basement membrane in tissues resected from patients 
with chronic epilepsy has been described (Kasantikul et al, 1983). Using concomitant 
intraoperative electrocorticographical recordings, Liwnicz and colleagues (1990) also 
found thickening of basement membrane in micro vessels from spiking cortical regions
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when compared to non-spiking control areas resected from patients with refractory partial 
seizures. These findings suggest a chronic reinforcement of the BBB in response to 
repeated seizures.
Since P-gp plays an important role in maintaining the integrity of the BBB (Part III; 
Section 1.2.5), the changes in P-gp expression observed in this study might reflect a 
prolonged post-ictal compensatory mechanism aimed at reinforcing the BBB, in an 
analogous manner to the structural alterations of the basal lamina described above. 
Whereas expression of the immediate early genes returns to basal level within 2 hours 
post-seizure (Burazin and Gundlach, 1996), mdrla P-gp remained significantly over­
expressed at 24 hours. It is possible that with repeated seizures, P-gp expression might 
become further increased, eventually progressing to a state of chronic elevation. A 
sufficient seizure frequency may, therefore, be required for the maintenance of over­
expression, and for P-gp to exert a "drug-resistance" role in chronic epilepsy. This might 
partly explain the relationship between refractory epilepsy and number of pre-treatment 
seizures (Part II; Section 1), and the observation of increased P-gp expression in brain 
tissues surgically removed from patients with pharmacoresistant epilepsy (Part III; Section 
1.3). Since some AEDs are substrates of P-gp (Part III; Section 2), over-expression of P- 
gp as a result of repeated seizures has the potential to inhibit their penetration of the BBB 
and limit their efficacy.
In conclusion, these preliminary data suggest that P-gp may be induced by a single seizure 
in brain regions of GEPRs involved in the seizure propagating pathway. A larger number 
of animals are required to confirm these findings. Further studies should include 
investigation of more post-seizure time points up to and beyond 7 days to better
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characterise the temporal changes. The effect of recurrent seizures and prolonged seizures 
(status epilepticus) on P-gp expression should also be investigated. Finally, other seizure 
models, including those of focal and generalised origin, should be studied to determine 
whether these changes are confined to GEPRs or are a consequence of seizures in general.
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6 Effects of laser-induced damage
6.1 Introduction and aim
Focal application of laser radiation was initially developed as a novel animal model of 
partial epilepsy by Dr Graeme J Sills, one of my PhD supervisors, at the Epilepsy Unit 
(Sills, 1994). The model was designed to impinge a laser beam of sufficient intensity upon 
a particular region of the cerebral cortex (in this case the primary motor cortex) to induce 
tissue damage which might become a local epileptic focus. The major advantage of such a 
procedure is the ability to employ a precise and quantifiably variable necrotic stimulus 
which could be reproduced with a high degree of accuracy in large groups of animals. In 
addition, the highly focused application of the laser beams permits the use of small animals, 
minimising expense and husbandry requirements.
The procedure was performed in 126 rats (78 laser-treated and 48 sham-operated) which 
were monitored for up to one year post-operatively. Less than 5% of the animals showed 
deviation from normal health and unexpected death occurred in less than 1%. In the laser- 
treated animals examined nine months post-operatively, a well-circumscribed lesion was 
observed which was approximately 1 mm in diameter at the cortical surface, tapering to 
around 60 |nm in cortical layer six, sparing the underlying white matter. 
Immunohistochemical staining revealed selective loss of neuronal cells and prominent 
gliosis and fibrosis without infiltration of chronic inflammatory cells. Consistent with 
histological findings, a reduction in local cerebral glucose utilisation and an increase in 
ligand binding to the peripheral-type benzodiazepine receptor (marker for brain damage) 
were confined to the lesioned area or its immediate vicinity (Sills, 1994).
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Although overt seizure activity was not observed, these preliminary results suggested the 
procedure to be safe and effective in creating a reproducible focal cortical lesion with 
associated histological and biochemical changes. It might, therefore, serve as a useful 
model of P-gp induction, in much the same way as other mechanisms of physical injury, 
such as heat shock treatment in certain cell types (Part III, Section 1.2.7; Chin et al, 1990).
The aims of the following pilot study were to explore the hypothesis that mdrl gene 
expression may be induced by physical damage, in this case by focal laser application to 
the rat brain, and whether a temporal effect could be observed.
6.2 Methods
6.2.1 Study design
Nine adult male Sprague-Dawley rats (200-3OOg) were randomly assigned into three 
groups, corresponding to a sacrifice time of 1 week, 4 weeks, and 8  weeks post-procedure 
(n=3 each group).
6.2.2 Instrument
The lesioning radiation was delivered by a Synrad 10-watt CO2 laser. It consisted of an 
extensive beam delivery and alignment apparatus, incorporating a zoom beam expander, a 
beam attenuator, a mirror block, a fine focus unit, and a magnifying lens. The invisible 
nature of CO2 laser radiation necessitated the inclusion of a helium/neon (HeNe) laser 
which has no ionising action of its own but whose red beam could be employed for aiming 
purposes. The HeNe laser was incorporated into the beam delivery assembly, and adjusted 
to be in direct alignment with the main CO2 beam. The desired laser output could be 
obtained by adjusting various parameters in the beam delivery apparatus. Absolute outputs
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ranged from 0.2 to 10.0 watts at intervals of approximately 0.1 watt. A foot pedal was 
incorporated to initiate the CO2 beam, allowing the operator to conduct the lesioning 
procedure in a safe, “hands-free” manner. An intrinsic timing device controlled the CO2 
laser output and allowed timed exposures of between 1 and 60 seconds at 1 second 
intervals.
6.2.3 Preparation of animals
Each operated animal was anaesthetised by placing it in a sealed chamber which was then 
flooded with 5% halothane delivered with oxygen (1.5 L/min). The animal was allowed to 
remain in the chamber for up to 5 minutes to ensure anaesthesia had progressed to a 
sufficiently deep stage.
6.2.4 Surgical procedure
On removal from the chamber, the animal was maintained under 1.5% halothane 
anaesthesia delivered via a face mask. The scalp was shaved and cleaned with a disposable 
alcohol swab and a midline incision of approximately 1.5cm in length was made with a 
scalpel. The skin was reflected in either direction and lightly clamped. The periosteal 
membranes overlying the right frontal and parietal bones of the skull were cleared with 
sharp forceps. A hand-held electric drill was used to produce a small burr hole of 
approximately 2 mm diameter in the skull, over the right primary motor region of the cortex, 
approximately 3mm anterior and 3mm lateral to zero Bregma (Paxinos and Watson, 1982). 
The drilling time was kept to a minimum (< 20 seconds) to prevent inadvertent heating of 
the skull. Care was also taken not to rupture the underlying dura mater.
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6.2.5 Production of a cortical laser lesion
The animal was briefly removed from the anaesthetic apparatus and placed in the path of 
the red HeNe aiming laser beam. The position of the animal was adjusted until the HeNe 
beam impinged directly on the centre of the circle of exposed dura mater. At this point the 
CO2 laser beam was initiated to deliver 0.5 watt in a 2-second period.
6.2.6 Recovery of animals
Following the lesioning procedure, animals were re-fitted with the anaesthetic face mask 
and the scalp incision was closed with 4-5 absorbable stitches. Animals were then placed 
in individual cages and monitored until consciousness was regained, and monitored 
thereafter on a twice daily basis. They were kept in a controlled temperature and humidity 
environment with day/night cycle conditions and access to food and water ad libitum until 
sacrificed by stunning followed by cervical dislocation.
6.2.7 Areas of interest and measurement of mdrl mRNA
Upon sacrifice, the brain was quickly removed and the cortex dissected free. The lesioned 
area was removed together with the adjacent margin in a cube of tissue of approximately 
60-80mg in weight. A similar sized brain tissue was removed from the same area of the 
contralateral hemisphere to serve as control. Individual samples were placed in 
microcentrifuge tubes and immediately snap frozen in liquid nitrogen before being 
transferred to storage at -70°C until required. Total RNA was extracted from the brain 
tissues and cleaned as described in Part III; Sections 3.2 and 3.3. M drla and mdrlb 
mRNA concentrations were measured by quantitative RT-PCR (Part III; Section 3.5).
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6.2.8 Statistical analysis
Group results were expressed as the mean of absolute values ± standard error of the mean. 
Mdrl mRNA concentrations in the laser-damaged and contralateral brain tissues were 
compared by paired Student’s t-test. Statistical calculation was performed using Minitab 
for Windows (version 11.21).
6.3 Results
Mdrla mRNA was detected in all samples. Its concentrations at various time points post­
injury are shown in Figure 37. There was no significant difference in the level of 
expression between the section circumscribing the damaged cortex and the contralateral 
region at any of the time points investigated.
Mdrlb mRNA was detected at an appreciable level only in the laser-damaged cortex 1 
week post-injury (Figure 38). It was not present at a quantifiable amount in any sample at 
4 weeks and 8  weeks.
6.4 Discussion
The limited literature available on pathological cerebral P-gp expression has focused on 
"natural" diseases, such as tumours (Matsumoto et al, 1991) and cortical dysplasia 
(Sisodiya et al, 1999). Whether external physical insult can induce P-gp expression in vivo 
has not been addressed. Focal laser application represents a novel technique in producing 
a localised injury to the cerebral cortex. Regulatory restrictions and limitation of facilities 
meant that only a small number of animals could be employed. This pilot study was, 
therefore, necessarily exploratory in nature. It was intended to examine the feasibility of
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Figure 37. Concentration of mdrla mRNA in laser-damaged cerebral cortex and 
contralateral cortex. Bars indicate standard error of mean.
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Figure 38. Expression o f mdrlb in cerebral cortex o f three rats 1 week after laser 
treatment. A=laser-damaged cortex; B=contralateral cortex.
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this technique for the study of P-gp expression, and to generate results that might guide the 
design of more definitive experiments in the future.
These preliminary data suggest that the laser lesion may be associated with a transient 
expression of mdrlb in the damaged cortical region, detectable at 1 week post-injury. 
Mdrlb was not expressed to an appreciable level in the contralateral undamaged cortex, or 
in the damaged area at 4 and 8 weeks after injury. The relevance of this transient induction 
is unclear. If it is translated to an increased P-gp expression at the protein level, it might 
represent a component of the cellular changes in response to injury. However, its 
disappearance by 4 weeks post-injury casts doubts over its possible long-term implication. 
Concomitant electrophysiological study would be required to examine whether these 
changes were due to physical damage per se, or any resultant neuronal discharges. 
Extension of the observation period beyond 8 weeks is needed to investigate any potential 
long-term effects of damage on P-gp expression.
There was no statistical difference in the expression level of mdrla between the damaged 
and undamaged cortical regions at any of the time points investigated. However, only 
three animals were studied in each group and whether the contralateral undamaged cortical 
area could be used legitimately as a control is open to question. It is possible that focal 
damage in one hemisphere could induce alterations in P-gp expression in contralateral 
areas. The two cerebral hemispheres are intimately interconnected by neuronal networks, 
as exemplified by the phenomenon of secondary epileptogenesis in animal models of focal 
epilepsy. In this scenario, a primary epileptogenic lesion is able to induce epileptiform 
behaviour in initially normal cell populations in the contralateral hemisphere via recurrent
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discharges, creating a “mirror focus” which, in time, becomes an independent source of 
epileptic activity (Morrell, 1991).
Only limited conclusions can be drawn from these preliminary data. Clearly, a larger 
number of animals are required to explore the full potential of this technique to induce P- 
gp expression. Future studies should, perhaps, focus on 1 week post-injury in view of the 
changes in mdrlb expression observed. Sham-operated (animals undergoing the operative 
procedures without exposure to laser radiation) and naive animals should also be used to 
control for the possible effects of the operation itself and anaesthetic agents on the 
expression of mdrl genes.
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7 Expression of MDR1 gene in human epileptogenic focus
7.1 Introduction and aim
Investigation of P-gp in animal models has clinical relevance only if its expression can be 
detected in human epilepsy. Although cerebral MDR1 expression is well documented in 
the normal, and in some cases diseased, human brain (Part III; Sections 1.2.5 and 1.2.6), its 
presence in the brains of patients with epilepsy has been reported in only a few published 
case series (D’Giano et al; 1997; Lazarowski et al, 1999). Only one study attempted to 
measure its expression by a semi-quantitative technique (Tishler et al, 1995).
The present study aimed to test the sensitivity of the RT-PCR technique as described in 
Section 3 (Part III) for the detection of MDR1 gene expression in brain tissues resected 
from patients with medically intractable epilepsy. If the assay technique is able to detect 
MDR1 mRNA in such surgical specimens, measurement of gene expression using 
competitive internal standards, similar to the quantitative RT-PCR technique used for rat 
mdrl, may be developed for absolute quantification.
7.2 Methods
7.2.1 Patients
Brain tissues resected from two patients during epilepsy surgery were obtained after 
consent had been obtained to use the materials for research purposes.
Patient 1 was 41 years of age when the operation was carried out. He had had 
uncontrolled epilepsy since the age of 6 months following an attack of meningitis. The 
seizures were predominantly complex partial in nature, or simple partial consisting of aura 
only, with occasional secondary generalisation. He had been treated unsuccessfully with a
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number of AEDs including PHT, CBZ and VGB. Neuroimaging and neurophysiological 
investigations all converged on his left mesial temporal lobe as the seizure focus and a left 
temporal lobectomy was performed.
Patient 2 was 11 years old when she underwent epilepsy surgery. She suffered febrile 
convulsion in her first year associated with herpes simplex virus infection. Since then she 
had been experiencing frequent complex partial seizures. A typical attack was heralded by 
an unusual smell, followed by aural automatism and staring without speech disturbance or 
loss of consciousness. Despite AED treatment, including PHT, LTG and TPM, she was 
having up to 16 seizures per month. Brain MRI showed right mesial temporal sclerosis. 
Inter-ictal EEG and SPECT also demonstrated right temporal abnormalities. A right 
anterior temporal lobectomy was performed.
7.2.2 Detection of MDR1 mRNA
A small portion of the resected brain tissue from each of these patients was obtained fresh 
during the surgical procedure. The sample was placed in a sterile container and snap 
frozen in liquid nitrogen before being transferred to storage at -70°C until required. Total 
RNA was extracted from brain tissues and cleaned as described in Part III; Sections 3.2 
and 3.3. RT-PCR (Part III; Section 3.5) was performed on the extracted RNA to determine 
the presence of MDR1 mRNA.
7.3 Results
Using primers specific for MDR1, a strong band corresponding to the expected size (161 
bp) was amplified from the total RNA prepared from brain specimens acquired from both 
patients (Figure 39).
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Figure 39. Expression o f MDR1 in brain tissues resected from patients 
with refractory temporal lobe epilepsy. Expected band size = 161.
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7.4 Discussion
A significant amount of MDR1 mRNA was detected in the brain tissues resected from 
these two patients with refractory temporal lobe epilepsy. The assay technique is, 
therefore, sufficiently robust for clinical specimens which are prone to handling 
degradation during resection.
Quantitative measurement was not carried out due to lack of control tissues. A previous 
semi-quantitative analysis found increased expression of MDR1 in brain tissues resected 
from patients with refractory epilepsy compared to “normal” tissues (Tishler et al, 1995). 
A study to compare MDR1 expression between epileptogenic brain tissues from patients 
with refractory epilepsy and “normal” tissues resected during removal of arteriovenous 
malformation is underway. Absolute quantification of MDR1 mRNA will be made with 
use of competitive internal standards.
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8 General discussion and conclusion
8.1 Discussion
The aim of this series of pilot experiments was to explore whether the drug transporter P- 
gp could play a role in the genesis of refractory epilepsy. It was hypothesised that over­
expression of P-gp at the BBB might contribute to drug resistance by limiting AED access 
to the seizure focus.
Using mdrla (-/-) mice that are devoid of cerebral P-gp, it was suggested that TPM, PHT 
and possibly CBZ may be substrates of P-gp at the BBB (Part III; Section 2). A 
reproducible, robust assay for quantifying mdr mRNA was developed, tested, refined and 
validated (Part III; Section 3), allowing the measurement of P-gp expression in various 
models in the subsequent pilot studies. P-gp is expressed in a region-specific manner in 
the rat brain. Mdrlb was found to be constitutively expressed to a significant level by the 
hippocampus alone, while mdrla was expressed uniformly throughout the brain (Part III; 
Section 4). A single seizure appeared to result in a sustained increase in P-gp expression in 
the GEPR along the seizure generating pathway, without affecting other brain regions (Part 
III; Section 5). Physical trauma produced by focal application of laser is associated with a 
transient expression of mdrlb to an appreciable amount at 1 week, but did not affect P-gp 
expression when examined at 4 and 8 weeks post-injury (Part III; Section 6). Lastly, P-gp 
expression was detected in brain tissues resected from patients undergoing temporal 
lobectomy for drug-resistant epilepsy (Part III; Section 7).
Very few studies have examined the potential relationship between P-gp and epilepsy (Part 
III; Section 1.3). Little guidance in experimental design and methodology could, therefore, 
be gleaned from the literature. Regulatory requirements have placed further restrictions in
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study techniques and protocols. These pilot studies were, therefore, necessarily 
exploratory in nature. They were primarily intended to examine the feasibility of the assay 
technique for the study of P-gp expression, and to generate results that might guide the 
design of more definitive experiments in the future. It is in this context that these results 
should be interpreted.
While only limited conclusions can be drawn from the experiments individually, when 
pieced together, these findings do strengthen the argument for a potential role of P-gp in 
the pathogenesis of refractory epilepsy, especially that related to MTS. The exclusive 
expression of mdrlb in the hippocampus might correlate with the particularly drug 
resistant nature of temporal lobe epilepsy (Semah et al, 1998). The low remission rate 
among patients with MTS (Part II; Section 4), and the relative insensitivity in a subset of 
amygdala-kindled rats to AEDs compared to other animal models (Loscher, 1997), might, 
therefore, be partly due to the anatomical location of the seizure focus.
The suggested ability of seizures to induce P-gp expression is consistent with clinical 
observations that a high number or frequency of seizures before treatment, and a long 
duration of seizures are associated with poorer response to AEDs (Table 8). No sustained 
changes in P-gp expression were produced by focal laser application to the cortex.
However, altered P-gp expression has been noted in cortical dysplasia (Part III; Section 1.3) 
and primary brain tumours in man, and after focal brain ischaemia in animals (Part III; 
Section 1.2.6). This suggests that the expression pattern of P-gp may also be related to the 
specific pathology, rather than a response to injury or insult in general.
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The relevance of these findings to epilepsy is underlined by the suggestion that several 
AEDs may be substrates of P-gp, raising the question of whether other drug transporters at 
the BBB may also limit cerebral penetration of AEDs.
8.2 Conclusion
While P-gp may contribute to “refractoriness” of epilepsy in a “universal” manner via 
seizure-induced expression, it may also have a region- and pathology-specific effect.
These effects might contribute to the particularly drug resistant nature of MTS-related 
seizures. Results from these pilot studies have generated testable hypotheses regarding the 
potential role of P-gp in epilepsy. Laboratory experiments to examine these issues further 
have been discussed in the individual sections. To test the hypothesis clinically, seizure 
control may be compared between patients treated with and without a P-gp inhibitor (e.g. 
dipyridamole) as an adjunct to a P-gp substrate AED, the best demonstrated of which 
appears to be TPM.
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OVERALL DISCUSSION AND CONCLUSION -  
PREVENTION OF REFRACTORY EPILEPSY: A HYPOTHESIS
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Based on an improved knowledge of the natural history of treated epilepsy derived from 
clinical data, including those described in this thesis, and accumulated laboratory findings, 
a hypothesis for the conceptual understanding and prevention of refractory epilepsy may be 
formulated.
Refractory epilepsy as a distinct condition
Although the criteria for defining “refractory epilepsy” are elusive e.g. number of drugs 
tried, dose of drugs, duration of treatment, etc (Perucca, 1998; Regesta and Tanganelli, 
1999), a hard-core of 20-30% patients have a seizure disorder that appears to be resistant to 
all pharmacological manipulations (Sander, 1993). These patients are often treated with 
multiple AEDs, which, in combination, may produce sedative and behavioural toxicity 
(Vermeulen and Aldenkamp, 1995; Drane and Meador, 1996). High seizure frequency, 
prolonged seizures and episodes of status epilepticus can lead to cognitive decline 
(Devinsky, 1999). A long period of imperfect seizure control produces disturbed 
psychosocial functioning resulting in, for instance, poor academic achievement, diminished 
self esteem, low rates of marriage and reproduction and unsatisfactory quality of life 
(Cramer, 1994; Sillanpaa et al, 1998). In addition, refractory epilepsy is associated with 
excess mortality, particularly due to sudden unexpected death in epilepsy (Nilsson et al, 
1999). “Refractory epilepsy”, therefore, may be better understood as a distinct condition 
comprising of a constellation of disabilities with recurrent seizures being only one of its 
manifestations (Table 29).
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Table 29. Refractory epilepsy as a distinct condition with multiple dimensions.
Intractable seizures 
Excessive drug burden 
Neurobiochemical plastic changes 
Cognitive decline 
Psychosocial dysfunction 
Dependent behaviour 
Restricted lifestyle 
Unsatisfactory quality of life 
Increased mortality
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Refractory epilepsy as a multifactorial condition
Important insights into the mechanisms underlying the genesis of a range of epilepsy 
syndromes are emerging (McNamara, 1999), but the biological basis of “refractoriness” 
has not been well studied. Potential candidates, including the underlying pathology and 
syndromic classification, abnormal neuronal circuitry, changes in neurotransmitter 
receptors, ion channelopathies, reactive autoimmunity, and access of AEDs to seizure 
focus, were discussed in Part I; Section 5. Several of these factors were explored in the 
clinical and laboratory projects described in this thesis.
Consistent with previous reports, epilepsies with a known or suspected cerebral 
abnormality were found to be more likely to remain uncontrolled than idiopathic (genetic) 
epilepsies (Part II; Section 1). Among the former group of patients, seizures related to 
MTS were most drug-resistant (Part II; Section 4). Raised titres of autoantibodies against 
GAD were found in a small proportion of patients with uncontrolled epilepsy (Part II; 
Section 5). Their relationship to refractoriness, however, is unclear. Animal experiments 
suggested that P-gp at the BBB limits brain access of certain AEDs (Part III; Section 2). 
The hippocampus appears to over-express P-gp, potentially contributing to the particular 
refractoriness of focal epilepsy associated with HS / MTS (Part III; Section 3). P-gp 
expression can be detected in brain tissues resected from patients with refractory temporal 
lobe epilepsy (Part III; Section 7). The pathogenesis of refractory epilepsy, therefore, is 
likely to be multifactorial and variable.
Refractory epilepsy as a progressive condition
There is an overwhelming body of experimental evidence to support the concept that 
seizures may be self-perpetuating. The most thoroughly studied substrate is that arising
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from the temporal lobe (Sutula and Hermann, 1999). Recurrent seizures, particularly those 
involving the limbic structures, are recognised to cause enduring disturbances in neuronal 
function independent of the underlying pathology (Glass and Dragunow, 1995; Liu et al, 
1995; Bliimcke et al, 1999). The characteristic pattern of neuronal loss and mossy fibre 
sprouting associated with human temporal lobe epilepsy can be produced by experimental 
seizures in animals (Meldrum et al, 1973; Sutular et al 1994; Babb, 1999; Coulter, 1999). 
Synaptic reorganisation of the mossy fibre axons of hippocampal dentate granule cells into 
the inner molecular layer of the dentate gyrus (Sutula et al, 1988) can form functional 
recurrent excitatory synapses which, in the presence of reduced inhibition, could promote 
seizures (Bausch and McNamara, 1999). Whether a brief seizure or even a cluster of 
events is sufficient to destroy neurones is less certain, but the degree of neuronal loss in 
susceptible regions of the hippocampus has been shown to correlate with the number of 
kindled-seizures (Cavazos et al, 1994). Even a single kindled seizure can induce apoptotic 
cell death in the dentate gyrus (Bengzon et al, 1997).
Long-lasting changes in excitatory and inhibitory neurotransmitter receptors and ion 
channels have been documented in these animal models of human epilepsy (Mody, 1999; 
Prince, 1999). Seizures are also recognised to trigger a cascade of gene expression 
including the immediate early genes (e.g. c-fos; Burazin and Gundlach, 1996), followed by 
neurotrophic factors (Bausch and McNamara, 1999), and a variety of late genes encoding a 
range of peptides, receptors, cytoskeletal proteins etc (Cole, 2000). Even a single seizure 
can produce prolonged increase in P-gp expression (Part III; Section 5).
The functional consequences of such neuronal plasticity remains to be fully elucidated, but 
these alterations may lead to a deleterious combination of disinhibition and
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hyperexcitability (Babb, 1999; Wasterlain et al, 1999). This process may also account for 
the phenomenon of secondary epileptogenesis, which is well described in animal models of 
focal epilepsy. In this scenario, a primary epileptogenic lesion is able to induce 
epileptiform behaviour in initially normal cell populations via recurrent discharges to 
create a “mirror focus” which, in time, becomes an independent source of epileptic activity 
(Morrell, 1991).
Are there data to support such self-perpetuation in human epilepsy? Hippocampal 
neuronal loss following prolonged febrile seizures (Vanlandingham et al, 1998) and 
progressive hippocampal atrophy in refractory temporal lobe epilepsy (O’Brien et al, 1999) 
have been documented in vivo by serial magnetic resonance imaging. Other recent 
neuroimaging studies have reported a correlation of increasing duration of epilepsy and / or 
numbers of seizures with more severe neuronal loss and dysfunction in temporal lobe 
epilepsy (Van Paesschen et al, 1997b; Kalviainen et al, 1998; Tasch et al, 1999), although 
the results are not as uniform as the laboratory data (Sutula and Hermann, 1999). A 
prolonged history of seizures prior to epilepsy surgery is associated with poorer outcome, 
suggesting the development of secondary epileptogenesis as a result of recurrent seizures 
in unresected tissue (Eliashiv et al, 1997). Other surgical studies have reported more 
severe cognitive impairment in patients with longer duration of temporal lobe epilepsy 
(Jokeit and Ebner, 1999). Significantly, such associations have persisted even in patients 
who became seizure-free after temporal lobectomy.
Whether such progression can be observed in other epilepsy syndromes has been less well 
studied. Electroclinical studies in patients with tumour-associated epilepsy support the 
operation of secondary epileptogeneis (Morrell, 1991; Lim et al, 1991). On the other hand,
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population-based epidemiological studies have traditionally failed to demonstrate the self- 
perpetuating effect of repeated seizures, particularly in children (Part I; Section 5.1). 
Randomised drug studies suggest that prevention of febrile seizures or posttraumatic 
seizures by AEDs does not reduce the risk of later recurrence (Part I, Section 5.1), although 
these seizures are clearly provoked and would not fulfil the diagnostic criteria of epilepsy 
(Commission, 1989; 1993). In the long-term outcome study of 470 adolescents and adults 
with newly diagnosed epilepsy described in Part II; Section 1, 47% became seizure-free on 
the first AED, 13% on a second monotherapy, but only 1% on the third drug. The 
probability of attaining seizure-freedom declined rapidly and progressively with successive 
AED regimens after the first two treatment manipulations.
Lastly, population-based epidemiological studies often focus purely on seizure control 
without consideration of the cognitive and psychosocial aspects of epilepsy (Kwan and 
Brodie, 2001). There is evidence to suggest that psychosocial dysfunction may not be 
reversible when the seizure disorder finally comes under control (Elishav et al, 1997; Engel, 
1999). Surgical outcome studies indicate that even when the operation is successful in 
eliminating seizures, patients with a long history often do not gain employment, marry, or 
have children, but rather remain dependent on family and the welfare system (Engel, 1999). 
Such irreversibility may also explain why patients with childhood-onset epilepsy suffer 
social and educational disadvantages even well after entering remission in adulthood 
(Sillanpaa et al, 1998).
Refractory epilepsy as a preventable condition
Can these deleterious neuronal and psychosocial changes be prevented by therapeutic 
intervention? Although epileptogenesis is a potential target (Dichter, 1997; Clark and
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Wilson, 1999) and some AEDs have demonstrated ability to retard the epileptogenic 
process in animal models (Loscher et al, 1998), the underlying neuropathology and the 
syndromic classification are at present considered to be constitutively determined. 
However, the other changes described above may have developed with time as a result of 
uncontrolled seizures. By interrupting this self-perpetuating process early, it might be 
possible to halt or even reverse the progression of seizure-related neurobiological, 
cognitive and psychosocial dysfunction.
The management of epilepsy is undergoing a revolution. Advances in neuroimaging have 
improved the identification of suitable candidates for epilepsy surgery, which can render 
up to 90% of selected groups seizure-free. The most well-defined of these are patients 
with MTS (Part I; Section 3.4). The timing of surgery remains controversial. Since 
secondary epileptogenesis at sites distant may develop with uncontrolled seizures (Eliashiv 
et al, 1997), early surgery to avoid deterioration in seizure control and controllability has 
been advocated (Engel, 1999).
Parallel to the advances in surgery, nine new AEDs have been licensed over the past 
decade, greatly broadening the physician's pharmacological armamentarium (Part I;
Section 3). The argument against combination therapy traditionally has been its propensity 
to cause greater toxicity without substantial improvement in outcome (Schmidt and Gram, 
1995). However, some of the newer agents may be better tolerated than their older 
counterparts (Brodie, 1999), potentially enhancing their overall effectiveness (Part II; 
Section 2). Their mechanistic diversity holds out the possibility of “rational” polytherapy 
(Deckers et al, 2000). "Synergistic" effects of certain combinations have been explored in 
laboratory and clinical studies, particularly those involving a sodium channel blocker and
267
an AED that enhances GABA-ergic inhibition or has multiple mechanisms of action (Part 
II; Section 3).
A working hypothesis
It may be hypothesised that early targetting of aggressive intervention, such as epilepsy 
surgery or “rational” polytherapy, may prevent the development of refractory epilepsy. A 
strategic plan for managing epilepsy should be formulated from the outset (Figure 40).
Such a rational approach is particularly important for “high risk” patients, including those 
with a known or probable structural cerebral abnormality (especially certain pathologies 
such as MTS, CD), or other poor prognostic clinical factors such as high pre-treatment 
seizure numbers. Among the newly diagnosed patients studied (Part II; Section 1), those in 
whom the first AED failed due to lack of efficacy were four times more likely to remain 
uncontrolled than those who switched treatment due to intolerable side-effects. Indeed, 
their chance of eventual seizure-freedom was only 11%
The aim of treatment in all patients should be the maintenance of a normal lifestyle by 
complete seizure control with no or minimal side effects (Brodie and Dichter, 1996), given 
that the majority will respond to monotherapy and require lifelong treatment. The first 
AED should be chosen by “matching” the individual characteristics of the patients (age, 
gender, body habitus, concomitant disease and medications, etc), the seizure disorder 
(seizure type, epilepsy syndrome), and the drug (range of efficacy, tolerability, side effect 
and interaction profiles; Brodie and Kwan, 2001). In this regard, efficacy and tolerability 
should both be considered when assessing the effectiveness of an AED (Part II; Section 2).
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Figure 40. Strategies for managing newly diagnosed epilepsy.
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If seizure control remains suboptimal despite a substantial dose of the first AED, it may not 
be beneficial to push on with monotherapy to the limit of tolerability since it is unlikely to 
be successful (Part II; Section 2). Rather, it may be more productive to substitute the 
original AED with one with a different mode of action or add in another with multiple 
pharmacological effects (Part II; Section 3). This decision will depend on the extent of the 
response to the first AED and the presence or absence of side effects.
Failure of two first-line AEDs due to lack of efficacy as monotherapy in a patient with 
correctable structural brain abnormality should prompt immediate consideration for 
epilepsy surgery (Part II; Section 1). For the majority of patients not suitable for 
“curative” resective surgery, two (or at most three) AEDs should be combined in a 
“rational” fashion. This should involve consideration of mechanism of action, range of 
efficacy, propensity for adverse interaction (pharmacokinetic and pharmacodynamic), and 
side effect profile (Brodie and French, 2000).
Future studies
This hypothesis may be tested at a number of levels. The main aim would be to better 
define the natural history of epilepsy, particularly in terms of response to AED treatment. 
Ideally, this should be examined in a prospective community-based setting, recruiting 
patients from their first seizure with pre-defined outcome measures and endpoints. To 
avoid selection effects due to local expertise and preference, muliple centres are required.
A defined protocal, including diagnostic and classification criteria, investigation modalities, 
and treatment plan, would allow standardisation of the data quality.
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Both cumulative and terminal remission of various lengths should be measured. Outcome 
measures should include not only seizure control, but also mortality and other important 
psychosocial aspects such as cognitive function, education attainment, employment, 
marriage and fertility, and other quality-of-life issues. Since drug response is heavily 
influenced by the underlying aetiology, subanalyses for different pathologies are required. 
An acturial approach should be undertaken when analysing putative risk factors.
For ethical reasons, patients with two or more unprovoked seizures should be offered an 
AED and a placebo arm should not be included. Specific drug choice should be left to 
each centre’s discretion to mantain the generic nature of the results, but titration regimens 
need to be standardised. Whenever the AED causes intolerable adverse events despite 
lowering the dose, it should be substituted.
To compare the effectiveness of early and delayed combination therapy, patients with 
inadequate seizure control despite taking a sufficient dose of monotherapy may be 
randomised to substitution or addition of a second drug. To evaluate the effectiveness of a 
mechanistic approach, patients in the second arm may be further randomised to 
combinations involving a sodium channel blocker and an AED with multiple mechanisms 
of action, or other combinations. If the epilepsy remains uncontrolled at this stage, patients 
with surgically remediable lesions (such as MTS) may be randomised to undergo surgical 
evaluation proceeding to epilepsy surgery, or futher medical treatment for a further defined 
period of time. This would allow comparion between early and late surgery.
To test the “MDR hypothesis”, a larger number of m drla/lb  knockout mice are required to 
analyse across a wider range of doses and time points. Other novel AEDs should be
271
screened. The effect of chronic dosing should also be investigated to mimic their clinical 
usage more closely, and to examine whether these AEDs, similar to many other substrates, 
also induce the expression of P-gp. Studies to determine whether co-administration of 
substrate AEDs with a P-gp inhibitor may enhance their access to the brain would aid 
assessment of the feasibility of such “rational polytherapy” in the clinical setting. 
Expression of P-gp at the protein level should be measured in different brain regions to 
correlate with the mRNA findings. The effect of recurrent seizures and prolonged seizures 
(status epilepticus) on P-gp expression should also be investigated in appropriate animal 
models. Other seizure models, including those of focal and generalised origin, should be 
studied to determine whether the changes in P-gp expression are confined to GEPRs or are 
a consequence of seizures in general. P-gp expression in different epileptogenic 
pathologies (e.g. MTS, cortical dysplasia) should be compared to correlate with clinical 
outcome data. Ultimately, to test whether the hypothesis has relevance to patient 
management, seizure control may be compared between patients treated with and without a 
P-gp inhibitor as an adjunct to a P-gp-substrate AED.
Conclusion
Conceptualisation of refractory epilepsy as a distinct condition characterised by 
progressive neuronal, cognitive and psychosocial deterioration would allow a better 
appreciation of its multifaceted dimensions. This would support timely utilisation of 
powerful therapeutic interventions at an early stage in the “natural history” of treated 
epilepsy. P-gp, or other drug transporters, may be an important factor in the pathogenesis 
of refractory epilepsy in some patients. Defining its exact role may open novel therapeutic 
approaches to the treatment of epilepsy.
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Appendices
Appendix 1 -  List of suppliers
Amersham Pharmacia Biotech, St Albans, UK 
Random hexamers
BioGene, Kimbolton, UK
“Hi-Pure” Low EEO Agarose
CLONTECH Laboratories UK Ltd, Basingstoke, UK 
AdvanTAge PCR Cloning Kit
Life Technologies Ltd, Paisley. UK 
MMLV reverse transcriptase 
Taq DNA polymerase 
dNTP’s
lOxPCR Mg2+-free buffer 
MgCl2 for PCR and RT 
W-l detergent 
Dithiothreitol
MWG-Biotech UK. Milton Kevnes. UK 
Oligonucleotide PCR primers
Promega. Southampton. UK 
PstI 
Ncol
Rnasin RNase inhibitor 
RQ1 DNase
RNAgent Total RNA Isolation System 
SP6 RNA polymerase 
Wizard DNA Clean-Up System
OIAGEN Ltd, Crawley. UK
QIAfilter Maxi Plasmid Kit
Sigma-Aldrich. Poole, UK
Diethypyrocarbonate (DEPC)
Ethidium bromide (EtBr)
Stratagene Europe. Amsterdam, The Netherlands 
NucTrap Probe Purification Column
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Appendix 2 -  Preparation of solutions
All chemicals were obtained from Sigma-Aldrich Co. Ltd, Poole, UK, unless otherwise 
stated in Appendix 1.
Electrophoresis buffer 
EDTA 
dH20
The pH was adjusted to 7.0 with 5M NaOH.
Tris Base 
dH20
3.72g
1000ml
48.4g
5000ml
This was mixed with the EDTA solution. The pH was adjusted to 8.0 with glacial acetic 
acid. The buffer was made up to 10 litres with dH20.
L-amp agar plates
LB agar tablets x 10 
dH20
16.8g
500ml
This was autoclaved and allowed to cool to hand warm.
Ampicillin sodium (25mg/ml stock) 2ml
502ml
This was poured into sterile 100mm plates, allowed to set at room temperature and stored 
at 4°C.
LB-amp medium (TOOlig/mD 
LB-broth
Ampicillin sodium (lOOmg/ml stock)
This was stored at 4°C.
LB-broth
LB broth tablets x 10 
dH20
This was autoclaved and stored at 4°C.
500ml
0.5ml
500.5ml
Hg
500ml
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DNA Loading dye
lml 
lml 
Pinch 
Pinch
350
Glycerol
dH20
Brornophenol Blue 
Xylene Cyanole FF
This was stored at 4°C.
